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Thesis Summary  
 
 
The facility to controlled triggered release from a “cage” system remains a key requirement for 
novel drug delivery. Earlier studies have shown that Bis-Azo PC based photosensitive liposomes 
are beneficial for drug delivery. Thus, the aim of this project was to develop photosensitive 
liposomes that can be used for the controlled release of drugs through UV irradiation, particularly 
therapeutic agents for the treatment of psoriasis. 
Bis-Azo PC was successfully synthesized and incorporated into a range of liposomal formulations, 
and these liposomes were applied for the controlled release of BSA-FITC. Bis-Azo PC sensitized 
liposomes were prepared via interdigitation fusion method. IFV containing optimum cholesterol 
amount in terms of protein loading, stability and photo-trigger release of protein was investigated. 
Further studies investigated the stability and triggered release of the HMT from IFV. Finally, 
permeation behavior of HMT and HMT-entrapped IFV through rat skin was examined using Franz 
cell.  
 
Results from protein study indicated that the stable entrapment of the model protein was feasible as 
shown through fluorescence spectroscopy and maximum of 84% protein release from IFV after 12 
min of UV irradiation. Moreover, stability studies indicated that IFV were more stable at 4 0C as 
compared to 25 0C. Hence, DPPC:Chol:Bis-Azo PC (16:2:1) based IFV was chosen for the 
controlled release of HMT and these studies exhibited that photo-trigger release and stability data 
of HMT-entrapped IFV are in line with the protein results. Franz cell work inferred that HMT-
entrapped IFV attributed to slower skin permeation as compared to HMT. CLSM also 
demonstrated that HMT can be used as a fluorescent label for the in vitro skin study. Overall, the 
work highlighted in this thesis has given useful insight into the potentials of Bis-Azo PC based IFV 
as a promising carrier for the treatment of psoriasis.      
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1.1. Introduction 
 
Light is one of the best known innocuous "materials" available to man due to its wavelength and 
intensity. Light intensity and wavelength can be regulated by the use of coloured filters, and 
fabricated photo masks or lasers which not only allocate for fabrication of complex features but 
also cover areas with resolution as small as approximately 1µm (Katz and Burdick, 2010). A recent 
advance in confocal microscopy has empowered a remarkable increase in resolution with three 
dimension control (Helmchen and Denk, 2005; Zipfel et al., 2003). Technology has allowed light to 
be employed in non-invasive deep tissue imaging modalities like diffuse optical tomography and 
photoaccoustic imaging (Charrois and Allen, 2003; Ishida et al., 1999). However, employing the 
same strategy towards drug delivery applications has not reached the same level. Light could be 
employed to accomplish drug delivery either by exploiting photophysical or photochemical 
principles. Photochemical means of drug delivery works as a result of photochemical reactions that 
take place in the drug delivery vehicle. The photochemical transformation can be planned in such a 
way that the stability of delivery vehicle is effectively destroyed, imposing molecular 
reorganization in the drug delivery vehicle. This reorganization method can be potentially 
consumed to let the leakage of drug presented in the interior of the drug carrier. The advantage of a 
photochemical transformation is that it can be designed to occur by a two-photon excitation process 
that offers better spatiotemporal control. Yet another potential advantage of the photochemical 
process of drug delivery is that the delivery vehicles are usually composed of only organic 
molecules that can be specifically metabolized by various enzymes in the body for elimination once 
the supramolecular assembly is destroyed after drug delivery (Karanth and Murthy, 2007; 
Torchilin, 2005). 
 
1.1.1. Light based therapies 
 
The success of light based therapies is completely reliant on the selection of ample light sources 
that can deeply penetrate the tissues for drug delivery and therapeutic applications. The bulk of 
light- responsive biomaterials are responsive in the UV spectral range which is not limiting step in 
an in vitro surroundings, and may be useful for different applications. But, these types of materials 
are not useful for in vivo surroundings due to the poor penetration of UV light deeply into tissues. 
The reason behind poor penetration is the scattering and presence of endogenous light absorbers, 
such as oxy- and deoxy-hemoglobin, lipids and water (Klohs et al., 2008). In order to hinder tissue-
penetration concerns, light based therapies have been more widely used for superficial areas such 
as skin and oral treatments (Donnelly et al., 2008; McCoy et al., 2007) than deeper skin furrows. 
However, the preferred choice for in vivo surrounding therapeutics is near-infrared (NIR) 
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responsive biomaterials. NIR light ranges from 700 nm to 2500 nm and penetrates deeply into the 
human skin and blood up to the 1 cm (Weissleder and Ntziachristos, 2003). Nowadays advances in 
two–photon microscopy and lasers as well as  the development of NIR active molecules have 
played important roles in the treatment of cancer and bladder diseases (Gurfinkel et al., 2004).  
 
Several nanocarriers are used in light based therapy, particularly, lipid based nanocarriers have 
become popular tool due to several reasons (Demirbag and Kucukturhan, 2011). Firstly, they 
protect the drug from lymphatic system. Secondly, they protect the non-target tissues from toxic 
effects of the bioactive agent. Thirdly, lipid based nanocarriers can be easily metabolized and 
excreted from the body without leaving any by-products behind. Lipid based nanocarriers are 
prepared by simple methods and exist in different forms and ranges of size. Moreover, they have 
the ability to encapsulate both water soluble and lipid soluble materials (Arias et al., 2011). Fig 1.1 
illustrates the different forms of lipid based nanocarriers.  
 
 
Fig 1.1: Different forms of lipid based nanocarriers [taken from (Dijkhuizen, 2011)]. 
 
Based on the preparation method, lipid based nanocarriers may range from 10 to 1000 nm in size. 
Drug loading of lipid based nanocarriers can be performed by several techniques. In order to avoid 
rapid clearance from the circulation via cells of the reticulo-endothelial system (RES), lipid based 
nanocarriers can be modified into hydrophilic shell, i.e. Polyethylene glycol (PEG)-lipid based 
nanocarriers (Allen and Chonn, 1987; Lasic et al., 1992). The size of tissue targeting of lipid based 
nanocarriers can be increased through introduction of ionisable groups which have a specific 
affinity towards specific tissue due to charge or size (Tam et al., 2013). Lipid based nanocarriers 
can exist in different forms which are presented in Fig 1.1. Among all these nanocarriers, 
liposomes are the oldest and the most common type used for biomedical applications (Liu et al., 
2005a; Torchilin, 2003). 
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1.2. Liposomes 
 
Liposomes, also known as fatty acid vesicles (Walde, 2006), are artificial spherulites that emerge  
highly ordered phospholipids when hydrated in aqueous media. Liposomes originated in the work 
of Alec D Bangham and co-workers (Bangham and Horne, 1964) at the Babraham Institute in 
Cambridge. While studying phospholipids with the help of electron microscope, they discovered 
bilayer lipid structure by adding negative stain to dry phospholipid. Initially they termed these 
materials as ‘smecticmesophase system’. Later on Gerald Weissmann  renamed them as liposomes 
and published a paper on diffusion of univalent ions across the lamellae of swollen phospholipids 
(Bangham et al., 1965). However in the early 1970s, for the first time, liposomes were considered 
as one of the safest carrier systems for drugs, antigens and enzymes (Gregoria.G and Ryman, 1971; 
Gregoriadis, 1993). Other early pioneers (Alahari et al., 1998) proved that liposomes could change 
the in vivo distribution of the entrapped drugs. From then on, liposomes have been used to deliver 
drugs for cancer and other diseases (Gregoriadis and Florence, 1993). Although it has been 
generally accepted that the use of liposomes with proper composition should result in increased 
drug transport in vitro and in vivo, many questions arise about the mechanism of action of these 
vesicular formulations 
 
1.2.1. Mechanism of action 
 
The term liposome originated from the Greek words: “lipo” which means fat and “soma” which 
means body. Liposomes are composed of a hydrophobic bilayer membrane which entraps an 
aqueous phase inside (Gregoriadis et al., 2002). As a result, during liposomal formulation, 
hydrophilic substances or drugs dissolved into this aqueous phase, and due to lipid bilayer coating 
these hydrophilic materials cannot bypass the membrane and remain inside the lipid bilayer. 
Hydrophobic materials or drugs can also be dissolved into the bilayer membrane. In this manner 
liposomes are able to carry both hydrophilic and lipophilic materials (Chrai, 2002). In order to 
deliver these types of materials to a target site, the lipid bilayer of liposomes should be able to 
readily fuse with the lipid bilayer of cell membrane. So by direct cell fusion, liposomes can deliver 
their contents (Kamps and Scherphof, 2003). Apart from cell fusion, liposomes also deliver their 
contents by diffusion mechanism. For instance, in case of pH sensitive liposomes, inner and outer 
pH values play important role and charged drugs can easily come out from the liposome membrane 
by pH-dependent diffusion mechanism (Ishida et al., 2006). In some cases, liposomes are used to 
target the endocytosis process by macrophagocytes. In that macrophages engulf liposomes with a 
particular size and this process releases the liposomes drug contents (Scherphof and Kamps, 2001; 
Scherphof and Kamps, 1998). Moreover, liposomes directly discharge their contents through 
Chapter 1-Introduction 
 
23 
 
adsorption mechanism (Kamps and Scherphof, 2003), and also deliver DNA material into the host 
cell membrane by transformation or transfection (Daemen, 1998). Fig 1.2 represents the possible 
ways by which liposomes can release their contents.  
 
 
 
Fig 1.2: Possible ways by which liposomes can release their contents [taken from 
(Kamps and Scherphof, 2003)]. 
 
1.2.2. Morphological aspects of liposomes  
 
Liposomes are termed as an ideal system for the study of the properties of contemporary 
biomembranes due to their close resemblance to biological membranes and, in studies examining 
the appearance, performance and the origin of cellular life (Monnard and Deamer, 2001; Mozafari 
et al., 2004; Pozzi et al., 1996). Just like biomembrane, liposomes are made up of phospholipids. 
These phospholipids contain phosphatidylcholines (PC), phosphatidylethanolamines (PE) and 
phosphatidylserines (PS) (Chapman, 2006). Phospholipids are amphiphiles which possess a 
hydrophilic head group and a hydrophobic tail group (Fig 1.3). The hydrophobic tail group is 
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composed of two fatty acid chains (10-30 carbon length) and the hydrophilic head group usually 
consists of negative charged phosphate group along with polar groups. As being amphiphiles in 
nature, structures like liposomes form instantly (Fig 1.3) when  placed in water, the hydrophilic 
head groups are easily attracted to water and assemble to form a surface facing the water whereas 
the hydrophobic tail groups are repulsed by water, and rearrange to form a surface away from the 
water (Frézard, 1999). The instant formation of liposomes not only forms the closed lipid bilayers 
within a lamellar arrangement (where hydrophobic tail group are sandwiched between the 
hydrophilic head group of phospholipids) but also passively entraps the aqueous media as 
phospholipids are placed in water. Because of this, the solutes such as drugs, enzymes, proteins, 
antibiotics and nucleic acids presented in polar solvent can easily be entrapped within these 
liposomes. As a result the entrapped materials are easily protected from surroundings and delivered 
to the appropriate site in order to give therapeutic effect (Gregoriadis, 1976). In short, liposome can 
encapsulate and efficiently deliver both hydrophilic and lipophilic substances (Akbarieh et al., 
1992; Fielding, 1991) and may be used as a non-toxic vehicle for insoluble drugs (Lidgate et al., 
1988).    
 
     
                                                                                                                                
                                       Aggregation of Phospholipids in water                    Formation of liposomes                          
                                                       
                                                                                   Liposome 
Fig 1.3: Schematic representation of vesicle formation from phospholipid. 
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Liposomes are categorized by their number of lamellae, lipid content and particle size distribution. 
All these factors dictate their stability and interaction capabilities.  
 
Based on the structure, they are classified into multilamellar vesicles (MLV), small unilamellar 
vesicles (SUV), large unilamellar vesicles (LUV), oligolamellar vesicles (OLV) and multivesicular 
vesicles (MMV) (O’Doherty, 2004) (Fig 1.4). Both small unilamellar vesicles (SUV) and large 
unilamellar vesicles (LUV) have one lipid bilayer. Therefore they are termed as unilamellar 
vesicles (ULV) (Perezsoler, 1989). Due to one lipid bilayer ULV enclose large central aqueous 
media. These characteristics are ideally suited for the encapsulation of water soluble agents 
(Harrington et al., 2002). 
 
 
Fig 1.4: Schematic representation of types of liposomes based on their size [adapted from 
(Liposome Quotes, (2013)]. 
 
a) Multilamellar vesicles 
MLV have diameters above 500 nm and, normally consist of five to twenty lipid bilayers. Because 
of bigger size and concentric phospholipid bilayer membranes, MLV internally acquire small 
aqueous compartment and higher lipid/aqueous distribution ratio (O’Doherty, 2004). Therefore 
they are good for encapsulation of lipid soluble agent i.e. hydrophobic drugs (Harrington et al., 
2002). These liposomes are very useful in the case of cancer therapy as most of the cytotoxic drugs 
are hydrophobic (Leylandjones, 1993). MLV are easily cleared by Reticuloendothelial System ( 
RES) and useful for targeting cells of RES (Sharma and Sharma, 1997). They are very stable 
compared to SUV. During formation step, MLV reorganize themselves in random order which is 
why the size of MLV cannot be controlled (Gregoriadis et al., 2002). 
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b) Small unilamellar vesicles  
SUV are vesicles that have size between 20 to 100 nm and considered as the smallest vesicles 
compared to all other vesicles. They have a single bilayer structure enclosing small aqueous core. 
SUV capture limited amount of hydrophilic macromolecules due to higher curvature and lower 
lipid/aqueous distribution ratio (Liu, 2000). However expert in Jena University (Decker et al., 
2013) used SUV for the delivery of lipophilic drugs. SUV are not easily cleared by RES and have 
long half-life (16 h) compared to MLV (Senior and Gregoriadis, 1982).  
 
c) Large unilamellar vesicles 
LUV vesicles are vesicles that usually have a diameter range greater than 100 nm. Like SUV, they 
have a single lamella and lower lipid/aqueous distribution ratio. Therefore they offer optimal 
loading capacity for water soluble drugs and lower capacity for lipid soluble drugs (Liu, 2000). 
They are rapidly cleared by Reticulo-endothelial system (RES), even though they have ability to 
entrap large percentage of hydrophilic drugs and possess a high aqueous space-to-lipid ratio (Szoka 
and Papahadjopoulos, 1978). 
 
d) Oligolamellar vesicles (OLV) 
OLV vesicles are vesicles that have large central aqueous core surrounded by five lipid bilayers. 
The Oligolamellar vesicles vary in size from 0.1 to 1µm. They are composed of several lamellas 
(Sherril D. Christian, 1995). In 1978, Szoka and Papahadjopoulos (Szoka and Papahadjopoulos, 
1978) used reverse phase separation technique in order to generate oligolamellar vesicles. These 
carriers are easily attacked by RES. Moreover, preclinical and clinical pharmacology studies 
showed that oligolamellar vesicles are deficient in the stability required to deliver drug to target 
organs (Lasic and Papahadjopoulos, 1998). Therefore, these lipid vesicles are not ideal choice for 
drug delivery.  
 
e) Multivesicular vesicles (MVV) 
Multivesicular vesicles are vesicles that have multicompartmental structure and the usual diameter 
is above 1000 nm (Rongen et al., 1997). 
 
Apart from the size, based on interaction mechanism, liposomes are generally classified into three 
main categories such as conventional liposomes, sterically stabilised liposomes (stealth liposomes) 
and polymorphic liposomes (Gregoriadis, 1976).  
 
a) Conventional liposomes are made up of simple lipid bilayers having phosphatidylcholines and 
cholesterol.  
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b) Stealth liposomes or sterically stabilized liposomes consist of lipid bilayers that can be coated 
with polyethylene glycol. Polyethylene glycol coating not only stabilises the lipid bilayer but also 
protects the liposomes from macrophages and RES. Consequently, stealth liposomes, compared to 
conventional liposomes, are retained longer in blood. Basically stealth liposomes are inert type of 
material and non-reactive towards the surrounding.   
 
c) Polymorphic liposomes are also known as activosome. They are very reactive towards specific 
agents. External stimuli alter the morphology of these liposomes. Categories such as cationic 
liposomes, pH sensitive liposomes, immunoliposomes, fusogenic liposomes and target specific 
liposomes are included into this. For instance cationic liposomes for nucleic acid delivery (Lasic D 
., 1996). As a delivery system of gene, cationic liposomes have several advantages. Firstly, the 
positive charged liposomes are easily biodegradable after administration in vivo. Secondly, the lipid 
composition-dependent modulation of surface charge density can regulate the interaction forces 
with negatively charged nucleic acids (Shim et al., 2013). Additionally, the insertion of lipophilic 
drugs in the lipid bilayers of cationic liposomes can deliver both anticancer drug and therapeutic 
nucleic acids (Shim et al., 2011)  As a result, cationic liposomes have been considered for the 
delivery of plasmid DNA (Hofland et al., 1996), Aptamers (Xiong et al., 2011) and siRNA (Barron 
et al., 1999). 
 
In this way, vesicles bilayer structure and interaction mechanism decide the types of liposomes. 
However it is important to understand how these different types of liposomes are generated, their 
characterization techniques and physicochemical attributes of liposomes play crucial role in the 
formulation and pharmacokinetics of liposomes.  
 
1.2.3. Preparation of liposomes 
 
Since 1965, numerous methods have been employed for formulation of liposomes. Among these, 
fifteen are most important methods (Lasch et al., 2003; Barenholz and Lichtenberg, 2009). Below 
is the list of common methods used to generate different types of vesicles (Fig 1.5). 
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Fig 1.5: Schematic representation of preparation of liposomes via different techniques 
[adapted from (Lopes et al., 2013)]. 
 
a) Thin Film Hydration Method (Bangham Method) (refer to Fig 1.5) 
Thin film hydration method, also termed as Bangham method (Bangham et al., 1965), is a simple 
technique to generate MLV. The method involves the introduction of phospholipids into a mixture 
of solvents (i.e. chloroform/methanol) that is then evaporated by vacuum. When the solvent is 
completely removed, the phospholipids are dried on the walls of the round bottom flask as a thin 
film. This thin film is then hydrated with aqueous phase. Instantly, phospholipids are hydrated and 
lamella like structure grow into thin lipid tubules (Lasch et al., 2003).Those are very hard to detach 
from the wall of round bottom flask (RBF). Merely mechanical agitation such as vortexing, 
swirling, shaking etc. induce the thin lipid tubules to split and repack the hydrophobic edges of 
lipid tubules into a big spherical liposome i.e. MLVs. As mentioned earlier these big spherical 
liposomes are composed of five to twenty lipid bilayers (onion like structure) that internally acquire 
small aqueous phase (O’Doherty, 2004). 
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b) Ultrasonication (refer to Fig 1.5) 
This method is also termed as ultrasonic irradiation (Barenholz and Lichtenberg, 2009). 
Traditionally ultasonication was the first mechanical treatment that involved the sonication of 
aqueous phosphatidylcholine dispersions (MLV) (Papahadjopoulos and Watkins, 1967). The 
method involves the formation of MLV by thin film hydration technique as described in thin film 
hydration method section above. Furthermore, with the help of ultrasonic irradiation above the 
(phase transition) Tc of phospholipids, opalescent dispersions of phosphatidylcholine (MLV) turned 
into the clear dispersions of phosphatidylcholine. These clear dispersions of phosphatidylcholine 
are due to formation of SUV (Barenholz et al., 1977; Huang, 1969). Ultrasonic irradiation is done 
by two methods –probe sonication and bath sonication (Lasch et al., 2003). In the case of probe 
sonication, the sonicator tip is directly immersed into the phospholipids dispersions whereas in the 
bath sonicator, phospholipids dispersions in a tube or beaker are positioned into bath sonicator. 
Probe sonication is the most commonly used method for the preparations of SUV. This method is 
very fast and can be directly applied to MLV dispersions because of higher energy output (Johnson 
et al., 1971; Papahadjopoulos and Watkins, 1967). But probe sonication has limitations such as, 
SUV dispersions is formed along with contamination of metal ions such as titanium particles that 
come from tip of  probe, and temperature of MLV is not fully controlled due to open system as 
probe  is immersed into the MLV dispersion (Barenholz and Lichtenberg, 2009). SUV that are 
produced by ultrsonication are usually metastable (Lasch et al., 2003). 
 
c) Extrusion (refer to Fig 1.5) 
Large unilamellar vesicles can be prepared by extrusion. Extrusion is a technique in which 
micrometric liposomes, such as MLV suspensions, are forced through polycarbonate filters (100 
nm of pore size) to generate LUV possessing diameters near the pore size of the polycarbonate 
filters used (Hope et al., 1986; Olson et al., 1979). Preceding extrusion through the polycarbonate 
filters, MLV suspensions are generally disrupted either via several freeze-thaw cycles or via 
prefiltering of the MLV suspensions. This process thwarts the lipid membranes from fouling and 
recovers particle size distribution homogeneity of the final suspension. 
 
d) Freeze-dried rehydration vesicles 
With the aim of increasing the entrapment efficiency of preformed vesicles, (Kirby and 
Gregoriadis, 1984) invented a well-known method called dehydration-rehydration vesicles. These 
vesicles entrap high amount of macromolecules. Ideal freeze-dried rehydration liposomes having 
high amount of proteins are produced by joining three methods (Lasch et al., 2003). The initial 
method in which SUV is successfully produced, is the same as mentioned earlier in ulrasoniaction 
section. The second methodology described by Kirby and Gregoriadis (Kirby and Gregoriadis, 
1984) in which SUV are mixed together with the proteins solution to be entrapped before freeze 
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drying, and then a drying step causes close intact of the lipid bilayers and proteins. During 
rehydration-dehydration step, SUV become destabilised and by fusion, freeze-dried rehydration 
liposomes entrapping high amount of proteins are obtained. Last method is extrusion method in 
which homogenization and size reduction of freeze-dried rehydration vesicles is done by 
polycarbonate filters.  
 
e) Reverse- phase evaporation techniques 
During 1978, Szoka and Papahadjopoulous (Szoka and Papahadjopoulos, 1978) successfully 
introduced reverse-phase evaporation method and developed reverse phase vesicles (REV) such as 
LUV and oligolamellar vesicles. These liposomes have the ability to entrap large percentage of 
hydrophilic drugs and possess a high aqueous space-to-lipid ratio. A range of lipids or lipid 
mixtures including cholesterol can be used to prepare REV and possess higher aqueous–to-lipid 
volume ratio as compared to SUV and MLV  (Lasch et al., 2003; Smirnov, 1984).  
 
f)  Ether and petroleum ether vaporization method 
This method is also termed as ether and petroleum ether infusion method (Barenholz and 
Lichtenberg, 2009). In this method, a single lamella is produced through the injection of 
phospholipids dissolved in an organic solvent into a large amount of hot water which is heated to    
60 0C. Due to high temperature, instant evaporation of organic solvent, i.e. evaporation of an ether 
or petroleum ether, causes the phospholipids to aggregate and form osmotically active single 
lamella that has a high aqueous space-to-lipid ratio (Cortesi et al., 1999; Barenholz and 
Lichtenberg, 2009). In 1972, Chowhan et al. (Chowhan et al., 1972) developed multilamellar 
liposomes through this technique. Later on, Deamer and Bangham (Deamer and Bangham, 1976) 
effectively developed osmotically active large volume liposomes. Volume trapping efficiency of 
these liposomes is nearly ten times more as compared to vesicles obtained through sonication and 
hand shaken techniques.  
 
g)  Detergent depletion 
This method involves the removal of detergent and formation of vesicles lamella. Classically four 
techniques are used for the detergent depletion (Lasch et al., 2003).  
 
1) Dilution (Schurtenberger, 1984) 
2) Dialysis (Milsmann et al., 1978) 
3) Gel filtration (Brunner et al., 1976) 
4) Adsorption (Holloway, 1973) 
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The size of liposomes that are obtained through detergent depletion techniques fully depends on the 
types of phospholipids and detergent. On lesser extent it depends on the method employed for the 
detergent depletion (Barenholz and Lichtenberg, 2009). This technique is extremely flexible. This 
facilitates the formation of various liposomes and recombinant proteoliposomes (Ollivon et al., 
2000). Most of the techniques like extrusion and sonication can sometime physically affect the 
functional properties of proteins and enzymes. On the safer side detergent depletion is very gentle 
and retains the nature of sensitive proteins and enzymes. Sodium cholate and alkoxypolyethylenes 
are most popular detergents that are frequently used in the detergent depletion technique (Matz and 
Jonas, 1982).   
 
h)  High pressure homogenization 
High pressure homogenization is achieved by different types of homogenizers. This method 
involves the passage of liposomes suspension through a sequence of nozzles of homogenizers 
(Barenholz and Lichtenberg, 2009). Due to high shear of nozzles, liposomes suspension is broken 
down into the desired liposomes. As per the size requirement of liposomes, nozzles size can be 
attuned. Homogenizers that are used for liposomes preparation are mainly categorised into three 
types (Lasch et al., 2003). 
 
1) The APV homogenizer 
2) Microfludizer 
3) Ultra-Turrax homogenizer 
 
Practically Homogenizers are important tool and are utilised for the liposome preparation in three 
common ways. 
1. In the first place liposomes are produced and then passed into the homogenizer to obtain 
the desired size of lamella. e.g. multilamellar vesicles (Mayhew et al., 1985) or dehydrated-
rehydrated vesicles (Gregoriadis, 1990). 
2. Production of excess amount of SUV (Brandl et al., 1990). 
3. Ether evaporation method as mentioned earlier homogenizers are used to homogenize the 
preparation of phospholipids dissolved in organic solvent that are later injected into the 
warm water. 
 
i)  Interdigitation fusion method 
Production of LUV via interdigitation fusion method was introduced by (Ahl et al., 1994). The 
method involves the addition of ethanol into the SUV which is further heated above the main 
transition temperature of vesicles. All these conditions cause bilayer interdigitation and LUV is 
generated. The phase transition temperature of vesicle (Tc or Tm), i.e. the temperature that is 
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essential for inducing the vesicle melting from a solid-ordered (gel) to a liquid-disordered (fluid) 
phase. The phase transition temperature of liposomes can be easily measured by calorimetry 
(Enders et al., 2004), magnetic resonance spectroscopy (YashRoy, 1990) and surface tension 
measurement (Gugliotti et al., 1998). Interdigitation fusion method is a very simple technique and 
the produced LUV have the ability to entrap large percentage of hydrophilic drugs (Smith et al., 
2007). One of the main objectives of this research is to prepare photosensitive LUV by 
interdigitation fusion method.   
 
Apart from these methods, methods such as calcium induced fusion in order to prepare LUV by 
EDTA (Papahadjopoulos et al., 1975); production of LUV by using nonelectrolyte solution (Reeves 
and Dowben, 1969); lyophilization or freeze drying techniques for the production of MLV (Szoka 
and Papahadjopoulos, 1980) are also used for the preparation of liposomes. Following the liposome 
preparation, it is also essential to characterize these vesicles. Characterization of liposomes 
provides information on the stability of the formed vesicles.  
 
1.2.4. Characterization of liposomes  
 
Different methods are used to characterize liposomes and they are classified as physical 
characterization and chemical analysis of liposomal components (Zuidam, 2003). 
 
1.2.4.1. Physical characterization 
 
Physical characterization of liposomes includes parameters such as the vesicles size distribution, 
zeta potential, lamellarity determination and entrapment efficiency of liposomes.  
 
a. Vesicle size distribution 
The size and size distribution of vesicles are very important and play a key role in parental drug 
delivery (Guiot et al., 1980; Vemuri et al., 1990). Liposome stability entirely depends on size and 
size distribution of vesicles. Several methods are used for the determination of vesicles size. One of 
the well-known approaches is electron microscopy. Electron microscopy such as freeze fracture 
microscopy is a precise method that allows one to view each individual vesicle. Visual inspection 
of liposomes is becoming easier with this techniques (Hope et al., 1985), but it is time-consuming. 
Another method which comes into this category is laser light scattering analysis. Liposomes up to 1 
µm can easily be determined by this method with instruments such as MastersizerTM, Sympatec 
GMBH Zetasizer (Germany) etc. The technique is dependent upon the dynamic scattering 
phenomena. In theory particles are suspended into a solution and then illuminated by a laser light. 
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As the index of refraction of particles is different from the index of refraction of suspending 
medium, particles scatter laser light and give signal to noise ratio (Bezot et al., 1978; Cummins and 
Pike, 1974). The limitation associated with this technique is insufficiency in determining 
aggregates of more than one particles. It considers them as single particle. Photon correlation 
spectroscopy also comes into this category. This is useful for the determination of small vesicles 
and is wbased on the Brownian motion of suspended particles (Ostrowsky, 1993). All these 
methods require expensive equipment. Last not least method that falls into this category is gel 
exclusion chromatography (Barenholz and Amselem, 1993; Lesieur et al., 1993; Sommerville  and 
Scheer, 1987). The requirement of this technique is gel materials and buffer. 
 
b. Zeta potential 
Another important factor which characterizes the liposomes is zeta potential. Lipid vesicles in 
solution always carry an electrical charge depending on the type of lipid composition (cationic 
lipid, anionic lipid and neutral lipid). This is termed as zeta potential and it is determined by 
measuring the velocity of particles (Cevc, 1993), e.g. ZetasizerNano ZS (Malvern,UK), Zetaplus 
(Brookaven,USA) etc. It also determines strength of attractive force and repulsive forces within the 
particles. In general zeta potential plays crucial role in liposome stability and drug delivery 
(Mozafari, 2009).  
 
c. Lamellarity determination 
As mentioned earlier in liposomes classification, lamellarity of liposomes can determine the type of 
liposomes. This lamellarity formation depends on the type of lipid and the method of preparation 
(Edwards and Baeumner, 2006) .Various techniques such as derivatization of the outer surface of 
bilayer; Nuclear magnetic resonance (NMR), Small-angle X-ray scattering (SAXS) and electron 
microscopy are used for the lamellarity determination (Zuidam, 2003). The derivation of the outer 
surface of bilayer is achieved through the combination of chemical method with spectroscopy. 
Procedures involve the production of trinitrophenylated (TNP)-phosphatidylethanolamine (PE) and 
measurement of this product by spectroscopy (Barenholz et al., 1977). Other technique used for 
lamellarity determination is nuclear magnetic resonance (NMR). In this, lamellarity determination 
is fully based on the addition of positively charged manganese ions (Mn2+) into the liposomes 
(Hope et al., 1985). In theory, liposomes are made up of phospholipids. All phospholipids head 
group contains phosphates that carry negative charge. When the manganese ions are added into the 
liposomes, they react with phosphorous which is situated on the outer surface of lamella and give 
broadened peak. The phospholipids head group which is located inside the vesicles does not react 
with manganese and give normal phosphate peak. Comparison between the broadened and normal 
peaks can easily determine the liposome lamellarity. A serious limitation of this technique in case 
of negatively charged liposmes is that positively charged manganese ions can provoke the fusion of 
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liposomes and give false results. Lamellarity is also characterized by electron microscopy 
(Sommerville  and Scheer, 1987) and small angle X-ray scattering (SAXS) (Bouwstra et al., 1993). 
SAXS allows the determination of the structure of individual vesicles aggregates as well as the 
structure of vesicular dispersions (Petoukhov and Svergun, 2013). SAXS also measure the 
membrane thickness and the bilayer–bilayer separation. The basic principle behind SAXS analysis 
is to scatter X-ray photons elastically off molecules in solution and to record the scattering intensity 
as a function of the scattering angle (Schmidt, 1971). This technique is very ideal, as this is non-
invasive and allow the characterisation of complex surfactant fluids in their natural state (Blanchet 
and Svergun, 2013).  
 
d. Entrapment efficiency of liposomes 
Entrapment efficiency of liposomes is commonly measured by entrapping water soluble markers 
such as radiolabel markers ([14 C] glucose, [14 C] Inulin,[99mTc]DTPA); enzymatic markers (soybean 
trypsin inhibitor, Superoxide dismutase) and fluorescent markers (Fluroscein, Calcein)(Zuidam, 
2003). The detection techniques which are used for the quantification of these hydrophilic markers 
are spectroscopy (NMR, electron spin resonance (ESR)), fluorometry, enzyme based assay, 
chromatography (gel exclusion chromatography, column chromatography, ion exchange 
chromatography), ultracentrifugation and electrochemical methods (Jesorka and Orwar, 2008; 
Madden et al., 1990). The mechanism behind the determination of entrapment efficiency of 
liposomes is very simple and straightforward. The liposome formulation contains both untrapped 
and trapped drug materials (Vemuri and Rhodes, 1994b; Vemuri and Rhodes, 1994a; Vemuri and 
Rhodes, 1995; Vemuri et al., 1990). The untrapped drug materials are also termed as free drug 
materials. Usually these untrapped drug materials are separated from the trapped drug materials by 
ultracentrifugation. Then the trapped materials are treated with lysis agent such as Triton x-100 and 
isoproponol. On the addition of these lysis agents, the fraction of drug materials released from the 
vesicles into the solvent is then quantified by spectroscopy and chromatography (Vemuri and 
Rhodes, 1994b). 
 
1.2.4.2. Chemical analysis of phospholipids 
 
By using chromatography and chemical assays, the phospholipids are easily characterized 
(Chatterjee and Banerjee, 2002). The table 1.1  illustrates the techniques used for the chemical 
analysis of phospholipids (Zuidam, 2003). 
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Table 1.1: Characterization techniques for the determination of phospholipids 
 
 Chemical stability Techniques 
1. Hydrolysis of phospholipids HPLC, HPTLC 
2. Determination of  amount of non- esterified fatty acids enzymatic assay, HPLC 
3. Autoxidation of phospholipid acyl chain Conjugated dienes, 
lipid peroxides, 
4. Autoxidation of cholesterol TLC, HPLC 
5. Degradation of active compounds TLC, HPLC 
6. Degradation of antioxidant TLC, HPLC 
 
 
In this fashion liposomes are prepared and characterized. But apart from the method of preparation, 
the study of another parameter i.e. physicochemical attributes of vesicles are imperative.  
 
1.2.5. Physicochemical attributes of vesicles  
 
Modifications in physicochemical attributes of vesicles not only influence the liposome 
formulation and stability, but also the drug encapsulation and pharmacokinetic behaviour of 
liposomes in vivo. This involves factors such as vesicles size and lamellarity, surface charge, dose 
of lipid, vesicles composition and structure, steric stabilization (Drummond et al., 1999; Lasic et 
al., 1992; Sharma and Sharma, 1997). 
 
a) Vesicle size and lamellarity 
The first influential factor which alters the pharmacokinetics of liposomes in vivo and drug 
permeability is vesicle size and lamellarity (Drummond et al., 1999; Yamauchi et al., 2007). The 
liposomes which are prepared by extrusion technique contain defined size ranging from 0.1 to 0.2 
μm (Szoka et al., 1980). But the actual diameters of these liposomes prepared through extrusion are 
always greater (20-50 %) than the pore size of nanoporous filters. Due to this increment these large 
vesicles are easily cleared out by RES through opsonisation (Hwang, 1987; Senior, 1987). This 
work is also supported by (Klibanov et al., 1991), and they proved that liposomes with diameters 
higher than 200 nm are easily cleared by RES as compared to the liposomes with diameters less 
than 100 nm. The rate of clearance also depends on the lipid composition. In most cases the lipid 
geometry can increase the size. For instance MLV containing phosphatidylcholine, cholesterol and 
dicetyl phosphate in the ratio of (7:2:1) are rapidly cleared out by RES (Gregoriadis and Ryman, 
1972). In diseases like cancer, liposomes containing vesicles size between 100 nm and 200 nm are 
easily permitted into the tumour tissue as compared to the liposomes containing vesicle size greater 
Chapter 1-Introduction 
 
36 
 
than 200 nm (Mayer et al., 1989; Papahadjopoulos et al., 1991). In addition, liposome size and 
lamellarity also influence the drug permeability. It has been shown that larger vesicles retain 
vincristine for longer period with slow the release (Yamauchi et al., 2007). Following NMR and 
trap volume measurement they have concluded that larger vesicles have greater size that ultimately 
gives the rigidity to the liposomes and slow the permeability of drug.  
 
b) Surface charge 
The second aspect of liposomes that amend the liposome stability, pharmacokinetics of liposomes 
in vivo and vesicles-cell interaction is the surface charge of liposomes (Drummond et al., 1999; 
Sharma et al., 1993b; Sharma and Straubinger, 1994). Liposomes are made from cationic lipids, 
anionic lipids and charge free lipids. Among these the liposomes which are made from charge free 
lipids are unstable and aggregate easily. For example, charge free lipids in case of SUV lead to 
aggregation due to their low surface potential (Sharma and Straubinger, 1994) whereas liposomes 
which are made up from cationic and anionic lipids do not form any aggregates. The reason behind 
this is the formation of electrical double layer in these formulations. As per DLVO, electrical 
double theory, similar charged lipid particles repel each other and avoid fusion (Russel, 1989). 
Numerous investigations have proved that liposomes resultant from the anionic lipids such as 
phosphatidylserine (PS), phosphotidylglycerol (PG) and phosphatidic acid (PA) are easily cleared 
by mononuclear phagocyte system (MPS) (Drummond et al., 1999; Senior, 1987). A detailed study 
on the clearance of charged liposomes has been done on mice by (Gabizon and Papahadjopoulos, 
1992). In this study liposomes containing anionic lipid were cleared by MPS in the following order 
(Phosphatidylserine>phosphatidic acid >phosphotidylglycerol). But the incorporation of another 
sterically shielded negatively charged lipid i.e. PEG-PG conjugate increased their half-life (t1/2) 
(Drummond et al., 1999; Papahadjopoulos et al., 1991). Liposomes containing neutral lipids are not 
easily cleared by MPS (Sharma et al., 1993b), in spite of the fact that they avoid the significant 
reaction with the cells. Therefore it is difficult to deliver drugs through these types of liposomes 
and only after leakage they can enter into the cell (Sharma and Sharma, 1997). Liposomes 
containing negatively charged lipids easily react with the cells / blood components and by 
endocytosis mechanism they release their contents into the blood (Sharma et al., 1993a). 
Liposomes resulting from cationic lipids significantly interact with cell membrane and through 
liposome-cell fusion mechanism they can deliver their contents into the cell (Felgner et al., 1994). 
Cationic lipids are usually used for gene delivery because of the polyanionic nature of DNA 
(Balazs and Godbey, 2011; Hofland et al., 1996). Briefly, Cationic lipids commonly acquire a 
positive charge through one or more amines that are present in the polar head region. This 
positively charge facilitates electrostatic binding with anions such as those found in DNA 
(Ruponen et al., 1999). 
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c) Dose of lipid 
The administered dose of lipid influences the pharmacokinetic behaviour of liposomes (Drummond 
et al., 1999). Half-life of conventional liposomes can be increased by a dose dependent process. 
Numerous experiments have established that an increment in the dose of liposomes reduces their 
plasma opsonisation and increases their half-life indicating saturation mechanism liable for their 
RES uptake or non-linear pharmacokinetics (Abra and Hunt, 1981; Drummond et al., 1999; Senior 
et al., 1985). In contrast, sterically stabilised liposomes such as1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol) (DSPE-PEG)  are potential for liposomal 
drug delivery because their linear pharmacokinetics of plasma clearance is independent of dose and 
half-life remains unaffected with larger dose (Allen and Hansen, 1991; Beaumier et al., 1983; 
Drummond et al., 1999). 
 
d) Vesicles composition and structure 
Apart from the vesicle size and surface charge, vesicle bilayer composition and choice of 
phospholipids play major part in manufacturing, stability and in vivo performance of liposomes. 
Liposomes are made up of phospholipids. The therapeutic activity of liposomes depends on the 
type of phospholipids. Five different types of phospholipids are available so far and are used to 
make liposomes (Barenholz and Crommelin, 1994; Kriftner, 1992; O’Doherty, 2004). These are 
outline as follows:  
 
1. Phospholipids derived from natural sources- Phospholipids such as phosphotydylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylinositol (PI) and sphingomyelin (SPM) fall into this 
category and they are obtained from two natural sources; egg and soya. Structurally, they are 
mixture of acyl ester phospholipids and unsaturated acyl chains, retaining double bond in the cis 
form. Acyl chain position can distinguish phospholipids from egg and soya (Lichtenberg and 
Barenholz, 1988).  
 
2. Phospholipids modified from natural sources- these are the phospholipids that are readily 
obtained by performing modification in already existed natural phospholipids. Modification 
involves partial or full hydrogenation of the natural phospholipids; and resultant phospholipids 
possess high transition temperature with shorter unsaturated structure .e.g translation of 
phopshatidylcholine into phosphatidylethanolamine (Eible, 1981). 
 
3. Semi-synthetic phospholipids- these are commercially obtained after replacing the acyl chain 
assembly of natural phospholipids with defined acyl chain (O’Doherty, 2004) e.g. conversion of 
phosphatidylcholine to 1,2-dipalmitoyl-sn-glycero-3-phosphocholine. 
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4. Fully-synthetic phospholipids- these types of phospholipids are generally prepared by synthesis 
e.g. erucylphosphocholine (ErPC) is a more effective drug than hexadecylphospholine (HePC) for 
systemic intravenous treatment of cancer (Eibl and KaufmannKolle, 1995). This is due to the fact 
that ErPC have a longer 22 carbon chain with a ω-9-cis-double bond as compare to HePC (Berger 
et al., 1998). This structural alteration resulted in reduced hemolytic activity, thereby facilitating 
intravenous administration (Kaufmann-Kolle et al., 1996). Furthermore, the erucylphosphocholine 
(ErPC) effectiveness can also be explained by the fact that ErPC generate preferentially lamellar 
structures in aqueous solutions instead of micelles (van Blitterswijk and Verheij, 2013). Fully-
synthetic phospholipids offer many advantages including that the composition of fatty acids 
remains unchanged. In addition, the phase transition temperature and bilayer fluidity of 
phospholipids are easily adjusted by selecting proper acyl chain and degree of saturation. But the 
preparation of fully synthetic phospholipid is very expensive and that is the limitation.  
 
5. Phospholipid with non-natural headgroups – in this approach, the head groups of phospholipids 
are derivatised with other agent. So far in case of immunoassays, phospholipids with non-natural 
headgroups such as avidin and streptavidin are used as generic liposome labels. For instance biotin 
conjugated lipids such B-PE can be built on liposome membrane (Rongen et al., 1997). 
 
Selections of proper phospholipids are essential. It not only plays a key role in case of bilayer 
rigidity but also to release of entrapped drug materials from the liposomes. For instance, fully 
synthetic phospholipid molecule, i.e. erucylphosphocholine (ErPC), is very effective for cancer 
treatment compared to hexadecylphospholine (HePC) (Eibl and KaufmannKolle, 1995). 
Phospholipids are lipids and they all possess special thermal characteristics including a phase 
transition temperature (Tc), and the temperature below and above the phase transition temperature 
(Tc) can decide their physical states such as gel like phase (solid form) exist below the (Tc) and sol 
like phase (liquid crystalline form ) exist above the (Tc) (Deb, 2001). This phase behaviour can 
significantly affect the drug release mechanism from liposomes as well. By elevating the 
temperature of liposome preparation, the gel form of phospholipid bilayer melts and is transformed 
into the liquid form and that leads the release of entrapped drug materials (Fig 1.6) (RRC, 1990).  
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             Gel consistency                                               Liquid crystalline consistency  
                                                                                     
        Solid ordered phase (below Tc)                                  Disordered phase (above Tc) 
 
Fig 1.6: The phase behaviour of lipid bilayer with increased temperature. 
 
 
The phase transition temperature (Tc) of a phsopholipid bilayer depends on four variables: 
 (Mozafari, 2009) 
 
I. Degree of saturation of the hydrocarbon chains  
II. Polar head group.  
III. Length of acyl chains 
IV. Strength and ionic nature of the suspension medium. 
 
Therefore, in theory, the phase temperature (Tc) of liposomes can be lowered by decreasing the 
length of acyl chains, unstauration of the acyl chains and the presence of bulky polar head groups 
(Szoka and Papahadjopoulos, 1980). Furthermore, Tc can fluctuate between 15 0C for egg yolk 
phosphatidylcholine equipped with high degree of unsaturation of the hydrocarbon chains to above 
50 0C for fully saturated distearolylphosphatidylcholine (DSPC) (Barenholz and Crommelin, 1994; 
O’Doherty, 2004). Phase transition temperature is essential in the case of liposome formulation and 
that is why liposomes are not obtained at temperatures below the phase temperature of 
phospholipids. With cholesterol addition, it is decreased to some extent, but not excluded 
(Leserman et al., 1994). Most of the experiments have also suggested liposome formulation to be 
conducted at temperatures well above the phase transition temperature of phospholipids. For 
 
 
           
 
 
          ∆ 
          Heat 
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example the phase temperature of dipalmitoylphosphatidylcholine (DPPC) is 41 0C and it has been 
recommended that liposomes formulation will be conducted at 10 0C greater than the phase 
temperature of DPPC i.e. 51 0C (Jurimaromet et al., 1990; Jurimaromet et al., 1992). A study of 
phase transitions and fluidity of phospholipid membranes is very important as they affect 
phospholipid-cell interaction in vivo. Liposomes which are composed of higher (Tc) phospholipids 
appear to have lower rate of clearance by RES as compared to liposomes possessing low (Tc) 
phospholipids (Gabizon and Papahadjopoulos, 1988). However inclusion of steroid molecule, i.e. 
cholesterol, into the bilayer of membrane can significantly maintain the bilayer stability and 
increase half-life of liposomes in vivo (Drummond et al., 1999; Kirby et al., 1980; Senior and 
Gregoriadis, 1982; Senior, 1987).  
 
e) Steric stabilization- 
Steric stabilization is the process in which liposomes are coated with a small fraction (5-10 mole 
%) of hydrophilic materials such as monosialoganglioside (GM1), phosphatidylinositol (PI) and 
polyethylene glycol conjugated with phospholipid (PEG-DSPE). This process of inclusion of 
hydrophilic materials in liposome preparation makes liposomes sterically stabilised and hence 
prevent the liposomes interacting with cell and blood proteins (Allen and Chonn, 1987; Allen et al., 
1985; Gabizon and Papahadjopoulos, 1988; Papahadjopoulos et al., 1991). As these liposomes 
avoid the interaction with cells and blood proteins, they will not be cleared by RES and are 
therefore considered as long circulating liposomes (Allen et al., 1985; Needham et al., 1992; 
Papahadjopoulos et al., 1991). One of the great advantages of these sterically stabilised liposomes 
is their unsaturablity and linear pharmacokinetics (Allen and Hansen, 1991; Beaumier et al., 1983; 
Drummond et al., 1999). 
 
1.2.6. Applications of liposomes in drug delivery 
 
From the drug delivery point of view, Liposomes are one of the safest nanocontainer when 
compared to other nanomaterials (e.g. quantum dots, nanowires etc.). Thus, it is widely used in 
several drug delivery system such as gene (Barron et al., 1999) and cancer drug delivery (Priebe 
and Perez-Soler, 1993), skin drug delivery and other clinical purpose (Samad et al., 2007). 
 
1.2.6.1. General considerations of clinically approved and emerging liposomes 
 
Liposomes have been studied for a long time (Allen and Hansen, 1991; Beaumier et al., 1983; 
Drummond et al., 1999; Fenske et al., 2008; Fenske and Cullis, 2008). Following these studies, 
liposomes containing neutral and negatively or positively charged phospholipids along with 
cholesterol have been successfully prepared. A Few of these formulations have been approved for 
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use in humans and others have reached Phase I/II/ III clinical trials. Table 1.2 (page 42) illustrates 
some examples of clinically approved liposomes and emerging liposomes for therapeutic use 
(Villaverde, 2011; Elbayoumi and Torchilin, 2009). It is remarkable to mention that DaunoXome 
(liposomes containing anticancer drug Doxorubicin Nexster pharmaceuticals) and Doxil/Caylex 
(PEG-liposomes containing anticancer drug Doxorubicin, Sequus pharmaceuticals) were the two 
honourable liposome based formulations approved for patients in clinics (Allen and Martin, 2004; 
Batist et al., 2001; Davies et al., 2008). 
 
Other primary examples of clinically approved liposome based products are AmBisome (Gilead 
Sciences , FosterCity, USA) which is used to deliver the antifungal drug amphotericin B 
(Veerareddy and Vobalaboina, 2004), Myocet (Elan Pharmaceuticals, USA) which is used  to 
deliver anticancer drug doxorubicin (Alberts et al., 2004). Currently Daunoxome is considered as a 
stable liposomal formulation as this is not cleared by MPS osponization and available in ready- to- 
inject formulation (Immordino et al., 2006).  
 
A number of formulations have also been prepared by combining sphingomyelin phospholipids and 
conventional liposomes (Immordino et al., 2006). For instance novel liposomal formulation 
vincristine (Marqibo Hana biosciences, USA) has been approved as orphan medical products in US 
and Europe and used to treat uveal melanoma (Bedikian et al., 1995). Furthermore, liposomal 
formulations such as INX-0125 (liposomal vinorelbine) (Semple et al., 2005) and INX-0076 
(topotecan) (Tardi et al., 2000) are also used as potential therapeutic agent. Clinical data have 
shown that incorporation of OSI-211 in the acid aqueous core of the vesicle can increases stability 
of the active compound as well as improve its tumour toxicity (Seiden et al., 2004). Therefore, 
OSI-211 (Lurtotecan, OSI Pharmaceuticals,Inc., NY)  has been successfully  used to treat ovarian 
cancers and B-cell lymphoma (Duffaud et al., 2004; Lu et al., 2005). 
 
A large number of MLVs from Neo Pharma Inc. have been used clinically and these include 
liposome formulations such as LEM-ETU (mitoxantrone-entrapped) (Ugwu et al., 2005), LEP-
ETU (paclitaxel-loaded) (Yavlovich et al., 2009; Zhang et al., 2005) and LESN38 (irinotecan- 
encapsulated) (Lei et al., 2004; Pal et al., 2005). Recently, DepoCyt (Pacira Pharmaceuticals, San 
Diego, CA)- a liposomal formulation entrapping cytarabin has been approved for 
neoplasicmeningitis and lymphomatousmeningitis and given by intrathecal route (Glantz et al., 
1999; Jaeckle et al., 2001; Mantripragada, 2002; Phuphanich et al., 2007). Other two MLV 
liposome formulations possessing saturated phospholipids such as dimyristoylphosphatidylcholine 
(DMPC) and dimyristoylphosphatidylglycerol (DMPG) have been approved for clinical use. For 
instance Nyotran® (Aronex Pharmaceuticals, The Woodlands, TX, USA) for treating antifungal 
infection (Anonymous (1999);(Arikan and Rex, 2001) and Aroplatin® (Antigenics Inc., Lexington, 
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MA, USA) for treating B-cell lymphoma (Han et al., 1993; Lu et al., 2005; Verschraegen et al., 
2003). Another remarkable liposomal formulations is made by Aronex Pharmaceuticals named as 
Atragen® which contains the active ingredients tretinoin, dimyristoylphosphatidylcholine (DMPC), 
soybean oil and is very effective against retinoid-responsive cancers and  acute promyelocytic 
leukemia (Ozpolat et al., 2003). 
 
A lipophilic anthracycline antibiotic i.e. Annamycin liposomes is primarily investigated by MD 
Anderson Cancer Institute (Priebe and Perez-Soler, 1993). This formulation has reached Phase II 
clinical trials and is being investigated as potential tool in the treatment of doxorubicin resistant 
breast cancer (Booser et al., 2002). Another potential drug candidate which entered Phase II 
clinical trial is EndoTAG™-1 (MediGene A.G., Martinsried, Germany). This is effective against 
pancreatic cancers (Eichhorn et al., 2006). Apart from this, Visudyne® was approved by FDA in 
2000 and for the first time age related macular degeneration was successfully treated with these 
liposomes. Other clinically approved liposomes are DepoDur® (containing morphine) which is used 
for postoperative pain after surgery; Definity® (containing octafluoropropane) for ultrasound 
imaging; Abelcet® (containing amphotericin- B) for fungal infection and Mepact® (containing 
Muramyl dipeptide) for osteosarcoma. During 2009, Octocogalfa (containing plasma factor VIII) 
has been approved for the treatment of haemophilia A. 
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Table 1. 2: Clinically approved liposomes and emerging liposomes for therapeutic use  
[adapted from (Allen and Cullis, 2013)] 
Marketed 
product 
 Company and   
marketing name 
composition API Target diseases Trial  
status 
DaunoXome® Nexstar 
Pharmaceuticals
, 1995 
DSPC/CHOL Daunorubicin Kaposi’s sarcoma approved 
DOXIL®/ 
Caelyx® 
Sequus 
Pharmaceuticals
, 1997 
SoyHPC/CHOL/DSPE-PEG Doxorubicin Kaposi’s sarcoma Approved 
Myocet®/ 
Evacet® 
ElanPharma, 
2000 
EPC/CHOL Doxorubicin Metastatic breast cancer Approved 
SPI-077 Sequus 
Pharmaceuticals 
SoyHPC/CHOL/DSPE-PEG Cisplatin Head and neck cancer I/II 
Lipoplatin™ Regulon Inc. SoyPC/DPPG/CHOL Cisplatin Several cancer type II/III 
Aroplatin AntigenicsInc DMPC/DMPG Oxaliplatin 
analog 
Colorectal cancer Phase II 
Depocyt SkyePharma 
1999 
DOPC/DPPG/CHOL/ 
triolein 
Cytarabin Lymphoma meningitis Approved 
LEP-ETU NeoPharmInc DOPE/CHOL/cardiolipin Paclitaxel ovarian, breast and lung 
cancer 
Phase I 
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Marketed 
product 
 Company and   
marketing name 
composition API Target diseases Trial  
status 
LEM-ETU NeoPharmInc DOPE/CHOL/cardiolipin Mitoxantrone leukemia, breast cancer Phase I 
LE-SN38 NeoPharmInc DOPE/CHOL/cardiolipin Irinotecan advanced cancer Phase I 
MBT-0206 MediGene AG DOPE/DO- 
trimethylammoniumpropane 
Paclitaxel Breast cancer Phase I 
OSI-211 Enzon Co. SoyHPC/CHOL Lurtotecan Ovarian cancer Head 
and neck cancer 
Phase II 
Marqibo®  Inex Pharm DSPPC/CHOL/sphingosine vincristine Non-Hodgkin’s 
lymphoma 
Phase II/III 
Atragen®  Aronex Pharm DMPC, and soybean oil t-retinoic acid renal cell cancer,  Phase I/II 
INX-0125 Inex Pharm DSPPC/CHOL/sphingosine vinorelbine breast, colon and lung 
cancer 
Preclinical 
Phase I 
INX-0076 Inex Pharm DSPPC/CHOL/sphingosine topotecan advanced cancer Preclinical 
Liposomal-
Annamycin® 
MD Anderson 
Cancer centre  
DSPC/DSPG/Tween Annamycin breast cancer Phase II 
Ambisome®  Fujisawa USA 
Inc. and Nexstar 
Pharm 1997 
SoyHPC/DSPPC/CHOL amphotericin Systemic fungal 
infections.  
Approved 
Nyotran® 
 
Aronex Pharm DMPC/DMPG/CHOL Nystatin Fungal infections Phase II/III 
Visudyne® Novartis,2000 EPG/DMPC Verteporfin Age related macular Approved 
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Marketed 
product 
 Company and   
marketing name 
composition API Target diseases Trial  
status 
(BPD-MA) degeneration 
DepoDur® Endo 
pharmaceuticals,
2004 
DOPC/Cholesterol/DPPG Morphine Postoperative pain after 
surgey 
Approved 
Definity® Dupont 
Merck,2001 
Gd-DTPA Octafluoro- 
propane 
Ultrasound imaging Approved 
Abelcet® Sigma-Tau 
pharmaceuticals,
2009 
DMPC/DMPG/CHOL Amphotericin 
-B 
Fungal infection Approved 
Mepact® Takeda,2009 POPC/OOPS MTP osteosarcoma Approved 
Octocogalfa® Bayer schering 
,2009 
Octogonalfa/POPC/MPEG20
0-DSPE 
factor VIII Haemophilia A Approved 
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In conclusion, to date a few number of liposome based formulations are clinically approved while 
other liposome based formulations are in the queue awaiting clinical trials, even though patient 
treatment can be improved by considering two aspects i.e. drug targeting potential and triggering 
mechanism of liposomes (Yavlovich, 2010) . 
 
1.2.7. Drug targeting potential of liposomes 
 
The requirement for drug targeting emerges when drug enters into blood after intravenous 
injection, then most of the drugs is wasted by distribution to other tissues and organs. A small 
amount of drug reaches to the disease affected area and remaining of the drug causes drug toxicity 
(Fielding, 1991). In order to increase the availability of drugs to the disease affected area and to 
diminish the undesirable side effects of drugs, drug targeting through liposomes is  essential 
(Hwang, 1987; Vadiei et al., 1989) .  
 
Drug targeting through liposomes has successfully been achieved by the use of a variety of ligands 
such as antibodies, hormones, peptides and tagged antibodies. This tagged ligand easily determines 
the exact receptor site and this mechanism pushes liposomes to saturate at such target sites 
(Torchilin, 1985). In this way, more drugs become available to the target site and distribution of 
liposomes into the RES region is minimised or precluded. The bio- distribution of lipid vesicles 
into RES region is effectively altered by the inclusion of protein or carbohydrates molecule (which 
show specific affinity towards a particular tissue or organ) into the lipid bilayer (Al-Angary et al., 
1995; Wolff and Gregoriadis, 1984). Drug targeting via liposomes is very important tool. However, 
from clinical point of view, success stories from these types of liposomes formulations are less 
frequent (Yavlovich, 2010). Therefore, it is imperative to focus on another aspect of drug delivery 
i.e. triggering of liposomes. 
 
1.2.8. Triggering of liposomes  
 
In a bid to increase the availability and diminish the rate of clearance of liposomes, a concept of 
sterically-stabilized liposomes has come forward. For instance-polyethylene glycol conjugated to 
distearoylphosphatidylethanolamine (PEG-DSPE). Liposome formulation containing sterically 
stabilized liposomes exhibit a prolonged circulation time in blood and reduced uptake by the liver 
and spleen and improved accumulation in implanted tumours (Gabizon and Papahadjopoulos, 
1988). Even though, the therapeutic window of these liposomes is very low due to the slow release 
of drug from the liposomes (Shum et al., 2001). To overcome this drawback, “intelligent” 
liposomes, which possess energy –activated release mechanism that speeds up the drug release 
rates and increases the therapeutic efficacy, have been developed (Lehner et al., 2012). These 
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“intelligent” liposomes not only improve the efficacy of drug but also increase intracellular 
stability and activity of drug (Kocer, 2007). Based on the type of stimulus, the “intelligent” 
liposomes, also termed as functional liposomes, are classified into internally and externally 
controllable vesicles (Lehner et al., 2012). Internal stimuli are caused by internal triggers such as 
activation by pH, redox potential and enzymes whereas external stimuli are caused by external 
triggers such as light, heat, ultrasound, electromagnetic fields or ionizing radiation (Yavlovich, 
2010). All triggerable liposomes follow the same mechanism and drug release depends on 
structural alteration caused by the disruption of the lipid bilayer via a stimulus at the weakest point 
(Bisby et al., 1999b; Cheong et al., 2006; Ganta et al., 2008; Jeong et al., 2002). Internal triggers 
possess some limitations. The pH-sensitive liposomes are easily cleared out by receptor mediated 
endocytosis and that is why they need to be coated with PEGylation material (Gabizon, 2001; 
Hatakeyama, 2007; Ichikawa et al., 2004). Moreover, all internal triggers (pH, redox potential and 
enzymes) are difficult to control because the reaction occurs in complex biological systems like an 
entire organism (Ganta et al., 2008). It is very hard to find the disease specific internal triggers for 
certain diseases. As a result external triggers are more beneficial than internal triggers for cancer 
treatment. External triggers can at time focus on certain body areas. So if the one site of target cell 
is involved in pathogenesis (for instance- stem cells from tumour) then  other site of the target cell 
can easily get targeted by external triggers (for instance –stem cells from bone marrow) 
(Yavlovich, 2010). External triggers also possess several limitations. Temperature sensitive 
liposomes cause hyperthermia along with major inflammation (Kocer, 2007). Ultrasound triggered 
release causes tissue damage whereas electromagnetically and magnetically controllable liposomes 
require smart design and neutron capturing principles from the tissue which is very difficult 
(Lehner et al., 2012). 
 
Among all of the triggers, light triggered release is versatile and has distinctive advantages over 
other systems for the controlled drug release. The major drawback associated with light is tissue 
penetration depth which could be solved by use of near infra-red (NIR) irradiation. A large number 
of light triggered liposomes have been approved for clinical trials (e.g. Visudyne). Therefore, one 
of the objective of this research has been to synthesize photosensitive liposomes which are 
explained in detail in the following chapter -2.  
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1.3. Photo-Sensitive Liposomes: Background 
 
Photosensitive liposomes are triggerable liposomes which release their contents on demand upon 
irradiation of light with an appropriate wavelength (Güven 2013). Biocompatible light-sensitive 
materials have been scrutinized from the early 1980s (Yavlovich, 2010). These molecular devices 
that are used for designing liposomes possess the ability to release their load in response to 
exposure to light (Alvarez-Lorenzo and Concheiro, 2008; Lohmann and Petrak, 1989).The depth of 
light penetration into the human body depends on the wavelength of light. The ultraviolet (UV) and 
the blue part of the visible spectrum superficially penetrate into the human body not more than 1-2 
mm and allow controlling some processes on the surface and inside the skin. A remarkable increase 
in penetration begins from orange light (>590 nm). Light with wavelengths exceeding 700 nm (red 
and near infrared light) penetrate to approximately 1 cm and can be used for controlling light 
sensitive devices inside the body and also for visualization of some internal processes (Alvarez-
Lorenzo et al., 2009; Mochizuki-Oda et al., 2002). Light sensitive lipid molecules have provided an 
opportunity to create stable nanosystems for controlled release of drugs in circulation together with 
photo-triggers for localized drug delivery. 
 
In theory, light-sensitive liposomes equipped with synthetic lipids and chromophores are 
responsible for light harvesting and light-dependent conformational transitions of molecules. In 
response to the light exposure, derivatives of azobenzene, cinnamoyl, and spirobenzopyran 
moieties can specifically alter their polarity and corresponding hydrophobicity due to cis-trans 
isomerization or modification in a number of charged groups (Lohmann and Petrak, 1989; Zhao, 
2007; Zhao, 2009).The cis-trans isomerisation of azobenzene can also transform the packing and 
phase state of lipids. For example, UV treatment of photo-sensitive liposomes containing 
phospholipid 1, 2-bis [4-4(4-n-butylphenylazo) phenylbutyroyl] phosphatidylcholine (Bis-Azo PC) 
can initiate transition from a planer structure present in the bilayer vesicles to inverted micellar 
structures. The conformational transition is reversible and can be controlled by light of different 
wavelengths. This allows regulation of the permeability and release of internal content from photo-
sensitive liposomes containing 6 % of Bis azo PC (Bisby et al., 2000a; Bisby et al., 2000b; 
Mochizuki-Oda et al., 2002). 
 
Azobenzene derivatives of cholesterol can also be utilized for regulation of liposomes permeability 
and stability. Cholesterol derivatives with a range of polarity and charge can adjust the sensitivity 
of liposomes to light exposure and the rate of drug release at different wavelengths and 
temperatures (Bisby et al., 2000a). The process of isomerization of lipid can also alter the shape of 
liposomes. For instance, reversible changes in shape could be observed on gigantic liposomes 
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containing lipid KAON12 when they were exposed to light of different wavelengths (Bisby et al., 
2000b). Briefly, in these liposomes, light triggered the isomerization of azobenzene chromophore 
moiety. Further, the isomerization of the lipid has initiated changes in the lipid bilayer structure. 
This shape modification can be easily confirmed by observing under a light microscope as 
invaginations or protrusions on the surface of gigantic liposomes. The changes are reversible and 
controlled by light of different wavelengths. In conclusion, the phenomenon could be applicable for 
triggering of photosensitive liposomes with light (Bisby et al., 1999b; Zhao, 2009).  
 
The success of photo-sensitive liposomal drug delivery entirely depends on several factors such as 
phototriggerable building blocks of nanocontainer, light source and instrumentation. Apart from 
photo-sensitive liposomes, another light based therapy i.e. photodynamic therapy is also commonly 
used to deliver drugs. Photodynamic therapy relies on the activation of photo-sensitizers via light 
and generation of reactive oxygen species (ROS) that cause the destruction of targeted cells and 
tissues (Dougherty, 2002; Yano et al., 2011). This therapy is very effective in many tumours and 
diseases such as tongue cancer in which photofrin acts as photosensitizer (Bicalho et al., 2013), bile 
duct cancer in which tempoforin acts as photosensitizer (Wagner et al., 2013) and in case of 
targeting pain in patients, 5-aminolevulinic acid /red light is used (Story et al., 2013). However, 
photodynamic therapy possesses several limitations such as issues related to the solubility of 
photosensitizer due to the presence of aromatic and hydrophobic structure, poor bioavailability due 
to lipophilic nature of photosensitizer etc (Chen et al., 2005; Yavlovich, 2010). Therefore, 
photosensitive liposomes are beneficial and have many advantages over the photodynamic therapy. 
 
1.3.1. Advantages of photo-sensitive liposomes 
 
As summarised by Shum and co-workers (Shum et al., 2001), photo-sensitive liposomes have the 
following advantages: 
a) They provide a broad range of adjustable parameters such as wavelength, duration and 
intensity that can be easily optimized.  
b) Rapid release of the encapsulated contents.  
c) Upon irradiation, photochromic bilayers can lead to membrane reorganization with 
possible application in imaging, sensing and therapeutics.  
d) Photosensitive liposomes show distinct advantages over photodynamic therapy due to their 
low toxicity and controllable drug release. This has created new applications in targeted 
drug delivery such as cancer, eye disease, sun lotion and tissue engineering. 
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1.3.2. Limitations associated with photosensitive liposomes 
 
Several problems are associated with the efficiency of targeting and with the ultimate fate of light-
sensitive liposomes in the body and thus examples of their medical applications are still rare. 
Clearance of liposomes by microphages in the liver and spleen reduces circulatory half-life and 
raises questions of hepatotoxicity and possible immune suppression. Another problem is the 
penetration of UV light. The UV penetrates into the human body not more than 1-2nm, i.e. 
superficial layer of the skin. Furthermore, most of the azobenzene based photosensitive liposomes 
are very toxic to the human body due to their azobenzene derivatives (Leung and Romanowski, 
2012). 
 
1.3.3. Synthesis of photosensitive liposomes 
 
Photo-sensitive liposomes have been developed from chemical synthesis by conjugating photo-
sensitive groups onto the phospholipid assembly (“designer lipids”). So far, a very few number of 
designer lipids have been successfully synthesized, each of which employs a definite mechanism 
for photo activation (Table 1.3) (Yavlovich, 2010). The phosphatidylcholines molecule is 
composed of three main parts: head group, glycerol backbone and fatty acyl chains (Fig.1.7). With 
the aim to produce photo-sensitive liposomes, each of these parts has been altered either by 
inserting additional groups or by modifying the existing chemical bonds such as polymerisable 
moieties (Chandra et al., 2005; Lamparski et al., 1992a; Lawson et al., 2003; Liu et al., 2005a; 
Thompson et al., 1996; Yavlovich et al., 2009; Zhang and Smith, 1999). 
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Fig 1.7: Sites for chemical modification in phospholipids. 
 
 
Table 1.3: Synthesis of Photosensitive liposomes via photoactivation 
 
Lipid modification Wavelength Mechanism Reference 
DC8,9PC 254nm Photopolymerization (Yavlovich et 
al., 2009) 
Bis-azo PC  
 
UV Cis-trans photoisomerization (Liu et al., 
2005b) 
O-nitrobenzyl 
conjugated lipid 
365nm Photo-cleavage upon radiation (Chandra et al., 
2005) 
NVOC-DOPE 345 nm Photo-cleavage upon radiation (Zhang and 
Smith, 1999) 
Plasmalogen 630-820 nm Photo-oxidation by bilayer 
sensitizer(Zincphthalocyanine, 
bacteria chlorophyll a) 
(Thompson et 
al., 1996) 
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Lipid modification Wavelength Mechanism Reference 
Bis-SorbPC 550 nm Photo-polymerization induced by 
Bilayer sensitizer (DiI) 
(Lamparski et 
al., 1992b) 
Head-group UV Polymerization by radical 
initiation  
(Lawson et al., 
2003) 
 1, 2-bis (10, 12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8, 9PC); 6-nitroveratryloxy carbonyl  
 chloride with dioleoylphosphatidylethanolamine (NVOC-DOPE); 1,2-bis- [ 10-(2’,4’- hexadienoyloxy)   
  decanoyl] -sn-glycero-3-phosphatidylcholin (Bis-SorbPC). 
Several approaches have been used to design photosensitive liposomes. These involve the 
photochemical modification of individual phospholipids in the bilayer, i.e. lipid photochemistry, 
the photoinduced change in the association of polyelectrolytes, the photoiniated polymerization of 
some or all of the lipids in the liposomes, i.e., photopolymerization and photochemical changes in 
the structure of individual lipids forming the bilayer. Each technique is briefly reviewed below 
(Chandra et al., 2006; Yavlovich, 2010) . 
 
1.3.3.1. Lipid photochemistry - photochemical modification of individual lipids in the bilayer 
The theory in the design of the photolabile liposomes involves the introduction of a photolabile 
linker that connects the polar and nonpolar parts of the lipid molecule. Under UV light exposure, 
the connection between polar and nonpolar parts of the lipid, i.e. photolabile linker, is damaged and 
the molecule loses its amphiphilic properties, and thus disturbing the bilayer and increasing bilayer 
permeability (Bennett et al., 1994; O'Brien D. F., 1993). These techniques also include mechanisms 
such as the trans-to-cis photoisomerization of lipid chromophores, the photoinduced chain cleavage 
of some or all of the lipids, photomodulated binding of  polyelectrolytes, and the photochemical 
changes in the structure of individual lipids forming the bilayer. The first three are appropriate for 
phosphatidylcholine (PC) and other phospholipids, while the latter has only been verified with 
synthetic amphiphiles (Bennett et al., 1994). 
 
a)  Photoisomerization of lipid chromophores- 
In order to prepare photosensitive liposomes, both azo and polyenes groups have been introduced 
into lipid chains. Due to this photosensitive liposomes acts as a molecular switch.  A molecular 
switch is a molecular assembly that disturbs when the system is subjected to an external stimulus, 
such as light, resulting in conformational and environmental changes of the switch (Merino and 
Ribagorda, 2012). Therefore, the rationale of a molecular switch is the reversible conversion of 
chemical species caused through light between two states of a molecule with different absorption 
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spectra. For instance, the trans form of azobenzene isomerizes into the cis form of azobenzene by 
irradiation of light with a wavelength between 330–380 nm. This reaction is reversible and the 
trans form of azobenzene is easily recovered when the cis isomer is irradiated with light of 400–
460 nm, or heated.  These photoisomerization processes not only alter the absorption band but also 
produce differences in different physicochemical properties of molecules, such as molecular 
geometry, dipole moment, refractive index, electrochemical behaviour (Henzl et al., 2006).In every 
method light has been successfully utilized to photoisomerize a double bond from trans to cis 
conformations which perturb the bilayer packing and raise the liposome permeability. The initial 
experiment in order to affect the membrane permeability using photosensitive lipid was carried out 
by Kano and colleagues in 1981 (Kano et al., 1981). They effectively incorporated amphiphilic 
compound 1 (Scheme 1.1) into the bilayer membrane of dipalmitoylphosphatidylcholine liposomes. 
Cis-isomer of azobenzene 1(2) was experimentally exposed to better maintain the bilayer structure 
than trans-isomer of azobenzene (1). Under UV exposure the azobenzene molecule undergoes 
trans-cis isomerization which disturbs the bilayers. For this study, they entrapped bromothymol 
blue dye inside the bilayer. In its acidic (closed ring) form, this dye is very hydrophobic and 
remains entrapped within the bilayer. With basification, bromothymol blue gets released into 
aqueous medium and carries negative charge. After irradiation with 366 nm light, liposomes 
possessing bromothymol blue (1) were shown to give rapid release of bromothymol blue dye upon 
basification (see Scheme 1.1).  
 
Moreover, osmotic shrinkage experiments also proved that after irradiation, liposomes possessing 
azobenzene derivative were more permeable to water. In short, this first attempt highlighted the 
possibility of using synthetic light sensitive amphiphiles to control the membrane permeability with 
photo irradiation.  
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Scheme 1.1: Isomerization of first azobenzene derivative [adapted from (Kano et al., 1981)]. 
 
Another interesting work was done by Morgan and his group (Morgan et al., 1985). They used a 
phospholipid analogue of dipalmitoylphosphatidylcholine. The azobenzene moiety was 
incorporated into one of the chains of the phospholipid to form Azo-PC lipid (8) (Scheme 1.2). 
Synthesis of (8) was started with nitroso compound (4) that was obtained by the oxidation of the 
amine (3), and amino acid (6) that was formed upon reduction of the nitrobenzene (5). Compounds 
(6) and (4) were combined together to form azo acid (7), which was then converted to Azo-PC (8) 
by mixed anhydride acylation of 2- palmitoylglycerophosphatidylcholine. Irradiation of compound 
(8) causes trans-cis isomerization of azobenzene chromophore (Scheme 1.2). Because of linear 
hydrophobic chains, trans-7 shows compatibility with other components of the membrane and is 
capable of maintaining bilayer stability. Under UV irradiation, trans-7 is isomerized to cis-7, which 
perturbs the membrane, thus causing its destabilization and increasing its permeability. Later on, 
the resulted Azo PC was combined with phosphatidylcholine (6 molar % of Azo-PC) and sonicated 
to form photosensitive Azo-PC. The results obtained from these liposomes clearly showed that 
upon irradiation, the permeability of the membrane increased insignificantly. Therefore, light 
scattering against temperature profiles gave only a slight decrease of phase transition temperature 
for the irradiated liposomes. 
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Scheme 1.2: Synthesis of Azo-PC [adapted from (Morgan et al., 1985)]. 
 
Overall, upon UV irradiation, liposomes possessing Azo-PC assembly alter their physical 
properties such as phase transition temperature and membrane permeability. But, the permeability 
was insignificantly related to photoisomerization mechanism.  
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                                        (9)                                                                                          (10) 
 
Scheme 1.3: Synthesis of Bis-Azo PC [adapted from (Morgan et al., 1985)]. 
 
In a subsequent work carried out by the same authors (Morgan et al., 1985), a new 
phosphotidylcholine i.e. Bis-Azo PC (9) was prepared (Scheme 1.3). Bis-Azo PC contains an 
azobenzene moiety in each hydrophobic chain. Upon UV irradiation, this molecule causes trans (9) 
to cis (10) isomerization of both azobenzene fragments that should lead to more disturbances in the 
bilayer than observed with Azo-PC. Bis–Azo PC was also synthesized in the same fashion as 
described for compound (8) (Scheme 1.2). Azobenzene derivative (6) was transformed to mixed 
anhydride with pivaloyl chloride and then was condensed with glycerophosphatidylcholine to give 
Bis-Azo PC (Sandhu et al., 1986). 
 
Numerous investigators (Morgan et al., 1985; Morgan et al., 1987b) have described a novel 
photosensitive lipid system based on a photochromic lipid molecule 'Bis-AzoPC' (1, 2-bis (4-(4-n-
butylphenylazo) phenylbutyroyl) - phosphatidylcholine) (Scheme 1.3). This lipid present in a 
photostationary state is predominantly composed of the trans- isomer which is visible under light 
illumination, but it is changed to a cis-enriched photostationary state on exposure to near-ultraviolet 
light. Liposomes of dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine in the rigid 
'gel' phase containing up to 5 % of Bis-Azo PC have reserved trapped marker dye for up to several 
months at room temperature (Morgan et al., 1985). Upon exposure to ultraviolet light at 355 nm, 
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conversion of Bis-Azo PC to the cis-photostationary state disrupts the bilayer membrane leading to 
rapid leakage of contents (Sandhu et al., 1986). Photosensitive lipids might well offer a suitable 
means to 'cage' water-soluble reagents compatible with the bilayer structure and may supply 
solutions to the potential problems mentioned above with covalently caged species. A wide number 
of water-soluble materials including biologically important ions such as calcium and copper and 
drugs such as methotrexate (Bisby et al., 2000a; Morgan et al., 1987b) can simply be encapsulated 
under mild conditions without the need for specialised apparatus, and photo-induced release of 
such solutes from liposomes containing Bis-Azo PC has already been demonstrated (Morgan et al., 
1987b). Additionally, liposomes might be appropriate as carriers to introduce reagents into cells by 
endocytosis, minimising the reagent’s exposure to degradative species until release is triggered. 
 
Numerous experiments (Bisby et al., 2000b; Bisby et al., 2000a) have shown that the trapped 
marker dye, calcein, which is highly fluorescent when dilute, is ‘quenched’ when trapped at a high 
concentration within photosensitive liposome. The cited work has shown the effect of phospholipid 
acyl chain length and temperature on release kinetics of calcein and verified that liposome 
composition could be tailored to allow for rapid solute release across a range of temperatures. 
Liposomes of DPPC containing Bis-Azo PC (6 mol %) and cholesterol (up to 15 mol %) showed 
no significant leakage of calcein for at least 8 weeks. In contrast, liposomes containing higher 
concentrations of Bis-Azo PC. (e.g., 10 mol %) were stable overnight, but released their contents 
on long term storage. A further modification of photosensitive liposomes based on photoinduced 
cis-trans isomerization was projected by Pidgeon and Hunt (Pidgeon and Hunt, 1983). Retinoic 
acid was effectively incorporated into phospholipid bilayer to serve as hydrophobic chain (12). 
From this approach, two different types of phospholipids were developed: 1-palmitoyl-2-retionyl-
glycero-3-phosphocholine (13) and 1, 2-diretinonyl-glycero-3-phosphocholine (14) (Scheme 1.4). 
The methodology used to prepare these two types of phospholipids was developed by Warner and 
Benson (Warner and Benson, 1977). In this technique, glycerophosphocholine was covalently 
attached with the imidazolide of retinoic acid in the presence of sodium methylsulfinylmethide. 
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Scheme 1.4: Synthesis of 1-palmitoyl-2-retionyl-glycero-3-phosphocholine and 1, 2-
diretinonyl-glycero-3-phosphocholine [taken from (Kulikov, 2006)]. 
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b) Photoinduced cleavage of lipid chains- 
Liposome permeability is altered by the photoinduced cleavage of one or both of the hydrophobic 
lipid chains which directly reconstructs the bilayer.  Two major approaches to the photoinduced 
cleavage of lipid chains have been reported in  previous articles: [1] the direct photoactivated 
cleavage of designed phospholipids, and [2] the photosensitized cleavage of plasminogen lipids 
(Bennett et al., 1994).  
 
In 1989, photodisintegratable liposomes data were reported by Kusumi (Kususmi, 1989). Their 
strategy relied on photoinduced formation of a polar moiety within the hydrophobic chains of the 
lipid. The investigators prepared phospholipids with 2-nitrobenzyl esters on the terminal carbons of 
both hydrophobic chains. Under UV irradiation, the 2-nitrobenzyl esters were broken (15) (Scheme 
1.5) and two carboxylate ions on the terminal carbons of the hydrocarbon chains were generated 
(16) which caused the disintegration of the bilayers. As per Scheme 1.6, the phospolipid analogue 
(20) was developed. Ortho-nitrobenzyl alcohol (17) was mixed with dodecanoyl dichloride (18) to 
yield ester (19). Further, the ester (19) was coupled with glycerophosphocholine in the presence of 
dicyclohexylcarbodiimide to give the final product (20). 
 
Scheme 1.5  
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Scheme 1.5: Disintegration of 2-nitrobenzyl esters via UVA irradiation [adapted from 
(Kulikov, 2006)]. 
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Scheme 1.6: Synthesis of phospholipid analogue of  ester [adapted from (Kulikov, 2006)]. 
 
Without the addition of natural phospholipids, liposomes were prepared from pure (20). Electron 
microscopy confirmed the complete disintegration of liposomes upon prolonged irradiation. The 
results obtained from an experiment on ovalbumin (protein with molecular weight of about 43 
kilodalton) entrapped within the liposomes verified that 75 % of protein was released after a brief 
period of irradiation and barely 5 % of phospholipid underwent the photochemical decomposition. 
These data suggest that a small fraction of lipid can easily decompose and that caused the 
disintegration of the liposome (Kulikov, 2006). 
 
During 1992, Anderson and coworkers (Anderson and Thompson, 1992) reported alternative 
approach to the photoinduced cleavage of lipid chains which was mainly based on the peroxidation 
of lipids. Moreover, Sensitized lipid photooxidation has been explained for PC liposomes 
(Grossweiner and Grossweiner, 1982; Kalyanaraman et al., 1987; Viani et al., 1991). 
Photooxidation of lipid causes cleavage of chains to occur that leads to increase in solute 
permeability (Kalyanaraman et al., 1987). Anderson and Thompson thoroughly examined the 
photooxidation of semisynthetic plasmalogen,1-alkyl-1’-enyl-2-palmitoyl-sn-glycero-3-
phosphocholine (21) (Scheme 1.7). This lipid alone or in combination with DPPC 
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(9µmoles:1µmoles) produced liposomes. A range of photosensitizers were employed in 
combination with these type of liposomes: the hydrophobic zinc phthalocyanine (ZnPc) with λmax 
674 nm, the hydrophilic aluminium chlorophthalocyaninetetrasulfonate entrapped in the liposomes 
(λmax 672nm) (Kalyanaraman et al., 1987) or membrane bound bacteriocholorohyll a (Viani et al., 
1991). 
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Scheme 1.7: Photooxidation of semisynthetic plasmalogen,1-alkyl-1’-enyl-2-palmitoyl-sn-
glycero-3-phosphocholine [adapted from (Anderson and Thompson, 1992)]. 
 
c) Photomodulated binding of polyelectrolytes-  
The non-covalent attachment of polyelectrolyte chains to lipid bilayers can disturb liposome 
structures. Tirrell and coworkers have thoroughly studied the reversible association of poly (2-
ethylacrylic acid) (PEEA) with PC liposomes (Seki and Tirrell, 1984; Tirrell et al., 1985; Devlin 
and Tirrell, 1986; Borden et al., 1987; Borden et al., 1988; Maeda et al., 1988; Eum et al., 1989; 
Laschewsky and Ringsdorf, 1988). The cause was a pH- dependent conformational transition of 
PEAA in aqueous solutions, from an expanded, highly ionized coil at high pH to condensed 
globular structures in acidic media (24). pH – dependent conformational transition of PEEA in 
aqueous solution was exposed by titrimetric, spectroscopic, and scattering techniques (Lohmann 
and Petrak, 1989; Alvarez-Lorenzo and Concheiro, 2008).  
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The photomodulated binding of PEEA has been conferred in two ways. In the first approach, 
PEAA-liposome altered by copolymerization of 2- ethyl acrylic acid with 4 mol % of N-[4-
(phenylazo)phenyl]methacrylamide, a light sensitive monomer (Ferritto and Tirrell, 1988). 
Photoisomerization of the phenylbenzene from the trans to cis changed trans form of the copolymer 
from a lipid attached polymer to a cis form with a lower surface affinity. The second approach, a 
water soluble diaryliodonium salt was used as a photoinitiator. Briefly, irradiation of egg pc 
liposome, PEAA and 3, 3’-Dicarboxydiphenyliodonium hydrogen sulfate at pH 7.7 with 254 nm 
light results in rapid release of entrapped calcein (You and Tirrell, 1991). 
 
d) Photo-polymerization 
Conjugated dienes and their derivatives contain double bonds separated by one single bond. These 
compounds can be readily polymerised under UV irradiation. In 1992, Lamparsky and O’Brien 
(Lamparski et al., 1992b) reported an interesting liposome composed of 3:1 molar mixture of 
dioleoylphosphatidylethanolamine (DOPE) and 1,2-bis [10-(2`-hexadienoyloxy) decarbonyl]-sn-
glycero-3-phosphatidylcholine (bis–SorbPC). Upon UV light irradiation, bis-SorbPC undergoes 
polymerization and gives a cross–linked poly-sorb PC network. This process isolated the liposome 
bilayer into polymeric and monomeric domains, which resulted in the disruption of the lamellar 
integrity, liposome fusion and eventually fast release of the encapsulated contents in the liposomes 
(50% of the contents were released within a few minutes). O’Brien’s studies also described that the 
rate and extent of liposome fusion was dependent on the extent of photo polymerization, the molar 
lipid ratio of bis-SorbPC, temperature, pH and the presence of Mg2+ ions, and that the fusion was 
initiated by intermediates that associated with the lamellar to Q2 phase transition of the liposomal 
membrane (Miller et al., 1996; Mueller et al., 2000; Bondurant et al., 2001; Spratt et al., 2003). 
Furthermore, studies demonstrated that the fusion rates and extents of DOPE/mono-SorbPC 
liposomes (Lamparski and O'Brien, 1995). This is due to the fact that photoactivated 
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polymerization of mono-SorbPC produces only short linear oligomers of 3-10 repeat units, and 
cannot necessarily produce a dramatic phase separation and the subsequent fusion of liposomes. As 
a result, these studies introduced the possibility of using photo-induced fusion of liposomes to 
trigger drug release. Taking advantage of the incomparable long circulation life of polyethylene 
glycol–liposomes (PEG-liposomes also known as stealth liposomes, which have been detected to 
accumulate preferentially in the interstitium of tumour site because of the increased permeability of 
the vasculature at those sites), O’Brien et al. further modified DOPE/bis-SorbPC photosensitive 
liposomes by incorporating PEG-2000 -1,2-distearoyl –sn- glycerol-3- phosphoethanolamine 
(PEG2000-DSPE) (Spratt et al., 2003).The liposomes were still very sensitive to UV irradiation; 2 
minutes UV irradiation promoted a 90% loss of monomer and nearly 60-fold increase in the rate of 
1–amino -3,6,8 –naphthalenetrisulfonic acid release from the liposomes (Spratt et al., 2003). 
Interestingly, the liposomal content release can be triggered even by visible light after 
incorporation of a green light absorbing dye [distearoylindocarbocyanine, DiIC(18)3] into the 
bilayer of DOPC/bis-SorbPC/PEG-DOPE liposomes (Mueller et al., 2000; Bondurant et al., 2001; 
Spratt et al., 2003). These observations demonstrated the possibility of using the available light 
source suitable for photodynamic therapy to trigger content release from the designed photo-
liposomes.  
 
e) Photomodification of the lipid hydrophilic head group- 
Incorporation of photolabile linker in the middle of the polar and nonpolar parts of the lipid 
molecule is an easy technique for the design of photocleavable lipids. These photolabile lipid 
molecules were designed on the basis of their susceptibility to UV light resulting in the breakdown 
products that will destabilize liposome membrane. Initially, this type of photosensitive liposomes 
was designed by the Kutateladze group (Wan et al., 2002). Later on, synthesis of a photocleavable 
lipid based on a dithianephotolabile linker was carried out by Li and co-workers (Li et al., 2003). 
These authors also reported the synthesis of a number of photocleavable amphiphiles based on a 
dithiane moiety. Scheme 1.8 represents the synthetic cycle of some of these phospholipid 
analogues. Basically, synthesis of these amphiphiles initiated by a coupling reaction between an 
appropriate aldehyde and the lithium salt of the dithio compound. Then, the free phenolic hydroxyl 
is esterified with phosphocholine upon treatment with cyclic chlorophospholane followed by 
trimethylamine.  All those photocleavable amphiphiles were revealed as effective materials for the 
development of stable liposomes and no leakage was detected in the dark due to the absence of 
light. 
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Scheme 1.8: Synthetic cycle of a number of photocleavable amphiphiles based on a dithiane 
moiety [taken from (Kulikov, 2006)]. 
 
In 2002, Nagasaki and his group (Nagasaki et al., 2003) had attempted to use photocleavable lipid 
analogs for the preparation of liposomes that could be used as gene delivery systems. With the aim 
to synthesize photocleavable lipid, they incorporated photolabile ortho-nitrobenzyl moiety between 
the polar and nonpolar parts of the lipid molecule (Scheme 1.9). 
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Scheme 1.9: Design of photocleavable lipid by incorporating photolabileortho-nitrobenzyl 
moiety between the polar and nonpolar parts of the lipid molecule [taken from (Kulikov, 
2006)]. 
 
Hydrophobic chains of this lipid analogue are depicted by two dodecyl hydrocarbon chains, while 
the polar head group of the lipid is composed of basic amino acids lysine or arginine, in the place 
of phosphocholine. Synthesis of lipid analogue (39) begins with an initiator i.e. amino acid (36) 
(Scheme 1.9). The amino acid (36) was nitrated and the amino functionality was protected with 
tert-butyloxycarbonyl derivative to give carboxylic acid (37). Then, coupling reaction occurred 
between the carboxylic acid (37) and didodecyl amine. On account of this, the tertbutyloxycarbonyl 
protection was cleaved. The product thus obtained was mixed with lysine (a) or arginine (b). Final 
deprotection then resulted in the desired product (39). Under UV irradiation of amphiphiles (39), 
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the whole molecule lost its amphiphilic characteristics and the amino acids were released as 
amines. 
 
With UV irradiation, the liposomes prepared with compounds (39) showed higher transfection 
activity than that of liposomes prepared with lipofectin (commercially available mixture of lipids 
for liposome preparation). A similar strategy to design photocleavable lipid was reported by 
Chandra (Chandra et al., 2005; Chandra et al., 2006). A photocleavable lipid with only one 
hydrophobic “tail” was the basis of their study and acidic amino acids such as asparagine and 
glutamine represented the polar part of the lipid. The complete cycle of synthesis of this lipid 
analogue is illustrated in Scheme 1.10. The synthesis cycle of lipids (43) is very similar to synthetic 
cycle of compounds (39). But, the yield of obtained lipid (43) was 53 %. 
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Scheme 1.10: Synthesis of photocleavable lipid with only one hydrophobic tail [taken from 
(Kulikov, 2006)]. 
 
Following the synthesis of photocleavable lipids (43), photosensitive liposomes were prepared with 
95% yield (by weight) 1, 2-distearoyl-glycero-3-phosphocholine and 5% photocleavable lipids 
(43). Further study with photosensitive liposomes entrapped with fluorescent marker demonstrated 
efficient release of liposomal contents upon UV irradiation and no leakage was detected in the dark 
due to absence of light. 
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All these are methods that are commonly used to synthesize photosensitive lipids. As mentioned 
earlier, the initial objective of this research has been to synthesize photosensitive liposomes. For 
that reason, in this investigation, lipid photo chemistry method has been used. (as explained in the 
lipid photochemistry  method section 1.3.3.1a) and formulated photosensitive lipid i.e Bis-Azo PC 
that has been further  incorporated into the  liposomes (DPPC:Chol) which are described  in detail 
in Chapter 3 and Chapter 4. 
 
1.3.4. Application of photo-triggerable formulations in drug delivery 
 
The first attempt to release doxorubicin from PEGylated liposomes with the help of laser 
irradiation was done by Yavlovich and co-workers (Yavlovich et al., 2011). In that study, 
doxorubicin entrapped PEGylated liposomes were formulated by conjugating doxorubicin 
entrapped DPPC liposomes with 10% of the photopolymerizablediacetylene phospholipid 
(DC8,9PC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-
2000] and then this was used in vitro for cell toxicity studies. A photo-triggerable release of 
doxorubicin was achieved by laser at 514 nm wavelength. Compared to unreacted cell in culture, 
laser treated culture of doxorubicin loaded liposomes and cells had showed 2-3 fold improvement 
in cells toxicity (Yavlovich et al., 2011). This finding provides the basic platform for photo-
triggerable formulations that are clinically suitable for skin cancer drug delivery (Perche and 
Torchilin, 2013). In terms of photodynamic therapy, targeting efficiency of folate-targeted 
liposomes have been achieved by incorporating photosensitizer i.e. zinc tetraphenylporphyrin 
(ZnTPP) into folate-targeted liposomes (Garcia-Diaz et al., 2011). Data obtained from the study 
clearly showed that this modification has not only increased the targeting efficiency, but also 
improved the photocytotoxicity of folate-targeted liposomes. However, phototoxicity of folate –
targeted liposomes was completely inhibited with an excess of folic acid present in the cell culture 
media. Moreover, O2 kinetics analysis in living cells clearly indicated the presence of ZnTPP in 
lysosome. Light sensitive liposomes have also been used to entrap the third generation 
photosensitizer i.e. m-THPC [5, 10, 15, 20-tetra-(m-hydroxyphenyl)chlorin] which is formulated 
by using dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol (DPPC/DPPG) 
liposomes encapsulating m-THPC (Lassalle et al., 2009). This light sensitive liposomal material is 
termed as Foslip and has showed improvement in photodynamic activity (Lasalle et al 2009). 
Moreover PEGylated liposomes have been used as nanocontainer for the same photosensitizer i.e. 
m-THPC [5, 10, 15, 20-tetra-(m-hydroxyphenyl)chlorin] (Bovis et al., 2012). Results obtained 
from the study clearly indicated that higher tumour photocytotoxicity was achieved via m-THPC 
incorporated PEGylated liposomes in comparison to standard m-THPC formulation (Foscan®). In 
theory, normal tissue damage has reduced and tumour uptake has increased with higher dose of m-
THPC incorporated PEGylated liposomes (Bovis et al., 2012; Perche and Torchilin, 2013). 
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To date, a large number of light sensitive formulations have been developed with the help of 
liposome based strategy and are being used for photodynamic therapy and imaging. Table 1.4 
illustrates some examples of light sensitive formulations (Loomis et al., 2011; Zharov et al., 2005) . 
Table 1.4: Examples of photosenitive formulations 
 
Recently, a novel photo-triggered release system based on metal ion has been successfully 
developed, which involves the use of carbon dots (C-dots) and photosensitizer-functionalized gold 
nanostars in order to achieve the photo-triggered theranostics (Bovis et al., 2012; Huang et al., 
2012; Huang et al., 2013; Perche and Torchilin, 2013; Wang et al., 2013). Another marvellous 
achievement in case of light triggered formulation has been obtained by Lin and colleagues using 
Ce6-loaded gold vesicles demonstrating both photothermal and photodynamic effects (Lin et al., 
2013). Furthermore, light triggered formulation using tuneable plasmonic nanobubbles has been 
used to disintegrate the lipid vesicles and to achieve the controlled release of drugs (Anderson et 
al., 2010). This formulation possesses gold nanoparticles that produce the vapour bubble through 
short laser and the vapour bubble disrupts the liposomes. This formulation also shows the 
beneficial in vivo application in case of zebrafish. However in vivo studies on mammalians are in 
yet to be carried out. 
Photo-sensitive 
formulations 
Reference Clinical  
status 
Photo-sensitive 
moiety 
Purpose 
C- dots 
(carbon dots) 
(Huang et al., 2012; 
Huang et al., 2013) 
in vitro/in 
vivo studies 
metal ions theranostics 
functionalized gold 
nanostars 
(Wang et al., 2013) in vitro/in 
vivo studies 
Photosensitizer 
(clorine 6) 
PTT/PDT 
tuneable plasmonic 
nanobubbles 
(Anderson et al., 
2010) 
in vitro/in 
vivo studies 
Gold 
nanoparticle 
Drug delivery 
light responsive 
Polymer 
nanoreactors 
(Baumann et al., 
2013; Tanner et al., 
2011) 
in vitro 
studies 
photosensitizer-
protein 
conjugate 
Production of 
Reactive 
Oxygen 
Species (ROS) 
Polymers (Fomina et al., 2010; 
Fomina et al., 2011) 
in vitro/in 
vivo studies 
Photoprins 
phthalocyanines 
neovasculariza
tion 
Dendrimers (Nishiyama et al., 
2007; Nishiyama et 
al., 2009) 
in vitro 
studies 
Porphyrin-
phthalocyanine 
Drug delivery 
Liposomes http://www.visudyn
e.com 
in clinics 
(visudyne)  
verteporfin Delivery of 
photosensitizer 
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Photosensitive polymer has also been developed using quinone-methide (2, 6-bis (hydroxyethyl)-p-
cresol), self-immolative dendrimer as photosensitive components and which show triggered release 
of drugs through near infra-red (NIR) light (Fomina et al., 2010; Fomina et al., 2011). Another 
noticeable nanosystem for drug delivery is produced by loading photosensitizer-protein conjugate 
along with polymers known as “light responsive polymer nanoreactor” that is easily triggered 
through light and produce highly reactive oxygen species (Baumann et al., 2013; Tanner et al., 
2011). Nowadays, photo–sensitive dendrimers and polymeric micelles are on demand for drug 
delivery and these are produced by using porphyrinphthalocyanine as photo-sensitive component 
(Nishiyama et al., 2007; Nishiyama et al., 2009). Even though all these light sensitive formulations 
are widely accepted as potential tool for photodynamic therapy in the case of cancer drug delivery, 
there is only one successful and clinically approved drug for photodynamic therapy, which is 
Visudyne®. Visudyne® is light sensitive liposome formulation which possesses the photosensitizer 
verteporfin (benzoporphyrin derivative monoacid ring A, BPD-MA) and is highly beneficial in 
treating age-related macular degeneration disease (AMD). Visudyne® is mainly comprised of 
BPD-MA: Egg phosphatidylcholine- glycerol:dimyristoyl PC in the ratio of 1:05:3:5. This light 
sensitive liposome was invented by Novartis and clinically approved by FDA in 2000.  
 
Apart from photodynamic therapy formulations, light sensitive liposomes are also used for other 
therapies. One of the well-known example is the use of photosensitive liposomes for tissue 
engineering (Smith et al., 2007). In this study, photosensitive liposomes were developed by using 
the photosensitive lipid (1, 2-bis (4-(4-n-butylphenylazo) phenylbutyroyl) phosphatidylcholine) i.e. 
'Bis-Azo PC' which is triggered by long wavelength ultra violet light at 385 nm. With UV 
irradiation, release of calcium chloride from liposomes occurs that causes cross linking of alginate 
solution and immobilisation of bone-derived cells that support 3D tissue construction. Therefore, 
this therapy plays an important role in the development of tissue engineering scaffold (Smith et al., 
2007).  
 
In conclusion, photosensitive liposomes have many possible uses in the biomedical field and have 
also been investigated as potential nanocontainer (Yavlovich, 2010). However, much research in 
the recent years has focused on cancer and other types of drug delivery. Photosensitive liposomes 
are also used for cosmetic purposes. But very few articles have reported the use of photosensitive 
liposomes for treating skin diseases. Most of the time photosensitive liposomes are used for 
cosmetic purposes. Morgan and co-workers (Morgan et al., 1991) has addressed the release of 
methotrexate from photosensitive liposomes and highlighted the application of these liposomes in 
case of psoriasis treatment. Therefore, another objective of this project is to trigger the release of 
psoralene derivatives from photosensitive liposomes in order to treat psoriasis conditions. From 
this, the question “what is psoriasis” arises?  
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1.4. Psoriasis 
 
Psoriasis is an inflammatory skin disease in which the human immune system mistakes a normal 
skin cell for a pathogen, and sends out defective signals that cause overproduction of new skin 
cells. It is also a chronic disease that is signalized by hyperkeratosis and epidermal hyperplasia of 
varying degrees (Gennaro, 2006). The epidermal patches are red and scaly. These scaly patches are 
found on the external surfaces of skin of the knees, elbows, back region and scalp. Furthermore, 
nails become pitted and ridged. Psoriasis is categorized in the minor disease category. However, 
generalised form and systemic manifestation can be determined (Male, 2013). Fig 1.8 illustrates the 
difference between psoriatic and healthy skin  
 
 
 
Fig 1.8: Difference between psoriatic and healthy skin  
[taken from http/www.fitnessremediesdiets.com] 
 
1.4.1. Epidemiology 
 
Approximately 1-2% of individuals in the UK possess some forms of psoriasis. In USA, this figure 
is about 1-3% (Gennaro, 2006). Northern European countries show a higher number of psoriasis 
patients. It depends on races. Both males and females are affected in equal rates. That is why 
psoriasis does not come under the social class linked disease (Farber and Nall, 1974). Psoriasis can 
occur at any age. Most dominant stages are in early and middle adulthood. 
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1.4.2. Etiology 
 
The exact prevalence of psoriasis disease is not known. However, most of the research work has 
proved that psoriasis is linked to hereditary genes (RDR, 1998). It is generally believed that 
heredity plays a very important role in this disease and these genes are induced and exaggerated by 
various environmental factors such as decreased humidity, an injury to skin through cutting, 
sunburns or insect bites (this whole mechanism is termed as Koebner response), smoking, stress 
and throat infection (Henseler and Christophers, 1995). Furthermore, psoriatic conditions linked 
with nutrition can range from nutritional deficiencies, excess nutrients or metabolic disorders 
(Basavaraj et al., 2010). 
 
1.4.3. Pathogenesis 
 
Psoriasis is mainly characterized by three features- (Griffiths et al., 2000) 
1) Hyperkeratosis and epidermal hyperplasia of varying degrees. 
2) Epidermal vascular hyper-proliferation and differentiation. 
3) T cell mediated inflammatory infiltrate of the intra-dermal and epidermal layers.  
 
It is widely accepted that psoriasis is an autoimmune disease that comes under the category of T 
cell-mediated diseases. The autoantigen which causes psoriasis condition is a mystery. Even though 
an epidermal protein such as keratin 17 is mainly considered as speculative superantigen (Ellis et 
al., 1991), T cells, which are considered as the immunity wall of human system, are responsible for 
psoriasis. In theory, due to superantigens induction, T cells start to attack the healthy skin. As a 
result human body produces large number of new skin cells and T-cells. This cycle of skin and T- 
cell production increases day by day. All these cells survive for up to five to six days rather than 28 
days and then dead skin cells thicken the dermal surface of skin in the form of scaly patches. 
Furthermore, this T-cell mediated reaction increases the release of T-helper 1(‘Th1’) cytokines 
such as IL-2 (Interlukin-2), IL-12, interferon- and T-helper 2(‘Th2’) cytokines such as IL-4, IL-
5, IL-10 (Fry, 1988; Voorhees, 1996). Because of this hormonal imbalance features, psoriasis is 
always associated with other T-helper 2 (‘Th2’) related diseases such as asthma, atopic dermatis 
and urtcaria. This whole mechanism is scientifically proven through an experiment in which 
psoriasis is effectively treated by T cell-targeted therapy (Elias, 1983; Gottlieb, 1995). In this 
experiment, drugs such as cyclosporine and an interleukin 2 (IL-2) fusion toxins were used to treat 
psoriasis.  
In summary, the pathogenesis of psoriasis may give ideas to develop targeted therapies for 
psoriasis treatment. 
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1.4.4. Treatment of psoriasis 
 
Treatment of psoriasis involves two main therapies: first line therapy and second line therapy 
(Griffiths et al., 2000). First line therapy involves the use of active ingredients such as emollients, 
coal tar, Dithranol and various forms of topical steroids. Route of administration for this category is 
topical and all these active ingredients are delivered in the form of ointments and creams (RDR, 
1998). In the UK, most of the psoriasis cases are treated by first line therapy only the most common 
side effects of all these topical preparations are irritation of uninvolved skin, inflammation of hair 
follicles, telangiectasia, stretch marks and Cushing’s syndrome (Hypercorticolism in case of 
corticosteroids) (Clark et al., 1998). But the severe and extensive forms of psoriasis 
(pustularpsorasis) are insensitive and are not controlled by topical therapy. Therefore, a physician 
would recommend second line therapy which involves the use of the phototherapy or light therapy 
along with drugs. Second line therapy takes place in clinics under the supervision of doctors or 
clinicians (Gawkrodger, 1997). Phototherapy involves the irradiation of human skin with UV light 
on a regular basis under medical supervision. Two types of UV light may be given, using special 
machines: ultraviolet A (UVA) which possesses wavelength between 400–315 nm and ultraviolet B 
(UVB) which retains wavelength between 315–280 nm (Krutmann, 1998). These are different parts 
of normal sunlight. Human skin is sensitive to UVB and psoriasis can be easily treated with 
UVB exposure (Goeckerman, 1931). In contrast, UVA directly penetrates to the body and requires 
sensitizing medication such as psoralen to treat psoriasis. This process is known as PUVA 
(combination of psoralen drugs and long wavelength ultraviolet A) (Roelandts, 1991). There are 
several routes of administration for taking psoralen drugs in case of PUVA therapy. First is oral 
route in which the patient can take psoralen drug in capsule two hours before the treatment with 
UVA light. Alternatively psoralen can be added to bath water (bath PUVA). Lastly is the topical 
application of psoralen gel or cream to small areas of psoriasis, about half an hour before UVA 
light treatment (Gawkrodger, 1997). 
 
There are several drawbacks of phototherapy for the treatment of psoriasis as summarised below:  
 
1) Both UVB and PUVA therapies increase the risk of skin cancer. 
2) In case of PUVA therapy, UV-sensitizing effects of psoralen persist for several hours. So after 
    PUVA treatment, patients must protect their skin and eyes from sun exposure for about 24 hours. 
3) Both UVB and PUVA therapies cause erythema and nausea. 
 
In order to provide effective treatment and reduce the limitations of first line and second line 
therapies, a few researchers have used photosensitive liposomes as nanocontainers to treat psoriasis 
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(Morgan et al., 1991). But they have used MLV. Apart from this, here in this project, IFV for the 
controlled release of psoralen derivative i.e. 4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-
trimethylpsoralen (HMT) has been used in order to treat psoriasis. This IFV offers many 
advantages. 
 
1) Clinical trial study shows that higher doses of psoralen work better to clear psoriasis than 
lower doses (Griffiths et al., 2000). However high dose means more side effects. Through 
photosensitive IFV it is possible to achieve a “burst release effect” therefore, this strategy 
can provide higher amount of psoralen to the affected area within a short period of time. 
2) Photosensitive IFV suspension can be applied topically and easily absorbed through skin 
and will remain in the human epidermis. By exposing to long -wavelength UVA light the 
entrapped psoralen is released form photosensitive IFV. After finishing this treatment, 
there is no need for the patients to protect their skin and eyes from sun exposure for 24 
hours (h) because in this treatment psoralen entrapped-IFV can be applied topically. 
According to the Neild and Scott (Neild and Scott, 1982), psoralen via topical route not 
only rapidly penetrate the skin but also detected in the urine after 4 hours whereas psoralen 
taken via oral route has a serum half-life of approximately 1 hour, however, the skin 
remains sensitive to light for 23 hours.  
3) It is a novel method and utilisation of UVA radiation is very less when compared to PUVA 
treatment. 
4) Erythema and nausea side effect observed in PUVA therapy can be minimised by 
photosensitive IFV, as IFV acts as barrier for the release of psoralen and thus the human 
skin is not directly exposed to psoralen compound.  
 
In this way, Photosensitive IFV along with PUVA therapy may be beneficial and in future it should 
become an important tool in treatment of psoriasis. As discussed earlier psoriasis is an 
inflammatory skin disease that is known to arise from the interplay of both genetic and 
environmental factors such as skin injury, stress and smoking which trigger excess skin 
inflammation resulting in psoriatic plaque (epidermal hyperplasia). In order to better appreciate 
predisposition to psoriasis, its etiologic link to skin, a better understanding of structure and 
behaviour of the human skin is necessary. In addition, an understanding of the skin structure and 
skin functions are sought in order to develop novel drug delivery tools improving on drug delivery 
efficiency and therapy efficacy. 
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1.5. Human skin   
 
The human skin covers the outer part of human body and is considered the largest organ of the 
human integumentary system. It is anatomically useful in containment of fluids and tissues, acts as 
an indispensable barrier to microorganisms and noxious chemicals, allergens and UV radiation and 
regulates heat and water loss (Proksch et al., 2008). Human homeostasis mechanism is entirely 
controlled by the skin. The skin of a 70 kg adult weighs about 3.6 kg and covers a total area of 
about 22 square feet (Williams, 2003). 
 
1.5.1. Skin Anatomy 
 
Anatomically, the human skin can be categorised into three main layers: - the epidermis, the dermis 
and the subcutaneous fatty tissue along with skin appendages, such as hair follicles, sebaceous and 
sweat glands (Bouwstra et al., 1991; Bouwstra et al., 2003; Tortora, 2008). Fig.1.9 illustrates the 
representation of human skin. 
 
 
 
Fig 1.9: A representation of human skin [taken from http://healthfavo.com/labeled-skin-
diagrams.html]. 
Chapter 1-Introduction 
 
75 
 
 
Epidermis is the outermost layer of skin which functions as a waterproof barrier and constructs our 
skin tone (Williams, 2003). Structurally, epidermis is made up of keratinocytes (~91%), merkel 
cells (5-9%), melanocytes and Langerhans (Kanitakis, 2002). This layer neither holds any blood 
vessels nor connects to blood capillaries. Therefore, for nourishment, epidermal cells entirely 
depend on the dermis layer (Stucker et al., 2002). The epidermis is a vascular complex that consists 
of five sublayers which are: stratum corneum, stratum lucidum, stratum granulosum, stratum 
spinosum and stratum germinativum (Tortora, 2008). 
 
Stratum corneum is the superficial layer of epidermis and is termed as a ‘horny layer’ which gives 
the skin its waterproof barrier properties (Bouwstra et al., 1991) Stratum corneum is made up of 
dead keratinocyte cells (Kanitakis, 2002). Keratinocytes are responsible for synthesis of keratin and 
have tendency to divide approximately every 28 days. Thus, keratinocytes play a major role in skin 
repair (Wilkes et al., 1973). They also diminish the transepidermal water loss and provide 
protection against the pathogens and chemicals. Several researchers points out that stratum 
corneum is a two compartment model, brick and mortar, in which keratinocytes are the bricks and 
the lipid lamellae represent the mortar (Forslind et al., 1997; Elias, 1983). In theory, this superficial 
layer serves as the main barrier to the body and thus is a major hurdle in skin drug delivery (Wertz, 
2000; Laugel et al., 2005). Stratum lucidum is situated in between the stratum granulosum and 
stratum corneum, and entirely made up of flattened keratinocytes. It has a translucent appearance 
which is easily seen through microscope (Flynn and Woodhouse, 2009). Stratum lucidum is also 
present in thick areas of skin such as palms of the hands and the soles of the feet (Mata and 
Dissanaike, 2012). Stratum granulosum is a thin layer that is situated in between stratum lucidum 
and stratum spinosum (Marks and Miller, 2006); its cells have keratohyalin granules that play an 
important role in binding of keratin filaments (Wilkes et al., 1973). Stratum spinosum is situated in 
between stratum granulosum and stratum basale and comprises polyhedral keratinocyte cells which 
are responsible for the beginning of keratinisation (McGrath et al., 2008; Marks and Miller, 2006) . 
Stratum germinativum, also referred as stratum basale, is the deepest (last) layer of epidermis 
which is found below the stratum spinosum (Tortora, 2008). Stratum germinativum is characterised 
as one cell thick epidermal sublayer which contains 5-10 % of melanocytes and is therefore the one 
responsible for melanin formation (Jimbow et al., 1976). Most of the skin diseases result from 
hyperproliferation of stratum germinativum (McGrath et al., 2008). 
 
Beneath epidermis is the dermal layer which provides support and nourishment to the epidermis. 
Dermis is made up of two fibrous materials - collagen and elastin fibres - which consist of collagen 
and elastin proteins, respectively (Tortora, 2008). The proteins increase the strength and elasticity 
of dermis. Further, dermis is divided into two sub layers: papillary and reticular. Papillary sub layer 
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is described as a thin layer due to loosely attached collagen fibres while reticular sub layer is 
described as a thick layer due to presence of coarse collagen bundles. In addition to the two sub 
layers, dermis contains skin appendages such as sweat glands, hair roots, nerve cells and blood and 
lymph vessels (Katz, 1971). Therefore, dermal layer functions as a temperature regulator, waste 
remover and stimulator for external stimuli (Kanitakis, 2002). 
 
Subcutaneous fatty tissue (also termed as hypodermis) is situated below the epidermis, and serves 
as the connector in-between the skin and muscles and bones (Bouwstra et al., 2003). It is composed 
of elastin fibres and loosely attached connective tissues. Additionally, it contains the macrophages 
and adipose tissue. Owing to adipose tissue presence, subcutaneous fatty tissue possesses 50 % of 
body fat that function as a padding and insulator (Madison, 2003). 
 
Skin appendages include the hair follicles, sebaceous glands and sweat glands and are widely 
distributed from dermal layer up to the stratum corneum sub layer of epidermis (Taylor, 2002). 
Hair follicles are responsible for hair formation while sebaceous glands produce sebum that gives 
lubrication to skin and sweat glands regulate the body temperature (Montero-Rievera, 1991). 
 
1.5.2. Skin permeability  
 
Skin permeation is complicated and happens primarily through the transappendageal route and 
additionally through transepidermal pathway  (Scheuplein, 1965). In case of transappendagel 
pathway, skin appendages like hair follicles, sweat and sebaceous glands are responsible for the 
skin permeation, whereas transepidermal pathway involves the permeation through stratum 
corneum (El Maghraby et al., 2008). Compared to transappendageal pathway, transepidermal 
pathway is a lengthy process and is further subdivided into intercellular and transcellular pathways 
(Scheuplein, 1965). Skin permeation is impacted upon by the size of the molecule, the 
physicochemical attributes of the penetrating drug and nanocarriers, the skin condition and the 
application site (Baroli, 2010) 
 
Skin permeability behaviour of a drug can be studied by several in vivo techniques, such as tape or 
skin stripping However in vivo permeation experimentation has shown enormous difficulty in case 
of transdermal drug delivery (Williams, 2003). As a result, in vitro techniques, such as Franz 
diffusion cells (Franz, 1975), have recently generated considerable research interest (Williams, 
2003). Therefore one of the the  objective of this study  is to conduct the Franz cell study on 
permeation of 4'-hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT) entrapped-interdigitation fusion 
vesicles (IFV). 
Chapter 1-Introduction 
 
77 
 
 
1.6. Franz diffusion cell (FDC) 
 
Franz diffusion cell is a hand blown diffusion cell frequently used for permeation assay. This 
technique was invented by Franz, T.M (Franz, 1978) while conducting studies on percutaneous 
absorption of organic compounds. Franz diffusion cell is composed of two borosilicate glass 
chambers that are separated by an excised skin membrane (Fig 1.10).  
 
 
 
Fig 1.10: Franz cell apparatus [taken from http/ www.particlesciences.com]. 
 
The upper compartment is often described as donor compartment. It is also called donor chamber, 
cell cap or cell top. The bottom compartment is termed as receptor chamber or cell body. The upper 
compartment is usually positioned on the surface of lower compartment in such way that together 
they form joint and an excised skin membrane is placed in the middle of the joint with the help of a 
metallic clamp. Thus, the donor and receptor compartments are separated by the excised skin 
membrane. Several researchers have used animal skin as the membrane but human skin is the 
preferred choice (Franz, 1975). In theory, drug formulation is directly applied to the skin 
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membrane through donor compartment. The bottom (receptor) compartment possess’ receptor 
medium that is continuously stirred throughout the experiment using a magnetic stirrer at mode 3. 
The Franz diffusion cells are connected to a closed circuit with circulating water bath at a constant 
temperature of 37 °C to keep the skin surface at approximately 33 °C. The epithelial skin fragment 
is equilibrated for 45 min with the receptor flowing while the donor compartment is dehydrated.  
At regular time intervals, the permeated drug formulation is withdrawn from the receptor 
compartment using a syringe (1,000 µl) and instantly replaced by an equal volume of fresh receptor 
medium in order to ensure sink conditions, and to maintain contact between the skin membrane and 
the receptor medium. The rate and extent of drug permeation via Franz diffusion cell varies 
significantly depending on the vehicle used. For a formulation scientist, Franz cell study gives an 
idea about whether the particular drug formulation delivers active agent via the excised skin or not, 
and to what extent. However, it is very difficult to find out the efficacy of drug formulation using 
Franz cell analysis and thus, this becomes its limitation (Karande and Mitragotri, 2009). The reason 
behind failure in determination of efficacy of drug formulation using Franz cell analysis is 
inadequate penetrability of chemical enhancers. Most of the chemical enhancers that have been 
studied in the transdermal literature for their capacity to increase transport across skin do not 
accomplish the desired skin disruption (Karande et al., 2004). They show limited permeation across 
the stratum corneum themselves and hence their movement is limited to the top few layers of the 
stratum corneum, as their concentration across the stratum corneum decreases. As a result, these 
chemicals offer poor transdermal delivery of candidate drug molecules using Franz cell analysis. In 
order to avoid such problem, here in this project, IFV were used to deliver drugs. This is because 
liposomes, micelles obtained from phospholipids have been successfully used as permeation 
enhancers (Cosco et al., 2008). Liposomes composed of lipids such as cholesterol and 
phospholipids typically act by entrapping drugs in their core and increasing their deposition in the 
stratum corneum (Fresta and Puglisi, 1996; Mezei and Gulasekharam, 1982; Touitou et al., 1994). 
Mezei and Gulasekharam (Mezei and Gulasekharam, 1982) already proved that triamcinolone 
acetonide deposition in skin to be 3- to 6-fold higher when delivered from liposomes as compared 
to conventional formulations. Skin drug delivery with skin-lipid liposomes was revealed to be more 
effective than delivery with phospholipid vesicles (Ramon et al., 2005; Kitagawa and Kasamaki, 
2006). Phospholipid vesicles do not have an appreciable effect when interacting with the stratum 
corneum as individual molecules. However, in the form of self-assembled structures as liposomes 
or micelles, they can easily fuse with the lipid domain of the stratum corneum thereby enhancing 
partitioning of encapsulated drug as well as disruption of the ordered bilayer structures (Williams 
and Barry, 1992).          
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1.7 Aim and Objectives  
 
As mentioned earlier, a few researchers have demonstrated that azo based photosensitive liposomes 
are beneficial and effective for drug delivery (Morgan et al., 1985; Sandhu et al., 1986). Moreover, 
Bisby and co-workers (Bisby et al., 2000a) confirmed that azo based photosensitive liposomes can 
be used for anti-cancer drug delivery. The research from Aston University has also demonstrated 
that photosensitive liposomes containing Bis-Azo PC are highly effective for tissue engineering 
(Smith et al., 2007). That means photosensitive liposomes containing Bis-Azo PC can be used for 
treating other diseases such as psoriasis, vitiligo. Therefore, the central aim of this project was to 
develop photosensitive liposomes that can be used for the controlled release of drugs through UV 
irradiation, particularly therapeutic agents for the treatment of skin diseases such as psoriasis, 
vitiligo. In order to achieve this aim, the following objectives need to be accomplished:  
 
 To synthesize photosensitive lipid i.e. Bis-Azo PC through lipid chemistry method and to 
characterize the synthesized lipid using NMR, UV, IR and Mass spectrometry. 
 
 To assess the incorporation of photosensitive lipid Bis–Azo PC into various IFV 
formulations (DPPC:Chol) and the entrapment of a protein marker i.e. bovine serum 
albumin conjugated with fluorescent isothiocyanate (BSA-FITC). Consequently, to 
examine the stability of IFV and evaluate the trigger release of protein marker.  
 
 To carry out the trigger release of protein marker using three different UV lamps and to 
select the most effective lamp that can give higher BSA-FITC release.  
 
 To investigate the incorporation of photosensitive lipid Bis–Azo PC into DPPC: Chol: Bis-
Azo PC (16:2:1) based IFV and entrapment of psoralen. Subsequently, to perform the 
stability studies and morphological analysis of IFV through confocal microscopy; and to 
estimate trigger release of psoralen.   
 
 To assess skin permeation behaviour of psoralen and psoralen-entrapped photosensitive 
IFV using Franz cell, and to study the permeation behaviour of psoralen and psoralen- 
entrapped photosensitive IFV via Leica confocal microscopy. 
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2.1. Introduction 
In recent years much research has focused on photochromism. Photochromism refers to the 
reversible photo-chemical conversion of chemical compounds to isomers by the absorption of 
electromagnetic radiation where the two forms possess different absorption spectra (Bouas-Laurent 
and Desvergne, 2003; Bouas-Laurent and Dürr, 2003; Irie, 2000) . The importance of 
photochromism in vision is well documented by Wald and co-workers (Wald, 1968). In this report, 
the researchers evidently indicated that the photoisomerization of 11-cis-retinal to 11-trans-retinal 
triggers photo-transduction in the retinal photo-receptor cells that ultimately leads to the visual 
perception. In addition to this, there are numerous other sectors in biochemistry where 
photochromism can be employed in order to regulate, control and synchronize biological systems. 
A notable example involves the intonation of ions or drug permeability via liposomes incorporating 
azobenzene derivatives to undergo photoisomerization upon UV and visible light illumination 
(Shimomura and Kunitake, 1987). Photoisomerization via UV and visible light irradiation has 
benefits of supplying a broad range of adjustable parameters such as wavelength, duration and 
intensity, which can be easily optimized in a non-disturbing manner; in contrast, other photo-
chemical transformations using photo-polymerization (Spratt et al., 2003; Bondurant et al., 2001; 
Miller et al., 1996) or photo-oxidation (Wymer et al., 1998; Collier et al., 2001; Smeds et al., 2001) 
of membrane lipids can disturb the integrity of bilayer membranes in order to enhance release of 
ions or drug materials from lipid vesicles. These photochemical processes using photosensitive 
liposomes have been discussed in detail in the general introduction chapter (see section 1.3.3.1).  
Photoisomerization via UV and visible light irradiation can be achieved by incorporating either 
azobenzene derivatives (Shimomura and Kunitake, 1981), stilbenes (Saltiel et al., 1968) or olefins 
(Adhikari et al., 2001). Contrary to stilbenes and olefins, whose photoisomerization reaction 
displays a high solution sensitivity, photoisomerization via azobenzene derivatives has been found 
to take place in viscous solutions, liquid crystals and solid materials (Bondurant et al., 2001; 
Bortolus and Monti, 1987; Haberfield, 1987; Monti et al., 1982; Rau and Lueddecke, 1982; Shinkai 
et al., 1982; Yamamoto, 1986). There is extensive literature available on the thermal and 
photoisomerization reactions using azobenzene derivatives (Siampiringue et al., 1987; Jones and 
Hammond, 1965; Hammond et al., 1964). Therefore, photoisomerization using azobenzene 
derivatives has received considerable interest and these derivatives are used as photoresponsive 
“triggers” for control of membrane permeability (Okahata et al., 1986). 
The photoisomerization of azobenzene and its derivatives occurs due to the presence of the azo 
group (–N=N-) in conjugation with two phenyl substituents. Even the UV/visible spectroscopic 
features of these aromatic compounds also depend on the presence of aromatic azo group. The 
presence of double bonds between the two nitrogen atoms gives rise to two different isomers i.e. E- 
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or Z- configuration. Therefore in the presence of UV light (about 320 nm), the more stable trans 
isomer of azobenzene (E)  is transformed into the less stable cis isomer of azobenzene (Z), while in 
the presence of visible light (about 430 nm) the cis isomer is transformed into trans isomer (Fig 
2.1). 
N N
UV light 320 nm
Visible light 430 nm
N N
Trans- isomer of Azo compound Cis- isomer of Azo compound
Fig 2.1: Trans-Cis isomerization of azo-compound in the presence of light. 
This cis-trans isomerization is supplemented by a huge geometrical and structural change. As a 
result, the para carbon atoms in the trans-isomer of azobenzene are at a distance of about 9.0 Å 
whereas in the cis-isomer they are only at a distance of about 5.5 Å. Even the retrenchment is 
higher in the cis form of azobenzene. Morgan and co-workers (Morgan et al., 1987b) have proven 
that the trans form of azobenzene has a virtually planner and linear structure with no dipole 
moment, whereas the cis form of azobenzene possesses dipole moment and the two aromatic ring 
of this isomer are out of plane due to orientation of the long axes of the aromatic ring at an angle of 
560. This research group also documented that photochemical decomposition is not major issue in 
case of azobenzene and its derivatives. Most importantly, azobenzenes are attractive because the 
isomerization is reversible and effective in terms of drug delivery on demand. All these unique 
features make azobenzene and its derivatives suitable candidates for the liposomal photo-triggers in 
terms of photosensitive liposomes. To date several different photo-triggering approaches 
incorporating azobenzene and its derivatives as the photo-control switch have been tried (Fig 2.2). 
Kano and colleagues (Kano et al., 1981) carried out the initial experiments in 1981 in order to 
investigate the membrane permeability of liposomes using a single chain amphiphilic azobenzene 
derivatives i.e. Azo-PC. They effectively incorporated C2-Azo-C12 and C4-Azo-C12 into the bilayer 
membrane of dipalmitoyl phosphatidylcholine (DPPC) liposomes. However, Shimomura and co-
workers (Shimomura and Kunitake, 1981) demonstrated that the single chain amphiphilic 
azobenzene derivatives stimulate the fusion and phase separation fusion process in bilayer 
membranes. Later on Morgan and  his research group (Morgan et al., 1985) introduced double 
chain azobenzene derivatives i.e. Bis-Azo Phosphatidylcholine (Bis-Azo PC) . UV irradiation 
causes trans to cis isomerization of both azobenzene fragments that lead to more disturbances in the 
bilayer than observed with single chain of azobenzene derivative i.e. Azo-PC.  
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Fig 2.2: Research involving Azo PC and its derivatives. 
1983 
 
In 1983, the modification of photosensitive liposomes based on 
photoinduced cis-trans isomerization was projected by Pidgeon and 
Hunt (Pidgeon and Hunt, 1983). 
 
In 1985 Morgan and co-workers validated the incorporation of a novel 
photochromic phospholipid molecule into vesicles of dipalmitoyl 
phosphatidylcholine (Morgan et al., 1985). 
 
During 1986, Sandhu and researchers proved the formation and 
Langmuir-Blodgett deposition of monolayers of novel photochromic 
azobenzene-containing phospholipid molecules. (Sandhu et al., 1986). 
 
Morgan and associates revealed in 1987 light-induced fusion of 
liposomes released trapped marker dye when sensitised by 
photochromic phospholipid (Morgan et al., 1987b). 
Bisby and collaborators verified rapid drug release from 
photosensitive liposomes upon UV photolysis (Bisby et al., 2000a; 
Bisby et al., 2000b; Smith et al., 2007). 
In 2007, Smith and their group researchers validated formation of 
alginate hydrogel scaffolds for tissue engineering by light activated 
release of calcium from photosensitive liposomes.  
 
 
 
1985 
1986 
1987 
2000 
2007 
First azobenzene derivative was synthesized by Kano in 1981. Kano 
and co-workers demonstrated that membrane permeability of 
liposomal membrane is affected by using photoreversible cis-trans 
isomerization of azobenzenes (Kano et al., 1981). 
 
1981 
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The liposomes containing Bis-Azo PC led to rapid release of entrapped drug upon UV light 
illumination. A few minutes of UV irradiation cause complete release of entrapped material which 
is not beneficial to the sustained or multipulsatile drug release. As a result, during 2000, Bisby and 
research group (Bisby et al., 2000a; Bisby et al., 2000b) introduced varying amount of Bis-Azo PC 
and cholesterol in order to minimize perturbation and spontaneous release to bilayer membranes. 
Similar research also indicated that liposome of DPPC containing Bis-Azo PC (6 mol %) and 
cholesterol (up to 15 mol %) showed no significant leakage of calcein for at least 8 weeks, while 
liposomes containing higher concentrations of Bis-Azo PC (e.g. 10 mol %) are stable overnight, 
but release their contents during a long term storage. Thus, by using cholesterol, liposomes 
containing Bis-Azo PC offer a suitable means to ‘cage’ water soluble compounds (e.g. calcium and 
copper) and drugs such as methotrexate (Morgan et al., 1991). For that reason, this system is 
beneficial in terms of drug delivery and photodynamic therapy. 
 
In 2007, Smith et al. (Smith et al., 2007) used Bis-Azo PC incorporated liposomes with the purpose 
of trigger gelation of an alginate solution by releasing calcium chloride upon irradiation with 385 
nm light for 1 min. This strategy plays a key role in tissue engineering.  
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2.2. Aim and Objectives: 
 
The aim of this part of the project was to synthesize and characterise Bis-Azo Phosphatidylcholine 
with the method reported previously by Sandhu and co-workers (Sandhu et al., 1986) with some 
modifications. In order to achieve this, specific objectives were: 
 
 Preparation and characterisation of 4-(n-butyl) nitrosobenzene. 
 Preparation and characterisation of Azo acid compound. 
 Synthesis and characterisation of Bis-Azo Phosphatidylcholine. 
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2.3. Materials and Experimental Methods 
 
2.3.1 Chemicals 
 
Unless otherwise noted all reactions were executed in oven dried glassware. Chemicals unless 
specified, were sourced from Sigma (Sigma-Aldrich, UK) or Fisher (Fisher Scientific, UK) without 
further purification. All aqueous solutions were prepared with double distilled deionised water. 
Pivaloyl chloride, 4-(4-aminophenyl) butanoic acid and 4 - butylaniline were purchased from Alfa 
Aesar, UK. Potassium peroxymonosulphate was obtained from Acros Organics, UK. Aluminium 
silica gel 60 F254 plates (Merck, Germany) were used for thin layer chromatography (TLC). B.D.H 
silica gel (MFC) (Merck, Germany) Kieselgel Art 7736 was used for flash column 
chromatography. 
 
2.3.2 Instrumentation 
 
NMR spectra were recorded on a Bruker AC- 250 instrument (250MHz for 1H; 62.9 MHz for 13C) 
spectrometer, at 23 °C, 64 scans at an acquisition time of 3 seconds. The samples were dissolved in 
DMSO-d6 and referenced at δDMSO = 2.50 ppm unless otherwise stated. 1H and 13C NMR 
chemical shifts are reported as parts per million (ppm) relative to TMS (0.00 ppm). A Mattson 
3000 FTIR spectrophotometer was used to obtain infrared spectra by using either KBr disc method 
or cast film technique using NaCl cells or a Thermo Scientific Nicolet is5 with iD5 ATR 
connection as a solid sample. The synthesized materials were poured into quartz cuvette 
(pathlength 1 cm) for optical absorption using a Cary 1 E UV–Vis spectrophotometer. A Hewlett-
Packard 5989B quadrapole instrument connected to an electrospray 59987A unit with an 
atmospheric pressure chemical ionisation (APCI) accessory and automatic injection using a 
Hewlett-Packard 1100 series autosampler was used to obtain APCI mass spectrum and 
Electrospray ionisation (ES) for some mass spectra  or a Waters 2795 LC/MS using Mass lynx 
software for others. Melting points were measured on a Reichert-Jung Thermo Galen hot stage 
microscope and corrected by calibrating against a compound of known melting point. 
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2.3.3. Experimentation 
 
2.3.3.1 Preparation of 4-(n-butyl) nitrosobenzene- method 1: 
 
 
 
This method was adapted from Kennedy and Stock (Kennedy and Stock, 1960) with some 
modifications. 4- Butylaniline (2.11 mL, 0.013 mol) was added into the RBF (150 mL) containing 
10 mL of diethyl ether. Potassium peroxymonosulphate (5 g, 0.033 mol) was dissolved in 30 mL of 
water in a beaker and this solution was added rapidly to the above solution. The mixture was 
allowed to cool to room temperature and the solution was made basic by the addition of sodium 
carbonate (0.5 g) while monitoring the pH. The ether layer and a yellow solid which had 
precipitated were separated from the aqueous phase of the mixture. Then, the aqueous solution was 
extracted continuously with diethyl ether for a period of 30 min. The diethyl ether extractions were 
combined, dried over anhydrous magnesium sulphate, filtered and evaporated to dryness. The 
crude 4-(n-butyl) nitrosobenzene thus obtained was recrystallized from ethanol, giving a yellow 
product (1.65 g, 78 %). Rf (chloroform): 0.43; melting point: 116 °C; 1H NMR (250 MHz, DMSO-
d6) δ: 8.16 (d, 2H, aromatic), 7.31 (d, 2H, aromatic), 2.66 (m, 2H, -CH2CH2CH2CH3), 1.60 (m, 2H, 
CH2CH2CH2CH3), 1.30 (m, 2H, CH2CH2CH2CH3), 0.91 (m, 2H, CH2CH2CH2CH3); 13C NMR (62.9 
MHz, DMSO-d6) δ: 146.50, 142.22, 129.22, 122.19, 36.02, 30.94, 22.28, 13.95. 
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2.3.3.2. Preparation of 4-(n-butyl) nitrosobenzene - method 2: 
 
 
 
This method was adapted from Okazaki et al 1969 (Okazaki et al., 1969) with some modifications. 
To a RBF, peroxybenzoic acid (1.44 g, 0.01 moles) was added to 10 mL of ice-cooled 
dichloromethane (solution A). In a separate flask, 4-butylaniline (0.5 mL, 0.003 moles) was added 
to 10 mL of ice–cooled dichloromethane (solution B). Then, solution B was added dropwise into 
the RBF containing solution A with constant stirring at 0 °C. The reaction was kept overnight at 0 
°C, after which the reaction mixture was shaken with aqueous sodium carbonate in order to remove 
benzoic acid. The organic layer was dried over anhydrous magnesium sulphate and then the solvent 
was evaporated under reduced pressure on the rotary evaporator. The crude product was 
recrystallized from ethanol, giving the final compound as a yellow coloured product (0.685 g, 30 
%). Rf (chloroform): 0.43; melting point: 116 °C; 1H NMR (250 MHz, DMSO-d6) δ: 8.16 (d, 2H, 
aromatic), 7.31 (d, 2H, aromatic), 2.66 (m, 2H, -CH2CH2CH2CH3), 1.60 (m, 2H, CH2CH2CH2CH3), 
1.30 (m, 2H, CH2CH2CH2CH3), 0.91 (m, 3H, CH2CH2CH2CH3); 13C NMR (62.9 MHz, DMSO-d6) 
δ: 150.70, 146.50, 129.70, 122.64, 36.02, 30.94, 22.28, 13.95. 
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2.3.3.3. General procedure for the preparation of 4-{4-[(4-butylphenyl) diazenyl] phenyl}             
              butanoic acid 
 
 
 
The synthesis of this compound was adapted from Morgan and co-workers (Morgan et al., 1987b; 
Morgan et al., 1985; Sandhu et al., 1986). 
 
4-(n-butyl) nitrosobenzene (1.3 g, 0.008 moles) and 4-(4-aminophenyl) butyric acid (1 g, 0.005 
mols) were dissolved in 6 mL of glacial acetic acid at room temperature, and the whole mixture 
was allowed to stand for several hours. At this stage, crystalline 4-(n-butyl)-4’ (3-carboxypropyl) 
azobenzene separated out and was filtered off. The product was dissolved in chloroform, washed 
with 10% aqueous sodium bicarbonate and dried over anhydrous magnesium sulphate. Purification 
of azo acid compound was done by column chromatography eluting with choloroform/petroleum 
ether (50:50, v/v). The final product was obtained as a brownish yellow solid (1.004 g, 62 %). Rf 
(Chloroform: petroleum ether 1:1) = 0.5; melting point: 35-40 °C; 1H NMR (250 MHz, DMSO-d6) 
δ: 7.80 (d, 2H, aromatic ), 7.80 (d, 2H, aromatic ), 7.32 (d, 2H, aromatic), 7.32 (d, 2H, aromatic), 
2.65 (m, 2H, HOOCCH2CH2CH2), 2.54 (m, 2H, CH2CH2CH2CH3), 2.33 (m, 2H, 
HOOCCH2CH2CH2), 2.18 (t, 2H, HOOCCH2CH2CH2), 1.68 (m, 2H, CH2CH2CH2CH3), 1.36 (m, 
2H, CH2CH2CH2CH3), 0.91 (t, 3H, CH2CH2CH2CH3 ); 13C NMR (62.9 MHz, DMSO-d6) δ: 178.45, 
150.99, 146.15, 129.84, 129.24, 122.70, 122.08, 37.73, 34.09, 32.47, 30.94, 26.99, 22.29, 13.94; 
MS: calculated for [C20H23N2O2] 324.18, found 323.17 (M-H); IR (near) cm-1 = 3419, 2954, 2928, 
2856, 1602, 1180, 1465, 839,548; λmax - 334 nm. 
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2.3.3.4. Synthesis of Bis-Azo Phosphatidylcholine  
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To a stirred suspension of 4-{4-[(4-butylphenyl)diazenyl]}butanoic acid (0.0091 g, 0.002 moles) in 
2 mL of dry methylene chloride, redistilled triethylamine (4.5 µL) and pivaloyl chloride (15 µL) 
were added. The reaction was incubated for 120 minutes at 25 °C with continuous stirring. The 
reaction was monitored by TLC to confirm the formation of mixed anhydride. The compound was 
vacuum dried for 120 minutes at 25 °C (Morgan et al., 1982). 
 
Next, sn-Glycero-3-phosphorylcholine (0.257 g, 0.001 moles) was suspended in 20 mL of freshly 
distilled anhydrous chloroform followed by the addition of 4-(N, N-dimethylamino) pyridine 
(DMAP (0.244 g, 0.002 moles) and mixed anhydride (0.810 g, 0.003 moles) synthesised. The 
reaction vessel was flushed with nitrogen, the reaction flask tightly sealed, and the mixture was 
stirred at ambient temperature. Protection from light was necessary because of the sensitivity of 
anhydrous ethanol-free chloroform. After completion of the reaction (35-40 hr), the solvent was 
removed under reduced pressure and the residue was treated with 20 mL of methanol 
/chloroform/water (5:4:1, v/v/v). After filtration through a sintered –glass funnel, the solution was 
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evaporated and the desired product was purified by column chromatography eluting with 
choloroform/methanol/water (65:25:10, v/v/v). In order to remove any silica gel particles, the 
phospholipids were filtered through a sintered –glass funnel as a solution in methylene chloride and 
dried to obtain final product as a brownish red solid (0.0115 g, 70 % ) yield (Radhakrishnan et al., 
1981). Rf (Chloroform) = 0.45; 1H NMR (250 MHz, DMSO-d6) δ: 7.84 (d, 1H, aromatic), 7.84 (d, 
1H, aromatic), 7.27 (d, 1H, aromatic), 7.27 (d, 1H, aromatic),  6.55 (m, 1H, OCH2OCHCH2), 4.22 
(d, 2H, OCH2OCHCH2), 3.66 (d, 2H, OCH2OCHCH2), 3.34(s, 1H, OOOPOCH2CH2N(CH3)3), 3.20 
(m, 2H, OOOPOCH2CH2N(CH3)3), 3.07(s, 9H, N(CH3)3), 2.58 (m, 4H, CH2CH2CH2CH3), 2.37 (m, 
4H, OOCCH2CH2CH2), 2.18 (t, 4H, OOCCH2CH2CH2), 1.92 (s, 4H, OOCCH2CH2CH2), 1.65 (m, 
4H, CH2CH2CH2CH3), 1.25 (s, 4H, CH2CH2CH2CH3 ), 0.94 (t, 6H, CH2CH2CH2CH3); 13C NMR 
(62.9 MHz, DMSO-d6) δ: 172.44, 155.12, 150.12, 149.68, 146.58, 129.17, 129.07, 123.15, 122.78, 
79.70, 70.90, 66.03, 62.96, 58.57, 56.92, 39.34, 35.57, 33.47, 30.94, 27.70, 22.34, 13.95; MS: 
calculated for [C48H64N5O8P] is (870.02), found mass: (870.50); IR (near) cm-1: 3390, 2958, 2927, 
2343, 2362, 1640, 1612, 1534, 1380, 1226, 1066, 946, 817, 663; λmax :- 256 nm, 332nm. 
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Fig. 2.3: General procedure involved in the synthesis of Bis-Azo Phosphatidylcholine.             
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2.4. Discussion 
 
The synthesis of Bis-Azo PC is not an easy process, though it looks very straightforward from Fig 
2.3. It involved the three major steps: 1) synthesis of Nitrosobenzene, 2) synthesis of azo acid and 
3) synthesis of Bis-Azo Phosphatidylcholine. The characterisation of these compounds has not 
been reported previously. However, few articles noted only NMR results of final compound i.e. 
Bis-Azo Phosphatidylcholine.   
 
2.4.1. Synthesis of 4-(n-butyl) nitrosobenzene  
 
4-(n-butyl) nitrosobenzene was synthesized by two methods. In both methods 4-butylaniline was 
used as the starting material but with different oxidizing agents. The first method gave prominent 
result and better yield compared with the second method. 
 
In the first method, the synthesis of 4-(n-butyl) nitrosobenzene involved the oxidation of 4- 
butylaniline with potassium peroxymonosuplhate in ether (Fig 2.4a and b). This was based on a 
method reported previously (Kennedy and Stock, 1960) with some modifications. As this was 
exothermic reaction, whole process was carried in an ice bath. During the reaction, ether was used 
to dissolve the starting material and water was used to dissolve the oxidizing agent, potassium 
peroxymonosulphate.  
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1-butyl-4-nitrosobenzene
b)
a)
1-butyl-4-nitroso-benzene
4-butylaniline
4-butylaniline
1-butyl-4-nitrosobenzene  
Fig 2.4: a) General equation for the synthesis of 4-(n-butyl) nitrosobenzene, and b) 
mechanism behind this synthesis. 
 
The whole reaction was completed within five hours. Furthermore, purity of product was 
determined by chromatography and melting point study. 
 
Thin layer chromatography (TLC) was conducted to determine the purity of 4-(n-butyl) 
nitrosobenzene. TLC results obtained from the resulting reaction mixture clearly indicated two 
spots (Fig 2.5 a) on silica plate. It could be inferred that the product was contaminated with some 
amount of starting material. Therefore, 4-(n-butyl) nitrosobenzene was purified by recrystallization. 
Several recrystallizations were attempted with various solvents including ether (the solvent which 
was used to dissolve the starting material) however, with very limited success. At last, 4-(n-butyl) 
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nitrosobenzene was recrystallized by ethanol. TLC analysis was conducted again in order to verify 
the purity of the product and the results showed a single spot (Fig 2.5 b). As can be seen from Fig 
2.5, analytical TLC on a silica gel plate showed that the starting material and the resulting mixture 
travel on silica adsorbent at different rates, when chloroform was used as the developing solvent. 
       
                                 
 
                                      
Fig 2.5: TLC analysis of 4-(n-butyl) nitrosobenzene before (a) and after (b) recrystallization 
with ethanol. 
 
The purified product was characterized by nuclear magnetic resonance (NMR), Ultraviolet (UV) 
spectroscopy (see Section 2.3.3.2) and its melting point was determined with Gallenkamp Variable 
Heater Melting Point Apparatus and found to be 116 °C.  
Starting material    
[4-butylaniline] 
 
Starting material 
[4-butylaniline] 
Product               
[(4-(n-butyl) 
nitrosobenze] 
Product             
[(4-(n-butyl) 
nitrosobenze]   
a) b) 
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Initially, while performing the nitrosobenzene synthesis, an additional undesired white powder was 
obtained, which could not be removed by recrystallization. Several recrystallization attempts were 
carried out in various solvents such as ether, chloroform, but without success. It was presumed that 
the undesired product might be due to the rapid addition of the oxidizing agent, potassium 
peroxymonosulphate. A dropwise addition of oxidizing agent in the solution reduced the formation 
of the undesirable white product.  
 
The second approach (see section 2.3.1 method- 2) to synthesize 4-(n-butyl) nitrobenzene using 4-
butylaniline with peroxybenzoic acid in presence of dichloromethane (Fig.2.6) was not to 
encouraging, because the product yield was very low (30 %). In addition, cooling and stirring for 
overnight was time consuming. Overall, second method did not give satisfactory results. . 
Therefore method 1 was used to prepare 1-butyl-4-nitrosobenzene.  
 
 
CH3
NH2
CH3
O
N
4-butylaniline
1-butyl-4-nitrosobenzene
3-chloroperoxybenzoic acid
 
 
Fig 2.6: General equation for the synthesis of 1-butyl-4-nitrosobenzene by second method. 
 
2.4.2. Synthesis of 4-{4-[(4-butylphenyl) diazenyl] phenyl} butanoic acid 
 
Azo Acid was successfully synthesized by the azo condensation reaction, in which, the equimolar 
amount of 4-(n-butyl) nitrosobenzene and 4-(p-aminophenyl) butyric acid was used (Fig 2.7). 
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Fig 2.7: a) General equation for the preparation of 4-{4-[(4-butylphenyl) diazenyl] phenyl} 
butanoic acid, and b) Mechanism behind this reaction. 
 
Though reaction was very simple and straightforward, but the product yield was very low and 
impure. Therefore, resultant product was separated by flash column chromatography (FCC).  
+ 
+ 
H
+
 
H
+
 -H2O 
b) 
a) 
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Fig. 2.8: TLC analysis of 4-{4-[(4-butylphenyl) diazenyl] phenyl} butanoic acid. 
Details of spots detected in above figure are as follows, red coloured spots from 4 to 6: fractions of desired 
compound, dark blue coloured spots from 7 to 9: contaminated with desired and undesired compound, yellow 
coloured spots 10 to 18: undesired compound and tan coloured spots 19 to 24: polar impurities. Elution 
solvent was choloroform/petroleum ether (50:50, v/v). 
Fig. 2.8 above illustrates a silica-gel plate, onto which were spotted samples, with the purpose of 
analysing and preparing azo acid. Column chromatography was performed using 
choloroform/petroleum ether (50:50, v/v) as eluting solvent, and the fractions collected in 
numbered test tubes (1-24). During this Azo acid separation, the mobile phase in the system 
migrate through the stationary phase i.e. silica gel with the help of isocratic pump; therefore the 
different components of crude sample are eluted at different rates due to their migration at different 
speeds. It has been reported that the elution of components was dependent on their polarities, the 
nature of the stationary phase (adsorbent), and the solvent used for elution (mobile phase) (Jack et 
al., 2002). As indicated in Fig.2.8, from left to right, the pure compound of interest Azo acid was 
1 2 4 3 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
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collected in tubes 4-6, meanwhile impure samples collected in tubes 7-9. Moreover, undesirable 
compounds were collected in tubes 10-18 and polar samples collected in tubes 19-24. In theory, 
Column chromatography removes any polar impurities, intermediate impurities and unreacted 4-(n-
butyl) nitrosobenzene. 
 
Based on the TLC results, it could be speculated that an eluting solvent which gives an Rf value of 
0.5 for the most polar compound gives a better Azo acid separation from the crude samples  
 
Product from test tubes 4-6 showed desired product i.e. 4-{4-[(4-butylphenyl) diazenyl] phenyl} 
butanoic acid which was characterized by NMR, UV, Mass spectrometry and Infra-red (IR) 
spectroscopy (see Section 2.3.3.3). 
 
2.4.3 Synthesis of Bis-Azo Phosphatidylcholine 
 
Bis-Azo Phosphatidylcholine was synthesized by azo acid and L-alpha glycero phosphatidylcholine 
(Fig 2.9). Reaction mechanism involved two steps: acetylation reaction and attachment of 
phosphatidylcholine. Synthesis and purity of Bis-Azo Phosphatidylcholine depends upon the azo 
acid anhydride formation and the phosphatidylcholine attachment (Fig 2.10). The stereochemistry 
of Bis-Azo pc in the presence of light is shown in Fig 2.11. The resultant product was characterized 
by NMR, UV and IR. 
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Step: 1  
 
 
 
 
 
        Trans- isomer of 4-{4-[(4-butylphenyl) diazenyl] phenyl} butanoic acid        Pivaloyl chloride 
                                              
                                                                           4-(N, N-dimethylamino) pyridine (DMAP)             
                 CH2Cl2 
 
 
                   
 
 
 
    Step: 2                                Trans- isomer of Mixed Anhydride    
 
N
N
O
O
N
+
O
P
O
O
O
-
O
O
N
N
                 
   Trans- isomer of Bis-Azo Phosphatidylcholine 
Fig 2.9: Preparation of Bis-Azo Phosphatidylcholine. 
Glycero-PC 
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Fig 2.10: The reaction mechanism involved in the synthesis of Bis-Azo Phosphatidylcholine. 
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Trans- isomer of Bis-Azo Phosphatidylcholine 
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Cis- isomer of Bis-Azo Phosphatidylcholine 
 
Fig 2.11: Stereochemistry of Bis-Azo Phosphatidylcholine.
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2.4.3.1. Stereochemistry of Bis-Azo Phosphatidylcholine 
 
The photoisomerization of Bis-Azo Phosphatidylcholine occurs due to the presence of the azo 
group (–N=N-) in conjugation with two phenyl substituents (Morgan et al., 1987b; Morgan et al., 
1985; Sandhu et al., 1986). The presence of double bonds between the two nitrogen atoms gives 
rise to two different isomers i.e. E- or Z- configuration. Bisby and co-workers (Bisby et al., 2000a) 
demonstrated that  in the  presence of UV light (about 360 nm), the more stable trans-isomer of  
Bis-Azo Phosphatidylcholine is transformed into the less stable cis-isomer of  Bis-Azo 
Phosphatidylcholine, while in presence of visible light (about 420 nm) the cis-isomer is 
transformed into trans-isomer (Fig 2.11). This cis-trans transformation plays a key role in case of 
drug delivery. 
 
2.4.3.2. NMR spectroscopy 
 
Due to strong overlaps of peaks in the Bis-Azo Phosphatidylcholine structure, it can be very 
difficult to fully interpret 1H NMR and 13C NMR spectra, hence it was decided to predict the NMR 
spectra of Bis-Azo PC from chemical database software and compare it with the product spectra. 
This would confirm whether the reaction was successful or not. These results are noted in section 
2.3.3.3. Along with 1H NMR and 13C NMR, the resultant product was also analysed by attached 
proton test (APT). 
 
The Attached Proton Test (APT) experiment is a common way to assign C-H multiplicities in 13C 
NMR spectra. It consists of a 90o pulse that creates transverse magnetization; followed by a 180 
pulse in the middle of the evolution period (serves to refocus the chemical shift). It provides the 
information for all sorts of carbons in one experiment (Siegmar Braun, 1998). 
 
Depending on the number of hydrogens bound to a carbon atom, n, CHn spin vectors evolve 
differently after the initial pulse. If the delay t is set to 1/J, CH and CH3 vectors have opposite 
phases compared to C and CH2. Therefore, the phase of CH and CH3 peaks is 180o different from C 
and CH2 peaks. It is slightly less sensitive than DEPT but a single experiment shows all carbon 
signals at once unlike DEPT that suppresses quaternary carbons and requires up to three different 
acquisitions to yield full results. 
 
APT result of Bis-Azo Phosphatidylcholine: 
 
Fig 2.12 shows the APT spectra of Bis-Azo Phosphatidylcholine (Refer to Fig 2.11 for structure): 
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Fig 2.12: APT spectrum of Bis-Azo Phosphatidylcholine showing CH and CH3 positive while 
CH2 and quaternary C are negative. 
 
As evident from the Fig 2.12, in an APT experiment for Bis-Azo Phosphatidylcholine (Refer to Fig 
2.11), positive signals were obtained for methine (CH) and methyl (CH3), whereas negative signals 
were obtained for quaternary (C) and methylene (CH2). 
 
2.4.3.3. UV spectroscopy 
 
UV absorption spectra of Bis-Azo Phosphatidylcholine had maxima at 256 nm and 332 nm. The 
maxima was observed at 256 nm because of the π - π* transition of benzene chromophore and at 
332 nm because of the n _ π* transition between benzene and azo chromophore. From UV analysis, 
it is apparent that resultant product showed a shorter wavelength shift, i.e. blue shift. 
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2.4.3.4. IR spectroscopy 
 
IR analysis of Bis-Azo Phosphatidylcholine (Bis-Azo PC) was performed on a Mattson 3000 FTIR 
spectrophotometer using KBr disc method. Fig 2.13 shows the IR spectrum of Bis-Azo 
Phosphatidylcholine (Refer to Fig 2.11 for structure). 
 
 
 
Fig 2.13: IR spectrum of Bis-Azo Phosphatidylcholine 
 
As depicted from the Fig  2.13, the IR showed important bands at 663 cm-1, 817 cm-1, 946 cm-1, 
1066 cm-1 (C-C stretching ), 1226 cm-1, 1380 cm-1 (C-N stretching ), 1612 cm-1, 1534 cm-1 
(Aromatic rings), 1640 cm-1 (C=O stretching ), 2362 cm-1, 2343 cm-1 (C=C stretching ), 2927 cm-1 
(C-H stretching), 2958 cm-1 (CH3) and 3390 cm-1 (O-H stretching). 
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2.4.3.5. Mass spectrometry 
 
With the intention to determine the exact mass of Bis-Azo Phosphatidylcholine, the WATERS LCT 
premier ESI-TOF-MS instrument was used. It determines the masses of compounds by analysing 
the mass-to-charge ratio of the charged species obtained from the compound after electrospray- 
ionization (Fenn et al., 1989). The Bis-Azo PC sample was dissolved in methanol prior to mass 
spectroscopy analysis. The sample was loaded onto the instrument and the molecular components 
in solution were vaporized into the gas phase by bombarding them with beam of electrons which 
produce an ionic molecule or ionic fragments of the original species. These ionic molecules were 
then passed through the magnetic or electric fields to the mass detector, where they were isolated as 
per their mass to charge ratio (m/e) and thus easily detected (Tanaka et al., 1988). The spectrum 
(Fig. 2.14) below clearly demonstrates the ion signals which were generated from Bis-Azo 
Phosphatidylcholine. 
 
Fig 2.14: Mass spectrum of Bis-Azo Phosphatidylcholine. 
 
Molecular formula of Bis-Azo Phosphatidylcholine is [C48H64N5O8P] with a calculated 
monoisotopic mass of 870.02. As depicted from Fig 2.15, the obtained mass of the product was 
870.50.  
 
It is evident from the NMR,UV,IR and mass spectrometry results that Bis-Azo Phosphatidylcholine 
was successfully synthesized and characterized by the above methods (Fig 2.3, see section - 2).  
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2.5. Conclusion 
 
In Conclusion, Bis-Azo Phosphatidylcholine was successfully prepared. This synthetic approach 
could advance the synthesis of azo based photosensitive liposome. There were a lot of difficulties 
encountered in Bis-Azo Phosphatidylcholine synthesis. Despite of these difficulties, Bis-Azo 
Phosphatidylcholine was synthesized successfully. 
 
Proton and carbon NMR results showed all desired peaks that can confirm the structure of Bis-Azo 
Phosphatidylcholine. Moreover, NMR spectroscopy can be used to differentiate trans and cis 
isomers, and this was confirmed by the coupling constant of trans isomer was larger than the 
coupling constant of cis isomer. UV and IR analysis verified the presence of N=N chromophore 
and functional groups such as OH, C=C, C-H, CH3, aromatic ring etc. These results also contribute 
to the presence of Bis-Azo Phosphatidylcholine molecule. 
 
Mass spectrometry proved the correct mass of the synthesised Bis-Azo Phosphatidylcholine. That 
means the route for the synthesis of Bis-Azo Phosphatidylcholine was workable. The developed 
synthetic strategy in this project could also be applied to prepare other new photosensitive lipid 
derivatives.  
.  
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CHAPTER 3 
Development of Photosensitive Liposomes for 
the Controlled Release of Bovine Serum 
Albumin-Fluorescein Isothiocyanate 
 (BSA-FITC) 
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3.1 Introduction  
 
Liposomes are established as drug delivery systems with products such as DaunoXome® 
Ambisome®,Visudyne®,Thermodox®. Some of them have been used as potential carriers for 
controlled release of drugs (Torchilin, 2005). In the past, scientists have reported that the controlled 
release of drugs from liposomes can be triggered by a variety of external stimuli such as heat 
(Gaber et al., 1996), light (Pidgeon and Hunt, 1983) and pH (Yatvin et al., 1980). Later on, 
attention has been directed towards the development of photosensitive liposomes which release 
their contents in response to irradiation with an appropriate wavelength of light. Photosensitive 
liposomes can be formulated by two methods: incorporation of photosensitive lipid into the bilayer 
membranes, for instance, incorporation of azobenzene based moieties (Lei and Hurst, 1999) and 
using nanoparticles to channel light energy into heat energy or mechanical energy, such as, gold 
nanoparticles (Park et al., 2006). 
 
This chapter primarily focuses on the formulation of photosensitive liposomes by incorporation of 
photosensitive lipid into the bilayer membranes. As discussed earlier (Section 1.3.3), 
photosensitive lipid is composed of three parts: a polar hydrophilic head group, a chromophoric 
group, which is responsible for light absorption and photoisomerization, and lastly, a hydrophobic 
tail. Upon UV irradiation, photosensitive liposomes incorporating photosensitive lipids become 
unstable due to photoisomerisation of the chromophore. This process results in the disruption of the 
lamellar integrity and the fast release of liposome-entrapped drugs (Fig 3.1) (Shum et al., 2001). 
Overall, the mechanism of the photo- triggered release mostly relies on the principle of membrane 
destabilization in response to light for the rapid release of trapped pharmaceuticals.(Wan et al., 
2002; Jeong et al., 2002; Anderson and Thompson, 1992) 
 
 
 
Fig 3.1: Exposure to long wavelength UV light causes rapid release of entrapped drug. 
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Numerous studies (Sandhu et al., 1986; Morgan et al., 1987a) have shown that stable light-sensitive 
liposomes of gel phase lipids can be successfully prepared by incorporating photosensitive lipid 
“Bis-Azo PC”, which is a phosphatidylcholine (PC) molecule having acyl chains incorporating 
azobenzene moieties. However, this photosensitive lipid exists in trans-isomer under visible light 
illumination, and it is transformed into the cis-isomer on exposure to UV light at 366 nm (Fig 3.2) 
(Morgan et al., 1985). This trans-cis isomerisation is responsible for the release of liposomal 
contents. During this transformation, azobenzene chromophores are very compact, relatively linear 
molecules of low polarity, whereas in cis-form, azobenzene chromophores are non-linear with a 
large molecular dipole moment (Morgan et al, 1995). 
 
 
 
Fig 3.2: On exposure to UV light, trans-form of Bis-Azo PC gets transformed into cis- form of 
Bis-Azo PC [adapted from (Morgan et al., 1985)]. 
 
Liposomes containing Bis-Azo PC have been used to ‘cage’ water-soluble solutes, which include 
biologically important cations, such as copper and calcium (Bisby et al., 1999b). In addition, 
liposomes with Bis-Azo PC have been successfully used to ‘cage’ water-insoluble drugs, such as 
methotrexate (New 1990). Photosensitive liposomes have an advantage as they could be applied as 
carriers for introducing biologically active material into cells by endocytosis, thus minimising 
materials exposure to degradative enzymes prior to release upon trigger. Indeed, Morgan and co-
workers (Morgan et al., 1987a) prepared azo based photosensitive liposomes from dipalmitoyl 
phosphatidylcholine (DPPC) containing 8 % (mole: mole) Bis-Azo PC, entrapping a fluorescent 
marker dye over a period of month with negligible release. Furthermore, they have used long 
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wavelength UV to release a similar dye, within minutes, from photosensitive liposomes. Morgan 
and co-workers also noted that in terms of size, Bis-Azo PC resembles DPPC and that both lipids 
contain a highly cooperative phase transition at 41 °C. 
 
DPPC are good building blocks for the production of liposomes due to their zwitterionic effect. In 
addition, phospholipids with a longer chain length possess higher encapsulation efficiency and 
stability than phospholipids with shorter chain length (Mohammed et al., 2004b). Hence DPPC is 
an ideal choice as compare to other PC. Moreover, the addition of cholesterol to this photosensitive 
liposomes increases stability and reduces permeability (Bisby et al., 1999b). However, cholesterol 
amount is vital; at small amounts, cholesterol could easily dissolve within the lipid bilayer while at 
large amounts ( ̴  50 % mol/mol), crystals of cholesterol monohydrate could be produced that lead 
to liposomal instability (Epand and Epand, 2003; Epand et al., 2003). Based on these results, Smith 
and co-workers (Smith et al., 2007) developed photosensitive interdigitation fusion vesicles (IFV) 
which they used for tissue engineering. In brief, they formulated IFVs from DPPC, Cholesterol and 
Bis-Azo PC by using interdigitation fusion vesicles method (Ahl et al., 1994) entrapping calcium 
ions within. Calcium ions released from this system by using light as a trigger mechanism are 
beneficial for the gelation of alginate i.e. tissue engineering. IFV are large unilamellar vesicles 
possessing diameters of 1-6 µm and entrap volumes of 20 µl/ µmoles lipid or above (Ahl et al., 
1992). IFV are ideal vehicles for drug delivery as these vesicles contain the large internal volume 
which not only increases drug entrapment efficiency, but also increases entrapment of compounds 
such as radiocontrast agents (Ahl et al., 1994). 
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3.2. Aim and Objectives: 
 
Following on Smith’s (Smith et al., 2007) and Ahl’s work (Ahl et al., 1994), the aim of this study 
was to develop a novel liposomal formulation encompassing the use of photosensitive trigger 
release mechanism. To achieve this aim, the following objectives were accomplished: 
 
 Incorporation of photosensitive lipid i.e. Bis–Azo PC (prepared in Chapter 2) into various 
liposomal formulations (DPPC:Chol) and entrapment of a protein marker i.e. Bovine serum 
albumin conjugated with fluorescent marker (BSA-FITC). Bovine serum albumin is a 
protein which is obtained from cows and generally used as a protein concentration standard 
in lab experiments (Deb, 2001; Hawkins and Dugaiczyk, 1982). Therefore, BSA has been 
used in various biochemical applications including microbial culture (Francis, 2010), 
ELISAs (Enzyme-Linked Immunosorbent Assay) (Xiao and Isaacs, 2012) and 
immunohistochemistry (Habeeb, 1978). 
 Use various UV lights leading to the selection of the ideal liposomal formulation. 
 Determine liposomal stability in order to detect the leakage of the protein marker.   
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3.3. Materials and Methods  
 
3.3.1. Materials 
 
3.3.1.1. Chemicals 
 
Chloroform and methanol were purchased from Fisher Scientific, Loughborough, UK. Bovine 
serum albumin-fluorescein isothiocyanate, Triton- X and phosphate buffered saline (PBS) tablets 
were purchased from Sigma-Aldrich, Poole, Dorset, UK. Distilled water was used throughout. All 
the chemicals used were of analytical grade.    
 
3.3.1.2. Lipids 
 
1, 2-Dimyristoyl-sn-glycero-3-phosphocholine (DPPC), with a chemical structure shown in Fig.3.3 
(a) and cholesterol, with a chemical structure shown in Fig 3.3 (b), were purchased from Avanti 
Polar lipids, Alabama, USA.    
 
               (a)          
 
                 (b) 
 
Fig 3.3: Chemical structures of (a) DPPC; (b) cholesterol. 
H H
H
OH
H
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3.3.2. Methods 
 
All tests were conducted at room (21-24 0C) except where particular conditions were required. 
 
3.3.2.1. Synthesis of photosensitive lipid Bis- Azo PC 
 
The chemical synthesis of photosensitive lipid 1, 2-bis (4-(n-butyl) phenylazo-4’-phenylbutyroyl) 
phosphatidylcholine (Bis-Azo PC) was that of Sandhu (Sandhu et al., 1986) as described  in 
Chapter 2 (Section 2.3.3.4). 
 
3.3.2.2. Preparation of multilamellar vesicles (MLV) 
 
MLVs were generated using thin film hydration method (Fig 3.4) (Bangham et al., 1965). Lipids 
such as DPPC, cholesterol and photosensitive lipid Bis-Azo PC were dissolved in a 9:1 (v/v) 
mixture of chloroform and methanol at a concentration of 10 mg/mL. As these lipids are sparingly 
soluble in either solvent, a mixture of chloroform and methanol was used to obtain complete 
dissolution of the lipid components. It should be noted all liposomes were prepared in PBS because 
the ionic strength and the pH (7.4) of PBS are almost identical with conditions met inside the 
human body. 
 
Fig 3.4: MLV formation by thin film hydration method [ taken from (Bangham et al., 1965)]. 
 
Liposomes containing controlled amount of DPPC (16 µmoles), with or without Bis-Azo PC (1 
µmoles) and varying amount of cholesterol (0-5 μmoles) were formulated. 
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The lipid compositions of the different formulations utilised in this study are divided into 6 groups 
and listed in Table 3.1.  
 
Table 3.1 IFV formulations based on the liposome composition 
 
Group  DPPC (μmoles) Cholesterol (μmoles) Bis-Azo PC (μmoles) 
1 16 0 0 
2 16 0 1 
3 16 2 0 
4 16 2 1 
5 16 4 1 
6 16 5 1 
 
Briefly, the dissolved lipids depending on the liposomal contents (Table 3.1) were added into a 50 
mL round bottom flask and the solvents were evaporated on a rotary evaporator (Buchirotavapor-
R) in order to form a thin dry lipid film which was further dried with nitrogen to remove any 
residual solvent. Thereafter, the dry film was hydrated with 2 mL of a 10 μg/mL hydration media 
(PBS) and then mixed, at intermittent vortexing, with Bovine serum albumin-Fluorescein 
Isothiocyanate which had been prewarmed above the transition temperature [Tm (41 ± 1 °C)] of the 
lipids, until a milky coloured suspension was obtained. The suspension was allowed to stand for 
about 30 min in a water bath above Tm with intermittent periods of vortex, during which multi-
lamellar vesicles were formed. Whole MLV formation was conducted above the transition 
temperature (Tm) of the lipids with the intention that a lipid is in the liquid crystalline phase for 
MLV formation. 
 
3.3.2.3. Preparation of small unilamellar vesicles (SUV) 
 
Small unilamellar vesicles were prepared from the MLV suspension prepared as described in 
section (3.3.2.2) with further sonication using probe and bath sonicator. 
 
For Probe sonication, the MLV suspension was sonicated in Soniprep 150 (MSE, UK) at >Tm 
using a titanium probe (3 mm diameter) which was slightly immersed into the suspension. With the 
high energy input, the milky suspension of MLV was converted to optically clear suspension of 
SUV. Based on the liposome content, the liposomal samples were sonicated for 30 s, 1 min and 2 
min at a power rating of 6 units. After sonication, the SUV was left to stand at the corresponding 
Tm for 15 min. 
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In case of bath sonication, MLV suspension was placed in bath sonicator (Fisher scientific, UK) 
and then sonicated at 55 °C until optically clear. Again based on the liposome content, the 
liposomal formulations were bath sonicated at 55 °C for 25 min, 35 min, 45 min and 1 h 
respectively.  After sonication, the SUV was left to stand at the corresponding Tm for 15 min. 
 
3.3.2.4. Preparation of interdigitation fusion vesicles (IFV) 
 
Interdigitation fusion vesicles were prepared by an interdigitation fusion method as described by 
Ahl and co-workers (Ahl et al., 1994). Briefly, absolute ethanol was added to a SUV suspension 
(prepared as describe in section 3.3.2.3) while stirring at room temperature until the ethanol 
concentration in the sample was 4M. The samples were instantly vortexed. This process quickly 
altered the transparent SUV suspension into an extremely viscous, opaque white suspension of 
interdigitated phospholipid sheets.  Following the inclusion of absolute ethanol, the samples were 
sealed and incubated for 15 min at room temperature, then incubated for 15 min at 50 °C (> Tm of 
the lipid). The caps of the sample vials were then loosened to allow ethanol evaporation, and the 
incubations were continued for another 30 min at the same temperature. After this time, the 
samples were bubbled at 50 °C (> Tm of the lipid) with a gentle stream of N2 to remove ethanol. 
Subsequently, External protein was then removed from the IFV suspension by repeated 
centrifugation (three times), decanting the supernatant and washing the pellet with isosmotic 
buffered saline until no protein could be detected in the supernatant. Lastly, resultant pellet were 
suspended with PBS and the vesicles were stored at 4 °C. 
 
3.3.2.5. Liposome characterization 
 
3.3.2.5.1. Determination of particle size 
 
The size distribution of liposomes play a key role when liposomes are applied as drug delivery 
systems (Franzen and Ostergaard, 2012). In this investigation, the sizes of MLV and IFV were 
characterised using the Sympatec (Helos, UK) particle sizer. In brief, for the size measurement, the 
liposomal suspension was diluted up to 100 times. Following this, 100 μL of a liposome 
formulation was pipetted into a glass quartz cuvette (with a marked signal of at least 15 % being 
mandatory for an ample reading) and stirred at 1200 rpm to reduce the inter particulate aggregation, 
and thereafter, the laser beam was focused using Helos software, and the experiment was repeated 
in triplicate (Plessis et al., 1994). The particle size and polydispersity index (PI) measurements 
were measured in triplicate. Sympatec (Helos, UK) uses a Helium Neon laser of 632.8 nm 
(Sympatec) with an R2 lens for laser generation and employs the Phillips-Twoney method 
(Sympatec Limited, UK) for calculation of particle size distribution. 
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Due to the very small size of SUV compared to MLV and IFV, the z-average diameter of SUV 
were measured using a Zetaplus (Brookhaven Instruments, UK) instead of Sympatec. During the 
measurement, 100 µL of SUV suspension was diluted to 4.5 mL using double-distilled water and 
the z-average diameter of SUV were recorded at 25 0C. Measurements were reported as a mean 
value of three readings and each reading was an average value of measurements recorded for 3 
min.  
 
3.3.2.5.2. Determination of zeta potential 
 
Zeta potential of a liposome is the overall charge that liposome acquires in a particular medium. In 
short, the process of an indirect measurement of the surface charge of a liposome is termed as zeta 
potential (Perrie et al., 2004). Knowledge of the zeta potential of vesicles can be beneficial in 
determining the fate of the vesicles in vivo (Jones, 1995). In this study, the electrophoretic mobility 
and zeta potential of liposomal dispersions were analysed by photon correlation spectroscopy using  
Zetaplus (Brookhaven Instruments, UK) in 0.001M PBS (pH=7.4) at 25 0C. 100µL of liposomal 
dispersions were diluted to 4.5 ml using 0.001M PBS prior to analysis. The final measurements 
were the mean values of ten readings. 
 
3.3.2.6. Removal of un-entrapped protein marker through centrifugation  
 
In bid to remove un-entrapped (BSA-FITC), the liposomal formulations (2 mL) were placed into 
3.9 mL of Beckman coulter centrifuge tubes, which were heat sealed and placed into Beckman 
coulter ultracentrifuge equipped with TLN-100 rotor. The centrifuge cycle began once the vacuum 
was switched on and had reached < 50. Figure 3.5 illustrates the step to remove un-entrapped 
protein marker through centrifugation. The ultra-centrifuge was used for speeds of 27, 000 g with 
the TLN-100 rotor for 3.9 mL tubes. 
 
 
 
 
 
 
 
 
 
Fig 3.5: Protocols used for the removal of un-entrapped protein through ultracentrifugation. 
Protocol 1 was repeated for three times in order to remove minor amount of un-entrapped BSA-FITC. 
Protocol 1 
1) Place 2 mL of liposomal samples in 3.9 mL of Beckman centrifuge tubes and 
    make up the remaining volume with PBS.                                                                    
2) Then Centrifuge at 27,000 g for 30 min at 4 0 C. 
3) Remove supernatant and resuspend pellet in 2 mL of PBS. 
× 3
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3.3.2.7. Determination of protein entrapment efficiency in IFV 
 
The loading efficiency of Bovine serum albumin conjugated with florescence isothiocyanate (BSA-
FITC) was determined by measuring the non-incorporated present in the hydration medium and 
wash media after separation of liposomes by centrifugation at 27,000 g for 30 min. Briefly, samples 
were prepared by addition of 500 μL aliquot of liposome suspension to 1 ml solution of phosphate 
buffer saline followed by addition of 500 μL Triton X-100 (0.1 % solution). Triton X-100 
solubilized the liposome membranes and induced release of entrapped contents. All samples were 
diluted, centrifuged and the supernatant was measured. The fluorescent protein content in the 
supernatant was determined by fluorescence spectroscopy (Perkin-Elmer Life Sciences) at 
excitation and emission wavelengths of 490 and 515 nm, respectively. The wavelength scan and 
optimisation of calibration curve of BSA-FITC through fluorescence spectroscopy are 
demonstrated in Appendix 1.  
 
The protein entrapment efficiency (% EE) was calculated using the following formula – 
 
% 𝐄𝐄 = (𝟏 −
𝐅
𝐅𝐭
) × 𝟏𝟎𝟎………………………  Equation (3.1) 
 
where F is the fluorescence prior to the addition of 0.1 % Triton X-100 and Ft is the fluorescence 
after the addition of Triton X-100  
 
3.3.2.8. Photo-triggered release study of fluorescent protein (BSA-FITC): 
 
The liposome samples was irradiated using three different lamps, a UV curing Flood Lamp, a 
ROHS 36 w professional UV curing lamp and a Nichia NSHU590E UV LED lamp (Fig 3.6). The 
emission characteristics of all these lamps were quantified using Accucal 50 UV intensity meter 
resulting in a calculated intensity (I) of 1.81 x 20 mW/cm2, 2.94 x 20 mW/cm2 and 0.74 x 20 
mW/cm2 respectively. In order to study the controlled release of fluorescent protein (BSA-FITC) 
from IFV, liposomes samples, stored in the dark prior to the study, were irradiated for different 
time intervals i.e. 0, 1 and 3 min before being evaluated using the fluorescent assay described 
above (section 3.3.2.7).  
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Fig 3.6: Exposure of UV light from three different lamp, lamp 1- UV curing Flood Lamp; 
lamp 2- ROHS 36w professional UV curing lamp and lamp 3- Nichia NSHU590E UV LED. 
 
3.3.2.9. Determination of 100 % release of fluorescent protein (BSA-FITC) from IFV  
using ROHS 36 w professional UV curing lamp. 
 
To measure protein (BSA-FITC) release from IFV, liposomes samples that had been stored in the 
dark were taken and irradiated using ROHS 36 w professional UV curing lamp for different time 
intervals i.e. 0, 1, 3, 6, 9, 12 and 15 min. The samples were diluted, centrifuged and the supernatant 
used to determine the fluorescent protein content using fluorescent assay as described above.  
 
3.3.2.10. Determination of IFV short term stability  
 
IFV stability is an important aspect that is considered during the development of photosensitive 
liposomes. It is well established that photosensitive liposomes containing Bis-Azo PC are not stable 
when stored in the dark at room temperature (Smith et al., 2007). Therefore, in order to evaluate the 
short term stability of the formulated IFV during storage, IFV were effectively stored at room 
temperature (∼23 °C) for up to 15 min, 24 h and 48 h. Fluorescent Protein (BSA-FITC) leakage 
was checked by fluorescence spectroscopy. In brief, after 15 min, 24 and 48 h, all samples were 
diluted, centrifuged and the supernatant was analysed for fluorescent protein content using 
fluorescence assay described above. 
3. Nichia NSHU590E UV 
LED 
2. ROHS 36w 
professional UV curing 
lamp 
1. UV curing Flood Lamp 
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3.3.2.11. Determination of IFV long term stability 
 
With the intention to estimate the long term stability, the formulated IFV were stored at fridge 
temperature (6 °C) in the dark for one and two weeks. Fluorescent Protein (BSA-FITC) leakage 
was checked by fluorescence spectroscopy. Analysis was carried out after one week and two weeks 
of sample storage. The samples were diluted, centrifuged and the supernatant used for fluorescent 
protein content determination using fluorescence assay described above. 
 
3.3.2.12. Confocal Microscopy  
 
A Leica confocal microscope was used and MLV, SUV, IFV with or without BSA-FITC were 
examined by a 60 X oil objective along with Helium and Argon lasers. Following the formulation 
step, the un-entrapped BSA-FITC was successfully removed through centrifugation and 
subsequently liposomal formulation was placed into a microslide and immediate drying out of 
sample was avoided by mounting cover slip on it. Furthermore, Fluorescein isothiocyanate (FITC) 
filters were used for the BSA-FITC analysis. 
 
3.3.2.13. Statistical analysis  
 
Graph-Pad Instant software (v.6.02, GraphPad Software, San Diego, CA) was used for statistical 
analysis. Particularly, using one-way analysis of variance (ANOVA) and a multiple comparison 
post-test Tukey for determining statistical significance (set at P<0.05) between data sets.  
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3.4. Results and Discussion 
Data obtained in previous studies (Fig 3.7) show that IFV can be easily prepared by interdigitation 
fusion method (Ahl et al., 1994). This technique requires organic solvent i.e. ethanol which induces 
interdigitation –fusion of SUV into large interdigitated lipid sheets, which are subsequently 
annealed into vesicles. Based on this methodology, interdigitation fusion vesicles (IFV) were 
generated following three steps: 
1) Multilamellar vesicles (MLV) were prepared using a method based on dry film hydration 
(Bangham et al., 1965). 
2) Small unilamellar vesicles (SUV) were formulated through probe and bath sonications. 
3) Interdigitation fusion vesicles were prepared using Interdigitation fusion method (Ahl et 
al., 1994). 
 
 
Fig 3.7: Formation of IFV from SUV [taken from (Ahl et al., 1994)]. 
As discussed previously (Sections 1.2.2 and 1.2.3.), MLV are more stable than SUV and are easily 
converted into SUV through sonication. Therefore, in order to study the effect of sonication on 
SUV formation, this study used both types of sonication. Probe sonication was done using Soniprep 
150 (MSE, UK) while bath sonication was done using ultrasonic bath (Fisher scientific, UK). 
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3.4.1. Effect of sonication on SUV formation 
SUV were obtained through sonication, using both probe and bath sonication methods, and were 
used to investigate the effect of cholesterol level on SUV formation. It is well known that probe tip 
sonicator delivers high energy input to the lipid suspension which instantly converts the MLV 
suspension into SUV (Papahadjopoulos and Watkins, 1967). However, probe sonication has 
limitations, such as, SUV dispersions contamination with metal ions such as titanium particles, 
limited control of MLV temperature of due to open system as probe is immersed into the MLV 
dispersion (Barenholz and Lichtenberg, 2009). However, SUV that are produced by bath sonication 
are usually metastable (Lasch et al., 2003). The finding in terms of sonication time is shown in 
Table 3.2 and in terms of resultant liposomes size, zeta potential are shown in Fig 3.8. 
Table 3.2: Formation of SUV through sonication 
Formulation Probe sonication time Bath sonication time at 
55°C 
 
DPPC (16 μmoles) 
 
0.5 min 
 
25 min 
 
DPPC:Bis-Azo PC 
(16 μmoles:1 μmoles) 
 
0.5 min 
 
25 min 
 
DPPC:Cholsterol 
(16 μmoles:2 μmoles) 
 
1 min 
 
35 min 
 
DPPC:Cholesterol:Bis-Azo PC 
(16 μmoles:2 μmoles:1 μmoles) 
 
1 min 
 
35 min 
 
DPPC:Cholesterol:Bis-Azo PC 
(16 μmoles:4 μmoles:1 μmoles) 
 
1.5 min 
 
45 min 
 
DPPC:Cholesterol:Bis-Azo PC 
(16 μmoles:5 μmoles:1 μmoles) 
 
2 min 
 
60 min 
 
Table 3.2 illustrates that SUV formation through probe sonication and bath sonication using 16 
μmoles of DPPC, with or without 1 μmoles of Bis-Azo PC and varying cholesterol content (0-5 
μmoles). Total volume was 2 mL for each formulation. 
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Fig 3.8: Particle size (nm) and zeta potential (mV) of various small unilamellar vesicle 
formulations prepared via bath and probe sonication. 
SUV formulations were prepared by using bath sonicator and probe sonicator. Particle size analysis and zeta 
potential measurement was measured at 25 0C using a Brookhaven Zeta Plus. The addition of cholesterol into 
the formulations showed substantial interference of the average size of the vesicles.  The data are expressed 
as means ± standard deviation of three independent experiments. Significance was measured by one-way 
ANOVA (*** p<0.001; **p<0.01; * p<0.05) and represent a significant increment in vesicle size due to the 
substitution of cholesterol into the formulations.                                                              
As can be seen from Table 3.2, the time for SUV formation varies with the amount of cholesterol in 
the formulations. Indeed, it is also evident from the results that increasing amount of cholesterol 
increases sonication time and SUV can be easily obtained from 16 μmoles of DPPC and 16 μmoles 
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of DPPC: 1 μmoles of Bis-Azo PC compared to other formulations. Moreover, the sonication times 
for SUV produced from 16 μmoles of DPPC and 16 μmoles of DPPC: 1 μmoles of Bis-Azo PC are 
almost identical. Therefore, inclusion of photosensitive lipid Bis-Azo PC has no effect on 
sonication time. In contrast, sonication time for SUV obtained from 16 μmoles of DPPC: 2 μmoles 
of cholesterol; 16 μmoles of DPPC: 2 μmoles of cholesterol: 1 μmoles of Bis-Azo PC; 16 μmoles 
of DPPC: 4 μmoles of cholesterol: 1 μmoles of Bis-Azo PC and 16 μmoles of DPPC: 5 μmoles of 
cholesterol: 1 μmoles of Bis-Azo PC varies as the cholesterol amount increases. The addition of 
cholesterol not only gives rigidity to the bilayer through lipid rearrangement process, but also 
improves the stability of liposomes. This is supported by previous experiments (Demel and De 
Kruyff, 1976; Senior, 1987; Kirby et al., 1980) in which they proved that the presence of 
cholesterol in liposome membranes resulted in increased packing densities of phospholipids. 
Data in Table 3.2 also suggest that SUV can be easily obtained from probe sonication within 
shorter periods of time when compared to bath sonication. Despite the fact that the processing time 
for SUV formation through bath sonication is more, this method avoids the contamination with 
titanium particles, which are produced in probe sonication. 
As depicted from Fig 3.8, particle size for SUV exhibited from16 μmoles of DPPC and 16 μmoles 
of DPPC: 1 μmoles of Bis-Azo PC are similar whereas the particle size for SUV revealed from 16 
μmoles of DPPC: 2 μmoles of cholesterol; 16 μmoles of DPPC: 2 μmoles of cholesterol: 1 μmoles 
of Bis-Azo PC; 16 μmoles of DPPC: 4 μmoles of cholesterol: 1 μmoles of Bis-Azo PC and 16 
μmoles of DPPC: 5 μmoles of cholesterol: 1 μmoles of Bis-Azo PC fluctuates as the cholesterol 
concentration increases. In terms of zeta potential, all the SUV formulations showed the negative 
zeta potential. However, the difference is not statistically significant. 
In general, there was significant difference (P˂0.05, ANOVA) in the size of SUV when comparing 
among all the formulations (Fig 3.8). It should be noted that SUV exhibited from16 μmoles of 
DPPC and 16 μmoles of DPPC: 1 μmoles of Bis-Azo PC were non-significant. Similarly, there was 
no significant difference in zeta potential among all the SUV formulations. Hence the substitution 
of cholesterol into DPPC:Bis-Azo PC based SUV had significant effect on the size of vesicles. 
Overall, it can be seen that the amount of cholesterol has a major impact on SUV formation using 
sonication. Furthermore, MLV formulation without cholesterol is easily converted into SUV, 
whereas MLV formulation with cholesterol takes more time in comparison to MLV formulation 
without cholesterol. In comparison to probe sonication, bath sonication is an ideal choice for SUV 
formation as it avoids the contamination of titanium particles (Barenholz and Lichtenberg, 2009) 
and circumvents the centrifugation step. Bath sonication has several advantages, such as, the 
sonicator being favourable for all sample sizes, with little risk of cross contamination and easier 
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control of the lipid dispersion temperature. However, bath sonication has very high energy 
requirement compared to probe sonication. Even though probe sonication has faster processing 
time, it necessitates the use of centrifugation for at least three times, in order to make sure that all 
titanium particles are removed. Therefore, bath sonication was chosen for further IFV formation.     
3.4.2. Effect of Interdigitation fusion vesicles content on vesicle size, zeta potential and 
protein entrapment efficiency 
Initial studies show that calcium entrapment efficiency of MLV and SUV was smaller than IFV 
(Smith et al., 2007). As a result, effect of IFV contents on vesicle size, zeta potential and protein 
entrapment was validated in this study. The particle size, zeta potential and loading efficiency of 
the different IFV that were investigated in this study are shown in (Table 3.3).  
3.4.2.1. Effect of vesicles lipid content on vesicle size 
The average particle size and size distribution of vesicles are vital parameters for vesicles intended 
for drug delivery, for instance, inhalation, parental drug delivery and cancer drug delivery (Juliano 
and Stamp, 1975; Juliano, 1981). In 1991, (Komatsu and Rowe, 1991) demonstrated that lipid 
content of liposomes and inclusion of cholesterol inhibits bilayer interdigitation. Thereafter, Ahl 
and co-workers (Ahl et al., 1994) suggested that interdigitation fusion process is very sensitive to 
the addition of cholesterol or the lipids that resist the interdigitation. As cholesterol concentration 
increases then there is reduction in the bilayer interdigitation. Therefore, vesicles content is the 
important parameter in case of IFV formulation. With the intention to investigate the effect of IFV 
content on vesicle size, varying amounts of cholesterol were used in liposomes (DPPC: Bis-Azo 
PC). The addition of cholesterol to IFV was found to significantly (p<0.05) increase the size of 
MLV, SUV and IFV (Table 3.3). SUV results are in line with those of (Frisken et al., 1999) and 
(Li-Ping Tseng, 2007). IFV prepared using DPPC:Chol:Bis-Azo PC (16:5:1) had mean diameter of 
about 15 μm whereas IFV prepared using DPPC:Chol:Bis- Azo PC (16:2:1) and DPPC:Chol (16:2) 
had mean diameters of 12 μm and 11 μm, respectively (Table 3.3). Similar results were obtained 
with MLV and SUV. The changes in size seen in all formulations suggest that incorporation of 
cholesterol may make DPPC bilayers more rigid. This is due to the cholesterol orientation 
behaviour into a phospholipid bilayer (Yeagle, 1985). Theoretically, within phospholipid bilayer, 
cholesterol upturns the degree of orientational order with its polar hydroxyl group and diminishes 
the rate of motion of the phospholipid hydrocarbon chains (Stockton and Smith, 1976; Yeagle et 
al., 1977). Furthermore, this process will produce a laterally more condensed membrane with 
increased packing density of the phospholipids (Lund-Katz et al., 1988; Smaby et al., 1994). That 
will increase the rigidity and decrease the permeability of the membrane (Needham and Nunn, 
1990).
  
Chapter 3-Development of Photosensitive Liposomes for the Controlled Release of Bovine 
 Serum Albumin-Fluorescein Isothiocynate (BSA-FITC) 
 
126 
 
                                Table 3.3 Effect of Interdigitation fusion vesicles content on vesicle size, zeta potential  
MLV SUV IFV 
Formulation  Size (PDI) ZP Size (PDI) ZP Size (PDI) ZP 
(μm) (mV) (μm) (mV) (μm) (mV) 
DPPC 5.93± 0.01 1.72±0.01 -5.48 ± 6.5 0.11±10.7 0.370 -6.34 ± 3.5 7.20 ± 0.6 6.88±0.7 -5.48 ± 6.58 
(16 ) μmoles 
DPPC:Bis-Azo PC  
(16:1) μmoles 
8.54±  0.20 6.25±0.16 -8.01 ± 0.7 0.10±9.6 0.286 -5.87 ±2.8 7.64±  0.8 3.94±0.2 -8.41 ± 0.70 
 DPPC:Chol 
(16:2 ) μmoles 
8.49±  0.25 2.71±0.10 -4.54 ± 4.8 0.12±9.6 0.328 -2.98 ±2.4 11.4 ± 0.6 2.37±0.0 -4.54 ± 4.82 
 DPPC:Chol:Bis-Azo PC 
(16:2:1) μmoles 
9.61±  0.77 3.90±0.31 -5.05 ± 2.5 0.15±6.1 0.295 -5.48 ± 6.5 12.4 ± 0.1 2.28±0.0 -5.65± 1.08 
 DPPC:Chol:Bis-Azo PC 
(16:4:1) μmoles 
10.15± 0.34 2.00±0.04 -8.58 ± 2.5 0.17±5.9 0.311 -9.83 ±5.1 14.6 ±0.7 3.62±0.9 -8.36 ± 1.64 
DPPC:Chol:Bis-Azo PC  
(16:5:1) μmoles 
10.74± 0.33 2.14±0.05 -7.78 ±3.0 0.18±2.2 0.276 -6.21 ±1.01 15.55 ± 0.2 2.45±0.01 -7.47 ±1.85 
  
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC, where applicable. All formulations were prepared by the 
interdigitation fusion method entrapping the BSA-FITC. Vesicle size and zeta potential of liposomes was measured in double-distilled water and 0.001 M PBS, respectively, 
at 25 0C using Sympatec and Zeta Plus. Results denote the mean ± SD from at least 3 independent batches.   
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Despite of changes in size, the polydispersity of all liposomes remained unchanged. However, it 
should be noted that polydispersity was expressed as polydispersity Index (PDI). The results in this 
study mirrors several other studies that have suggested that cholesterol structure is very different 
from other lipids because of its flat, rigid fused ring structure, enabling cholesterol to develop more 
stable stacked aggregates compared to other lipids (Epand et al., 2003). Earlier researcher (Lee, 
1977) and (Nayar et al., 1989) verified that in the absence of cholesterol homogenous LUV 
composed of long-chain phosphatidylcholines generate packing defects upon cooling below to their 
phase transition temperatures. In contrast, other studies (Demel et al., 1972; Corvera et al., 1992) 
demonstrated that the addition of higher amounts of cholesterol in liposomes increased the packing 
densities of phospholipids and reduced the bilayer permeability to drugs. Similarly, results from 
this study (Table 3.3) suggest that at smaller concentrations of cholesterol produced stable 
liposomes. On the other hand, at higher concentrations, it increases the particle size and rigidity of 
liposomes.    
It is also evident from Table 3.3 that the addition of photosensitive lipid Bis-Azo PC into the 
vesicles has neither effect on the size of MLV, SUV and IFV nor the polydispersity of Liposomes. 
Consequently, IFV prepared using DPPC had a similar particle size distribution with the IFV 
prepared using DPPC:Bis- Azo PC.  
3.4.2.2. Effect of Interdigitation fusion vesicles content on zeta potential  
The net surface charge of vesicles is an important parameter that will affect the electrostatic 
interaction between vesicles and surrounding molecules, particles and surfaces. In theory, it is 
constrained by the various parameters, such as, head group of lipid, pH and ionic strength of the 
dispersion medium. Liposomal stability relies on the magnitude of zeta potential. If all the particles 
in liposomes acquire a large negative or positive zeta potential then they will have a tendency to 
repel each other and that will avoid the aggregation (Paolino, 2006). 
From Table 3.3, it is apparent that all liposomes show a slight negative zeta potential. It is well 
known that DPPC is a neutral lipid and possess a net neutral charge because at neutral pH, the head 
group of phospholipid always carries a both a negative zeta potential (at the phosphate group) and a 
positive zeta potential (at the choline group) and therefore does not possess a net charge. This is 
reflected in the results obtained in this study that show negative zeta potential. The outcome could 
possibly be due to two reasons: 
1. Fisar already reported that over a wide range of pH values, phosphatidylcholine molecules are 
completely electroneutral as the negative charge of the phosphate group is compensated by the 
positive charge of the choline head (Fisar, 2005) even though, neutral PC shows negatively 
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zeta potential. This is due to the hydration of the surface and the orientation of the charged 
elements of the lipids. Based on the pH, the head region of phospholipids is expected to be 
cations at pH values lesser than one, zwitterions over a large range of pH and probably anions 
at higher pH (Deb, 2001). 
 
2. DPPC’s shows negative zeta potential due to conformational changes in the lipid head group 
region of the liposomes (Law et al., 1988; Makino et al., 1991). In their lab study, they noted 
that the direction of the lipid head region of phospholipid is very sensitive to the temperature 
and the ionic strength of dispersion medium. According to their data, at a constant temperature, 
when the ionic strength of dispersion medium increased, the choline group proceeds towards 
the outer part of the bilayer surface, while the phosphatidyl group lies behind the bilayer 
surface. Moreover, at the phase transition temperature, the choline group lies in the inner most 
region whereas the phosphatidyl group is located in the outermost region. 
 
Interestingly, some studies inferred that incorporation of cholesterol has little effect on head group 
separation in the liposomes made from the zwitterionic egg phosphatidylcholine (PC) and anionic 
egg phosphatidylglycerol (Yeagle et al., 1977). Their results clearly indicate that the inclusion of 
cholesterol up to 50 mole % in the bilayer produced null effect on the zeta potential of liposomes 
and eventually addition of sterols among the fatty acyl chains of phospholipids causes little or no 
displacement of the head group at the bilayer surface. Parallel results are also obtained in case of 
lanosterol and epicoprostonol, a sterol with a non-planar ring system (A/B cis) (Rottem et al., 
1971). It is also clear from Table 3.3 that there are no changes in the zeta potential of MLV, SUV 
and LUV and that all the liposomes had parallel zeta potential. Therefore, we can say the inclusion 
of varying amounts of cholesterol has considerable effect on the zeta potential of DPPC liposomes 
which need further study. 
3.4.2.3. Investigation of interdigitation fusion vesicles content on protein entrapment 
To investigate protein entrapment within photo-sensitive liposomes, a protein labelled with 
fluorescent marker i.e. bovine serum albumin conjugated with fluorescein isothiocyanate (BSA-
FITC) was used. BSA-FITC was selected as a model protein and has been studied in terms of 
interaction with liposomes.  Preliminary results demonstrated the influence of bilayer composition 
on BSA-FITC loading (Fig 3.9). 
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Fig 3.9: Effect of IFV contents on protein entrapment. 
IFV formulations were prepared by the interdigitation fusion method entrapping the BSA-FITC. The 
entrapment efficiency of BSA-FITC was determined by using fluorescence spectroscopy. Result represents 
mean ± SD, n=3. 
As can be seen from Table 3.3 and Fig 3.9, IFV prepared using DPPC and DPPC:Bis-Azo PC had a 
higher protein loading efficiency compared with IFV prepared using DPPC:Chol and 
DPPC:Chol:Bis-Azo PC. However, there was no any significant difference seen between the IFV 
formulations. The protein loading efficiency of IFV prepared using DPPC and DPPC:Bis-Azo PC 
was found to be 29 % and 30 % respectively. These results are similar with previously published 
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data by others (Pick, 1981; Ohsawa et al., 1984; Liu and Yonetani, 1994) who prepared LUV using 
different method i.e. freeze- thaw method. 
Studies by the above named researchers (Pick, 1981; Ohsawa et al., 1984; Liu and Yonetani, 1994), 
using LUV for the encapsulation of protein drugs or solutes, have shown entrapment levels of up to 
from 20 to 30 %, similar to levels observed in the results in Fig 3.9. However, in these studies the 
freeze-thaw method was used, which involves formation of SUV from MLV which is then rapidly 
frozen and followed by slow thawing. Owing to this rapid freezing and thawing process, SUV fuse 
with each other and these aggregates get converted into LUV. Ideally, this technique promotes 
higher drug loading because of morphological changes, which occur during the process of freezing 
and thawing of the liposomes and thus resulting in increased aqueous volumes of liposomes (Mayer 
et al., 1989). Other techniques available for the formulation of LUV include the reverse phase 
evaporation method; here LUV are generated from water-in-oil emulsions using buffers and excess 
organic phase, under reduced pressure (Szoka and Papahadjopoulos, 1978). LUV prepared from 
this method possess higher aqueous–to-lipid volume ratio and entrap larger percentage of 
hydrophilic drugs. Earlier, LUV are prepared by extrusion method (Hope et al., 1985) in which the 
rapid production of LUV are carried out by repeated extrusion under moderate pressure (≤ 500 
lb/in2) of MLV through polycarbonate filters (100 nm pore size). 
From Fig 3.9, it is evident that the photosensitive lipid Bis-Azo PC has no effect on protein loading 
efficiency as the protein loading efficiency of DPPC was 29 % and DPPC:Bis-Azo PC was 30 %, 
although 1 µmoles of Bis-Azo PC was used. However, it should be noted that inclusion of varying 
amounts of cholesterol reduces the protein loading efficiency of IFV. This may be a result of 
increased packing densities of phospholipids (Semple et al., 2005). To ascertain whether this was 
indeed surface pressure measurement a study was done by (Rogerson et al., 1987) which clearly 
show a decrease in effective area per molecule as the cholesterol content of the monolayer is 
increased.  
Earlier investigations on examining the effect of liposome composition on drug entrapment  
(Gregoriadis and Davis, 1979a) established that addition of 50 % mol/mol cholesterol within a 
liposome formulation not only increased the stability, but also reduced the permeability of bilayers. 
In terms of photosensitive liposomes, it was revealed (Bisby et al., 1999b) that inclusion of varying 
amounts of cholesterol (up to 25 mol %) within the bilayers increased the visible light sensitivity of 
photosensitive liposomes. On the other hand, supplementation of DPPC:Bis-Azo PC bilayer with 2 
μmoles of  cholesterol resulted in a reduction in protein loading from 30 % to 26 %  (Fig 3.9). 
Furthermore, increasing cholesterol amount leads to reduced protein loading efficiency i.e. with 4 
μmoles and 5 μmoles of cholesterol, protein loading efficiency was reduced to 21 % and 19 %, 
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respectively (Fig 3.9). It would appear that with different formulations the protein loading tend to 
be affected only marginally i.e. 2-4 %. 
This cholesterol –induced effect on protein loading in IFV was consistent with other results (Smith 
et al., 2007) (Ahl et al., 1994) that proved that the cholesterol hampered the formation of IFV by 
making obstacle to the formation of the interdigitated lipid sheets. Conversely, it is recognised that 
inclusion of cholesterol increased the stability of liposomes (Gregoriadis, 1993) and triggered 
wavelengths in blue region of visible the spectrum (> 400 nm). As a result, the presence of 
cholesterol in the SUV liposomes used as precursors for IFV may possibly result in liposomes with 
higher stability. However, limiting the appropriate interdigitation process ultimately inhibits the 
production of IFV with higher entrapment. This fact was further confirmed by the increment in 
vesicle size for IFV containing 4 μmoles and 5 μmoles of cholesterol with sizes 14 µm and 15 µm 
compared with    ≤ 7 µm for the cholesterol free DPPC liposomes (Table 3.3) and (Fig 3.9). 
Data shown in Table 3.3 and Fig 3.9 indicates that incorporation of cholesterol may make DPPC 
bilayers more rigid which further reduced the protein entrapment efficiency. This rigidity could be 
the reason for increment in the particle size of liposomes with the varying amounts of cholesterol. 
According to (Bernsdorff et al., 1997; Mohammed et al., 2004b), hydrophobic interaction could be 
another reason due to which entrapment efficiency of IFV was decreased. Therefore entrapment 
efficiency of IFV prepared using 4 μmoles and 5 μmoles of cholesterol was 21 % and 19 %, 
respectively. Smith and co-workers (Smith et al., 2007) also revealed that entrapment efficiency of 
photosensitive IFV decreased with increased concentration of cholesterol. 
3.4.3. Confocal microscopy 
One of objective of this study was to visualize the morphology of vesicles and to check whether 
BSA-FITC gets entrapped within well-formed vesicles using light microscopy.  In this study, 
vesicles with or without entrapped protein marker, BSA-FITC, were prepared using formulations of 
DPPC:Chol:Bis-Azo PC (16:2:1 μmoles) and visualized on a Leica multiphoton confocal 
microscope using an 63 X oil objective. Fig 3.10 illustrates the MLV, SUV and IFV without BSA-
FITC and Fig 3.11 represents the MLV, SUV and IFV with BSA-FITC. 
 
 
  
Chapter 3-Development of Photosensitive Liposomes for the Controlled Release of Bovine 
 Serum Albumin-Fluorescein Isothiocynate (BSA-FITC) 
 
132 
 
   
MLV                                        SUV                                       IFV 
Fig 3.10: Confocal microscopy images of DPPC:Chol:Bis-Azo PC at 16:2:1 μmoles liposomes  
(MLV, SUV and IFV) without fluorescent protein taken with a multiphoton Confocal 
Microscope using a 63 X objective. 
 
 
 
 
 
 
 
 
 
 
Fig 3.11: Confocal microscopy images of DPPC:Chol:Bis-Azo PC at 16:2:1 μmoles liposomes 
(MLV, SUV and IFV) entrapped with BSA-FITC taken with a multiphoton Confocal 
Microscope using a 63 X objective. 
The green fluorescent marker shown is BSA-FITC and is present inside the liposomes i.e. internal aqueous 
compartment of liposomes.  
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It is revealed from the images (Fig 3.10 and Fig 3.11) that the IFV were prepared using 
interdigitation fusion method. Moreover, diameter of IFV is greater than SUV and smaller than 
MLV. Furthermore, Fig 3.11 also evidences that the BSA-FITC can be seen entrapped within the 
internal aqueous core of all the vesicles. 
3.4.4. Photo-induced protein release 
Morgan and co-workers (Morgan et al., 1995) previously demonstrated that photosensitive 
liposomes containing Bis- Azo PC required only a few minutes for total release of the drug from 
the liposomes and the similar  liposomes cease to trap calcein when the Bis-Azo PC content 
exceeds about 8 % (mol:mol) of the total lipid content of Bis-Azo PC and dipalmitoyl-l-α-
phosphatidylcholine (DPPC). Later on, (Bisby et al., 1999a) revealed that effective photo-induced 
calcein release and better stability was achieved for liposomal composition containing 6 % 
(mol:mol) of Bis-Azo PC in the DPPC. Therefore, smaller amount of concentrations of 
photosensitive lipid i.e. Bis-Azo PC were used in subsequent studies reported within this chapter. 
BSA-FITC leakage from liposomes prepared from DPPC; DPPC:Chol; and DPPC with  varying 
levels of cholesterol and containing a fixed level of 1 µmoles of Bis-Azo PC is shown in Table 3.4 
and Fig 3.12. Each formulation tested for protein release using 3 different UV lamp systems: a UV 
curing flood lamp, a ROHS 36 w professional UV lamp and a Nichia NSHU590E UV LED lamp 
with emission centered at 365 nm. 
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                                                                                   Table 3.4: Photo-induced protein releases from liposomes 
Photosensitive and non-photosensitive IFV: Photosensitive and non-photosensitive IFV were prepared via interdigitation fusion method. IFV composed of 16 μmoles of 
DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC, where applicable. Photo-trigger release studies were done by using three different UV lamps. The percentage 
releases of BSA-FITC were measured using fluorescence spectroscopy. The data are expressed as means ± standard deviation of three independent batches.
Formulation Initial drug 
loading (%) 
No light 
(% released) 
UV 
exposure time 
Lamp 1 
(%released) 
Lamp 2 
(%released) 
Lamp 3 
(%released) 
DPPC  (16 ) μmoles 29.10 ±0.7 0% 1 min 0% 0% 0% 
 29.10 ±0.7 0% 3 min 0% 0% 0% 
DPPC:Bis-Azo PC (16:1) μmoles 30.33 ±2.51 0% 1 min 70.33±1.52 73.56±5.13 39.2±3.70 
 30.33 ±2.51 0% 3 min 71.66±6.50 78±8.02 40.33±5.50 
DPPC:Chol (16:2 ) μmoles 25 ±1.05 0% 1 min 0% 0% 0% 
 25 ±1.05 0% 3 min 0% 0% 0% 
DPPC:Chol:Bis-Azo PC (16:2:1) μmoles   26.5 ±0.5 0% 1 min 67.66±7.02 70.66±8.02 31.33±1.52 
 26.5 ±0.5 0% 3 min 69.16±4.04 70.33±6.50 33.56±13.8 
DPPC:Chol:Bis-Azo PC (16:4:1) μmoles 21.66 ±3.78 0% 1 min 63.86±14.1 65.33±3.51 25±5.56 
 21.66 ±3.78 0% 3 min 66.01±10.0 70.33±7.50 31.66±3.05 
DPPC:Chol:Bis-Azo PC (16:5:1) 19.33 ±2.08 2% 1 min 55.33±4.50 58±6.55 18±6.01 
 19.33 ±2.08 2% 3 min 56.66±1.52 59.26±1.78 22.33±6.50 
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Fig 3.12:  Photo-induced protein release by using three different UV lamp: a) UV curing 
flood lamp b) ROHS 36 w professional UV lamp and c) Nichia NSHU590E UV LED lamp. 
Only 4 bars are visible in the following graphs but with six samples. Bars of DPPC (16) and DPPC:Chol 
(16:2) overlap each other due to 0 % release. 
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Table 3.5: Summary of measured intensity of UV lamps used for this investigation   
Lamp number UV lamp Power intensity  (I)  
mW/cm2 
1 UV curing flood lamp 1.81 x 20 mW/cm2  
 
2 ROHS 36 w professional UV lamp 2.94 x 20 mW/cm2 
3 Nichia NSHU590E UV LED lamp 0.74 x 20 mW/cm2 
 
For photo-trigger release study, three different UV lamps were used. The emission characteristics 
of all these lamps were measured by Accucal 50 UV intensity meter.  
From Table 3.5, it can be seen that the measured intensity of lamp 1 and lamp 2 is I = 1.81 x 20 
mW/cm2 and I = 2.94 x 20 mW/cm2, respectively, which is greater than the measured intensity of 
lamp 3 (I = 0.74 x 20 mW/cm2). Hence, due to power difference lamp 1 and lamp 2 showed better 
protein release than lamp 3 (Fig 3.12).  
As can be seen from Fig 3.12, prior to exposure to UV, no protein release was detectable ; 
however, after UV exposure the three different lamps gave different patterns of release of 
fluorescent protein from the liposomes, yet with all three lamps the presence of photosensitive lipid 
Bis-Azo PC in the DPPC liposomes promotes a triggered release of the protein. This is supported 
by observation of control samples, in which only DPPC and DPPC along with the 2 μmoles of 
cholesterol are used (Fig 3.12). These formulations are not sensitive to the blue light at 365 nm and 
thus no release of BSA-FITC is seen after UV irradiation at 1 min and 3 min. In contrast, 
DPPC:Bis-Azo PC (16:1) based IFV showed 73 % and 71 % release after UV irradiation (ROHS 
36 w professional UV lamp) at 1 min and 3 min. These results are consistent with results reported 
by Bisby et al. (Bisby et al., 1999b) who also suggested that threshold concentration of 
photosensitive lipid Bis-Azo PC is required for the photo-induced release of solutes in response to 
laser light. According to their study, Bis-Azo PC showed photo-isomerization with laser irradiation 
and two types of effects could be observed in case of laser-induced photo-isomerization. Firstly, 
there might be a rapid perturbation of the liposomal membrane tempted by the volume expansion 
from the trans- form of the lipid (compacted structure) to the cis-form of the lipid (expanded 
structure). Consequently, there might be a time-dependent relation phase in which bulky, polar, cis 
Chapter 3 -Development of Photosensitive Liposomes for the Controlled Release of Bovine 
Serum Albumin-Fluorescein Isothiocyanate (BSA-FITC) 
137 
 
form of lipid, rearranges to an equilibrium state i.e. lateral redistribution of isomerized lipids and 
entrapped material is released. They also noted that during laser pulse experiment, small 
reproducible lag phase is obtained before the release of solutes and which is correlated with the 
lateral redistribution of Bis-Azo PC. The data obtained from our experiments (Fig 3.12) also gave 
the same conclusion as burst release of BSA-FITC obtained due to the presence of Bis-Azo PC. 
Statistical analyses (P<0.05) from Fig 3.13 shows that the difference between values of protein 
release from photosensitive liposomes due to lamp 2 vs lamp 1 was statistically significant 
(P<0.01), lamp 2 vs lamp 3 was very significant (P<0.001) and lamp 1 vs lamp 3 was very 
significant (P<0.001).
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Fig 3.13: Summary of ANOVA analysis.  
All the protein release data in Fig 3.12 passed the normality test using one-way analysis of variance 
(ANOVA) and a multiple comparison post-test Tukey. 
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Another interesting difference was observed between photosensitive liposomes prepared from 
DPPC:Bis-Azo PC with varying amount of cholesterol (Fig 3.13). The protein release pattern from 
photosensitive liposomes was significantly (P < 0.001) reduced as the amount of cholesterol is 
increased. From Fig 3.13, it is also clear that photosensitive liposomes containing DPPC:Chol:Bis-
Azo PC (16:2:1) have significantly (P < 0.001) higher release of BSA-FITC in comparison with 
other photosensitive liposomes containing DPPC:Chol:Bis-Azo PC (16:4:1) and DPPC:Chol:Bis-
Azo PC (16:5:1). With lamp 2 UV irradiation, photosensitive liposomes containing 
DPPC:Chol:Bis-Azo PC (16:2:1) gave 70 % protein release after 1 min. On the other hand, 
photosensitive liposomes containing DPPC:Chol:Bis-Azo PC (16:4:1) and DPPC:Chol:Bis-Azo PC 
(16:5:1) gave 65 % and 58 % protein release after 1 min. Similar trend of the protein release was 
obtained after 3 min UV irradiation using the same lamp and the same liposomal formulations. 
Therefore, the inclusion of 4 and 5 μmoles of cholesterol had a dramatic effect on protein leakage 
in this system. This major influence of cholesterol on the properties of these liposomal 
formulations evidenced a possible way to control their permeability. Previous work (Morgan et al., 
1987a) has shown that cholesterol has a major impact on the percentage release of solute from 
photosensitive liposomes containing Bis-Azo PC and a single azo benzene moiety known as “Pazo 
PC”. According to them, Cholesterol is very complex in nature and well recognised to act as 
‘buffer’ of membrane order. In fluid phase, cholesterol increases the order and packing density 
within the bilayer, whereas in the gel phase, the order and packing density within the bilayer is 
decreased (Bisby et al., 1999c). As a result, cholesterol has two noteworthy effects, primarily 
cholesterol affects the lateral phase separation and subsequently it alters the overall rigidity of the 
lipid bilayer (Ohvo-Rekilä et al., 2002). Both of these two effects will influence the kinetics of 
solute release from photosensitive liposomes. Later on Xu and London (Xu and London, 2000) 
demonstrated how cholesterol induces lipid domain formation and considered sterols which do not 
induce lipid domain as anti-cholesterols. They also evidenced that cholesterol promotes tight 
packing of saturated lipids which promote domain formation and this lipid domain formation plays 
a key role in lateral phase separation. However, the promising role of cholesterol in phase 
separation and the photo-induced release process needs further investigation. Analytical methods 
such as Differential scanning calorimetric (DSC) measurements, freeze-fracture electron 
microscopy, and NMR and electron spin resonance (ESR) spectroscopy would be beneficial in this 
respect. 
A BSA-FITC release of 2 %, without the use of UV irradiation, from photosensitive liposomes 
containing DPPC:Chol:Bis-Azo PC (16:5:1) was noted (Table 3.4). Conversely, all other liposomes 
showed 0 % release without UV irradiation. Liposomes containing higher amounts of cholesterol 
and photosensitive lipid Bis-Azo PC have been noted to give a trigger release without UV 
irradiation (Bisby et al., 2000b). The reason behind this leakage is that cholesterol containing 
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liposomes allow stepped partial release of entrapped solute, following multiple periods of short 
visible illumination. 
Overall, results presented in Fig 3.12 demonstrated that release of BSA-FITC was achieved with 
very low exposure to UV light. This protein release during UV irradiation is likely due to the 
photo-isomerisation (trans-cis isomerisation) of Bis-Azo PC (Bisby et al., 1999a). It should be 
noted that photosensitive lipid, Bis-Azo PC, can exist in several forms, with one or both chains in 
the trans- form. During photo-isomerisation, trans-form of Bis-Azo PC is converted to cis-form 
allowing the entrapped content to be released. For that reason, IFV containing photosensitive lipid 
Bis-Azo PC, showed the release of protein after UV irradiation, whereas IFV without Bis-Azo PC 
showed 0 % release after UV irradiation, for instance, DPPC (16) and DPPC:Chol (16:2), (Fig 
3.12). 
From this study, photosensitive liposomes of DPPC:Chol:Bis-Azo PC (16:2:1) seem to be the 
optimal liposome formulation for the controlled drug release under a UV light. Apart from this 
formulation, IFV prepared using DPPC:Chol:Bis-Azo PC (16:4:1) is also good for the photo-
induced drug release. However, it is evidenced that the protein loading efficiency of this 
formulation is low (21 %), in comparison with protein loading efficiency of DPPC:Chol:Bis-Azo 
PC (16:2:1) which is 26 % (Fig 3.9). Therefore, IFV prepared using DPPC:Chol:Bis-Azo PC 
(16:2:1) was used for further investigation. For UV irradiation, lamp 2 (ROHS 36 w professional 
UV lamp) (Fig 3.6 ) was selected as the best choice for further study, as lamp 1 and lamp 3 gave 
less protein release from photosensitive IFV ( Fig 3.12).   
The amount of cholesterol in photosensitive liposomes has a major influence in protein release. At 
low concentrations, cholesterol gives stability to the liposomal bilayer and show burst release of 
entrapped materials after UV irradiation. On the other hand, at higher concentration, Cholesterol 
gives rigidity to the bilayer and reduces the release of entrapped materials after UV irradiation. As 
can be seen from Fig 3.12, photosensitive IFV prepared using small concentrations of cholesterol, 
DPPC:Chol:Bis-Azo PC (16:2:1), gave the burst release of protein after 1 and 3 min of irradiation. 
In contrast, photosensitive IFV prepared using higher concentrations of cholesterol, 
DPPC:Chol:Bis-Azo PC (16:5:1), gave smaller release of protein after 1 and 3 min. Furthermore, 
this photosensitive IFV released 2 % of protein without the use of UV irradiation. Hence, the 
photosensitive IFV prepared using higher amounts of cholesterol have reduced stability.  
3.4.5. Investigation of the 100 % of protein release from DPPC IFV using ROHS 36 w 
professional UV curing lamp. 
Although photosensitive IFV formulations containing BSA-FITC were found to be photo active by 
using three different lamps, the most important question was whether they would  give 100 % 
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release of protein or not. Therefore, based on the photo-induced release data described in section 
3.4.3, similar IFV formulations were selected for this experiment. The formulations were irradiated 
through, using lamp 2 (ROHS 36 w professional UV curing lamp) for different time intervals i.e. 0, 
1, 3, 6, 9, 12 and 15 min. It should be noted that for this study, lamp 2, which was used because of 
showing better release in comparison to lamps 1 and 3.  The data obtained from this investigation 
are presented in Fig 3.14. 
 
Fig 3.14: Photo-triggered release of protein from IFV with ROHS 36w professional UV 
curing lamp:  
IFV were prepared via interdigitation fusion method. IFV composed of 16 μmoles of DPPC, 2 μmoles of 
cholesterol and 1 μmoles of Bis-Azo PC, where applicable. The 100 % releases of BSA-FITC were achieved 
with lamp 2 by measuring fluorescence emission. The data are expressed as means ± standard deviation of 
three independent experiments. Significance was measured by one-way ANOVA (**** p<0.0001; *** 
p<0.001; ** p<0.01; * p<0.05). 
Fig 3.14 clearly indicates that there is no further protein release from the IFV, after 12 min of 
irradiation. A plot of cumulative percentage of drug release vs irradiation time, revealed protein 
release patterns of all IFV formulations except DPPC and DPPC:Chol, whose release are slow but 
increases with increased UV exposure time.  
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It is also clear from Fig. 3.14 that after 12 min of UV irradiation, IFV prepared using 
DPPC:Chol:Bis-Azo PC (16:2:1) shows maximum protein release of up to 84 % as compared to 
other IFV. Indeed, IFV prepared using DPPC:Chol:Bis-Azo PC (16:5:1) shows minimum protein 
release, of up to 77 %, while, IFV prepared using DPPC:Chol:Bis-Azo PC (16:4:1) shows protein 
release of up to 81 %. These results demonstrate that the inclusion of very high amounts of 
cholesterol reduces the % protein release. Interestingly, control experiments, in which IFV 
formulations prepared using DPPC and DPPC:Chol (16:2) show 0 % release after prolonged 
exposure to UV irradiation. This further cements the hypothesis that the presence of photosensitive 
lipid Bis-Azo PC into the phospholipid causes disruption and releases the entrapped solutes (Bisby 
et al., 1999b).  
Statistical analyses (P < 0.05) shows that the % of protein release from IFV after 1 and 3 mins of 
UV exposure compared to % of protein release after 12 min and 15 min, as statistically significant 
(P<0.0001) (Fig 3.14). It was also noted that the % of protein release difference between 
DPPC:Chol:Bis-Azo PC (16:2:1) vs DPPC:Chol:Bis-Azo PC (16:4:1) was statistically significant 
(P<0.05), while, DPPC:Chol:Bis-Azo PC (16:4:1) vs DPPC:Chol:Bis-Azo PC (16:5:1) and 
DPPC:Chol:Bis-Azo PC (16:2:1) vs DPPC:Chol:Bis-Azo PC (16:5:1) was very significant, 
(P<0.01) and (P<0.001), respectively (Fig 3.14). 
It is also revealed from Fig 3.14, that IFV prepared using DPPC:Bis-Azo PC (16:1) shows % 
protein release of up to 78 % after 3 min irradiation compared to other IFV. This may be possibly 
due to the presence of Bis-Azo PC, this formulation does not contain cholesterol, thus the fast 
release (Sandhu et al., 1986). Conversely, IFV prepared using the DPPC, Bis-Azo PC 
supplemented with 2 and 4 μmoles of cholesterol shows release of up to 70 % after 3 min, 
demonstrating the importance of cholesterol.  From earlier experiments, Demel et al (Demel et al., 
1972) and Papahadjopoulous (Papahadjopoulos et al., 1973a), established that cholesterol has the 
ability to complex with phospholipids and that this complex could  reduce bilayer permeability to 
hydrophilic drugs or solutes. Apart from this, other researchers (Mohammed et al., 2004b; 
Sułkowski et al., 2005), had reported that addition of cholesterol into the liposome increases 
liposomes stability and reduces permeability of entrapped materials. In theory, Cholesterol 
combines with phospholipids and acts as a stabiliser. 
It seems that 100 % protein release from photosensitive IFV was not achieved (Fig. 3.14) due to 
incomplete recovery of the added protein. Therefore, IFV prepared using DPPC:Chol:Bis-Azo PC 
(16:2:1) show high protein release with a maximum of 84 % after 12 min UV exposure. This 
formulation had cholesterol content of 2 μmoles which not only gives stability to the IFV, but also 
reduces the bilayer permeability. Other IFV formulations, such as DPPC:Chol:Bis-Azo PC showed 
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protein release of upto 81 %. However, this formulation contains cholesterol up to 4 μmoles which 
increases rigidity and reduces protein entrapment efficiency.  
3.4.6. Stability assessment of IFV formulations 
In order to develop highly efficient photosensitive controlled release systems, it is necessary that 
the formulated IFV to have high retention of the loaded BSA-FITC when in a non-photoreactive 
environment; thus, a stability study was carried out at two different temperatures- 1) Short- term 
stability at room temperature (∼23 °C) and 2) Long-term stability at 4 °C. 
3.4.6.1. Short-term stability 
In this stability study, IFV  formulations of DPPC 16 µmoles, DPPC:Bis-Azo PC 16:1 µmoles, 
DPPC:Chol:Bis-Azo PC 16:2:1 µmoles,  DPPC:Chol:Bis-Azo PC 16:4:1 µmoles, DPPC:Chol:Bis-
Azo PC 16:5:1 µmoles were stored at room temperature (∼25 °C) for up to 15 min, 24 h and 48 h, 
respectively and assessed in terms of variation in size, zeta potential, span and drug retention inside 
the liposomes. The results are presented in Figs 3.15, 3.16, 3.17. 
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Fig 3.15: Initial protein loading IFV for short-term stability.  
IFV were prepared via interdigitation fusion method. IFV composed of 16 μmoles of DPPC, 2 μmoles of 
cholesterol and 1 μmoles of Bis-Azo PC, where applicable. Results represent mean ± SD of n=3 batches. 
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Fig 3.16: Stability assessment of IFV formulations stored at room temp for 15 min, 24h and 
48h.  
Measurements were taken of (a) Size (µm) and (b) zeta potential (mV) and (c) span measurement after 15 
min, 24h and 48h at room temperature. Results represent mean ± SD of n=3 batches. 
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Fig 3.17: Drug leakage (%) from IFV stored at room temp for 15 min, 24 h and 48 h.  
IFV: Liposomes were prepared via interdigitation fusion method. Liposomes composed of 16 μmoles of 
DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC where applicable. % leakages were taken after 
15 min, 24 h and 48 h at room temperature and measured by UV spectrophotometer. Results represent mean 
± SD of n=3 batches. Significance was measured by one-way ANOVA (**** p<0.0001). 
Liposomes vesicle size at 25 0C has no significant difference when comparing IFV formulations at 
15 min, 24 h and 48 h of drug release (Fig 3.16). Although there were some fluctuations over the 
time points, the general trend suggests IFV were stable over 15 min, 24 h and 48 h. Similarly, there 
were also no significant changes to the span over the same time period. In terms of zeta potential 
(Fig 3.16) there was no significant difference in surface charge under storage in the dark at 25 0C 
for two days. This means all IFV were stable in terms of size, size distribution and zeta potential at 
25 0C for 15 min, 24 h and 48 h. This is because the storage conditions assessed, especially 
temperature, was not above the transition temperature of the lipid, which is 41 0C for DPPC 
(Mabrey and Sturtevant, 1976). However, according to Casals and co-workers (Casals et al., 2003), 
neutral liposomes such as DPPC have a tendency to aggregate by Van der Waals force of 
interaction whereby aggregation phenomenon is more pronounced and common in large vesicles. 
However, this was not observed in this study (Fig 3.16). The outcome of negative charge indicates 
the presence of BSA-FITC which acquires negative charge in the PBS at pH 7.4 due to ionisation. 
**** 
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In terms of liposomal drug retention (Fig 3.17), DPPC IFV 16 µmoles stored in the dark at room 
temperature exhibited 0 % release. On the other hand, DPPC IFV containing 1 μmoles of Bis-Azo 
PC exhibited release rates of 2.71±0.15 % (of total amount entrapped) after 15 min. Interestingly, 
DPPC IFV 16 µmoles stored in the dark at room temperature exhibited release rates of 5.74 % (of 
total amount entrapped) after 24 h with a total release of 10.42 % following 48 h incubation, 
whereas DPPC IFV sample containing 1 μmoles of Bis-Azo PC exhibit higher release rates with 
31.48 % loss within 24 h and a total of 54.61 % within 48 h when stored in the dark at room 
temperature. This may be due to the presence of photosensitive lipid, Bis-Azo PC, within DPPC 
liposomes which causes the photo-isomerisation (trans -cis isomerisation) during the formulation of 
IFV (Sandhu et al., 1986). 
 
DPPC:Bis-Azo PC  IFV containing 2 µmoles  stored in the dark at room temperature exhibited 0 % 
release after 15 min and 21 % and 41 % (of total amount entrapped ) after 24 h and 48 h, 
respectively, suggesting that the percentage release could be reduced with the inclusion of 
cholesterol in the IFV (Fig 3.17). Furthermore, DPPC:Bis-Azo PC  IFV containing 4 µmoles 
exhibited release rates of 3 % (of total amount entrapped ) after 15 min and 22 % (of total amount 
entrapped ) after 24h with a total release of 48 % following 48 h incubation. On the other hand, 
DPPC:Bis-Azo PC containing 5 µmoles of cholesterol and stored in the dark at room temperature, 
exhibited higher release rates with 3.3 %, 25% and 53% loss within 15 min, 24 h and  48 h, 
respectively. It should, however, be noted from Fig 3.17 that IFV prepared using DPPC and 
DPPC:Bis-Azo PC 16:2:1 shows significantly less leakage of protein as compared to other IFV. 
Therefore, these were considered stable IFV formulations.   
 
Statistical analyses (P < 0.05) shows that  the % of leakage  from DPPC:Chol:Bis-Azo PC 16:2:1 
IFV after 15 min, 24 h and 48 h is statistically significant (P < 0.0001) compared to the % of 
protein leakage from DPPC:Chol:BisAzo PC 16:4:1 and  DPPC:Chol:BisAzo PC 16:5:1 (Fig 3.17). 
There is no significant difference seen between the IFV prepared using DPPC:Bis-Azo PC 
compared with the IFV prepared using DPPC:Bis-Azo PC 16:2:1. It can thus be said, statistically, 
that the amount of cholesterol plays an important role in IFV stability. Earlier studies evidenced 
that the tendency of cholesterol to persuade membrane stability was thought to happen due to the 
strong interaction between the rigid hydrophobic ring structure of cholesterol molecule and alkyl-
side chains of phospholipids that ultimately reduces membrane permeability (Wiseman et al., 
1993). 
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3.4.6.2. Long- term stability 
Subsequent to short-term stability, it was important to assess the long term stability of IFV 
formulations. Long-term stability study was carried out assessing formulations of DPPC 16 
µmoles, DPPC:Bis Azo PC 16:1, DPPC:Chol:Bis Azo PC 16:2:1, DPPC:Chol:Bis Azo PC 16:4:1 
and DPPC:Chol:Bis Azo PC 16:5:1. The effect of placing the aqueous dispersion at fridge 
temperature (at 4 °C) in the dark for two weeks was observed by assessing the three 
physicochemical parameters of size, size distribution, zeta potential and drug retention inside the 
liposomes ( Figs 3.18, 3.19 and 3.20 ).  
D
P
P
C
 (
1 6
 
m
o
le
s )
D
P
P
C
: 
B
is
-A
zo
 P
C
 (
1 6
:1
 
m
o
le
s )
D
P
P
C
 :
 C
h
o
l :
 B
is
-A
zo
 P
C
 (
1 6
:2
:1
 
m
o
le
s )
D
P
P
C
 :
 C
h
o
l :
 B
is
-A
zo
 P
C
 (
1 6
:4
:1
 
m
o
le
s )
D
P
P
C
 :
 C
h
o
l :
 B
is
-A
zo
 P
C
 (
1 6
:5
:1
 
m
o
le
s )
0
1 0
2 0
3 0
4 0
F o rm u la tio n s
P
ro
te
in
 e
n
c
a
p
s
u
la
ti
o
n
 e
ff
ic
ie
n
c
y
 (
%
)
 
Fig 3.18: Initial protein loading of IFV for long-term stability.  
IFV were prepared via interdigitation fusion method. IFV composed of 16 μmoles of DPPC, 2 μmoles of 
cholesterol and 1 μmoles of Bis-Azo PC, where applicable. Results represent mean ± SD of n=3 batches.  
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Fig 3.19: Stability assessment of IFV formulations stored at 4 0C for two weeks.  
Measurements were taken of (a) Size (µm) and (b) zeta potential (mV) and (c) span measurement after One 
week and two week at 4 0C. Results represent mean ± SD of n=3 batches.      
Chapter 3 -Development of Photosensitive Liposomes for the Controlled Release of Bovine 
Serum Albumin-Fluorescein Isothiocyanate (BSA-FITC) 
148 
 
T im e  (W e e k s )
%
 
L
e
a
k
a
g
e
0 1 2
0
2 0
4 0
6 0
8 0
D P P C  (1 6 m o le )
D P P C : B is -A z o  P C  (1 6 :1 m o le s )
D P P C  : C h o l : B is -A z o  P C  (1 6 :2 :1 m o le s )
D P P C  : C h o l : B is -A z o  P C  (1 6 :4 :1 m o le s )
D P P C  : C h o l : B is -A z o  P C  (1 6 :5 :1 m o le s )
****
***
Fig 3.20: % leakage of IFV stored at 4 0C for two weeks:  
IFV were prepared by using interdigitation fusion method. Liposomes composed of 16 μmoles of DPPC, 2 
μmoles of cholesterol and 1 μmoles of Bis-Azo PC where applicable Measurements were taken after one 
week and two week at 4 0C. Results represent mean ± SD of n=3 batches. % leakages were taken after 15 
min, 24h and 48h at room temperature and measured by UV spectrophotometer. Results represent mean ± SD 
of n=3 batches. Significance was measured by one-way ANOVA (**** p<0.0001; *** p<0.001). 
It is clear from Fig 3.19 that in terms of size at 4 0C there was no significant changes in size when 
comparing IFV formulations for two weeks. Nonetheless, there were slight variations in particle 
size of vesicles that were minor. Similarly, long term stability study has no major influence on the 
span of IFV (Fig 3.19). In terms of Zeta potential measurement (Fig 3.19), there was no significant 
difference in surface charge of IFV comparing one week and two weeks of storage in the dark at 4 
0C. This result suggests that IFV are stable at 4 0C for two weeks. The outcome of negative charge 
was due to the BSA-FITC, otherwise DPPC IFV without BSA-FITC shows neutral charge. It is 
worth noting that the enhanced physical stability of BSA-FITC stored at 4 0C in refrigerator 
confirms the interpretation of (Plessis et al., 1996) who demonstrated that good stability in terms of 
size, span and zeta potential should be achieved by storing liposomes in fridge at 4 0C.   
 
As can be seen from Fig 3.20, DPPC interdigitation fusion vesicles (IFV) which are stored at fridge 
temperature exhibit a release rate of 33.11 % (of total amount entrapped) after one week and a 
release rate of 43.86 % following two weeks of storage. On the other hand, DPPC IFV sample 
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containing 1 μmoles of Bis-Azo PC shows higher release rates, with 34.86 % of the total entrapped 
amount lost within one week and 49.10 % within two weeks following storage at the same 
temperature. This further demonstrates that the inclusion of Bis-Azo PC within liposomes 
influences the % leakage of protein. In comparison to short-term stability, % release differences 
between these IFV were significantly (P< 0.05) low owing to the storage condition at 4 0 C. 
 
It is also observed from Fig. 3.20 that the extent of the leakage was reduced in DPPC: Cholesterol: 
Bis-Azo PC (16:2:1), with 31 %, 42 % release after one week and two weeks, respectively. This 
further cements the hypothesis that cholesterol plays a key role in liposomal stability. Previous 
studies clearly indicate that the amount of cholesterol, alters the fluidity of liposomes by modifying 
the orientation of mobile hydrocarbon chains of liquid crystalline phospholipid bilayer which 
reduces the permeability behaviour and increases the vesicle drug retention mechanism; in theory it 
diminishes gel–to-liquid phase transition of lipid bilayer (Vilcheze et al., 1996; Ohtake et al., 2005; 
Vingerhoeds et al., 1994). Interestingly, IFV prepared using the supplementation of DPPC:Bis-Azo 
PC with 4 and 5  µmoles of cholesterol results in higher release rates of 33.98 % and  34.78 % (of 
total amount entrapped ) respectively  after one weeks; with a  release of 50.86 % and 52.9 % 
respectively following two weeks of storage in the dark at 4 0C. This suggests that as the amount of 
cholesterol increases the IFV stability decreases (Fig. 3.20).   
 
Statistical analyses (P< 0.05) show that the difference in protein leakage from IFV DPPC:Chol:Bis-
Azo PC (16:2:1) vs protein leakage from IFV DPPC:Chol:Bis-Azo PC (16:4:1) was statistically 
significant (P < 0.001) while % of protein leakage from IFV DPPC:Chol:Bis-Azo PC (16:2:1) vs % 
of protein leakage from IFV DPPC:Chol:Bis-Azo PC (16:5:1) was very significant (P < 0.0001) 
and % of protein leakage from IFV DPPC:Chol:Bis-Azo PC (16:2:1) vs % of protein leakage from 
IFV DPPC:Bis-Azo PC (16:1) was very significant (P < 0.0001) (Fig 3.20). All the protein release 
data in Fig 3.20 passed the normality test using one-way analysis of variance (ANOVA) and a 
multiple comparison post-test Tukey. 
 
Overall, short-term and long-term stability studies show that the DPPC: Chol: Bis-Azo PC (16:2:1) 
should be the better choice for drug release as compared to other IFV. However, long- term shelf 
life of these IFV should be improved by the use of freeze-drying (lyophilisation) technique 
(Mohammed et al., 2004b) in which water gets removed from the liposomes and thus liposomes are 
stored as freeze-dried powder form.   
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3.5. Conclusion 
In conclusion, IFV with or without Bis–Azo PC sensitized were successfully prepared by ethanol 
induced fusion method. This technique is beneficial and eye-catching because it produces 
qualitative and similar vesicles which are confirmed through confocal microscopy and IFV 
characterisation methods, such as, size analysis. 
Within this study, the one of aim of this research was to quantitatively and qualitatively estimate 
the impact of cholesterol content on the stability of IFV prepared. Results revealed that cholesterol 
has a major impact on the stability of IFV prepared. These findings from this study mirror 
conclusions from previous researchers (Mohammed et al., 2004b) who found that the presence of 
cholesterol improves bilayer stability, and that, in spite of bilayer charge, liposomes rich in 
cholesterol were more stable than cholesterol free liposomes.   
Formation of SUV from MLV is a very important step in IFV formation. For that reason we 
prepared SUV by bath and probe sonication. It can be concluded based on the results of this study 
that SUV formation using both types of sonication depends on the liposome composition and 
cholesterol content. Preliminary results validate the suggestion that IFV without cholesterol forms 
SUV within a short time whereas IFV with cholesterol takes more time for SUV formation. 
Interestingly, insertion of enhanced cholesterol increases the sonication time and influences SUV 
formation.  
Our results also demonstrated that incorporation of protein into liposomes was seen to be 
influenced by the IFV cholesterol. Enhanced cholesterol incorporation in neutral liposomes i.e. 
DPPC liposomes, was shown to coincide with an increased vesicle mean volume diameter; 
although the presence of cholesterol did not significantly influence the zeta potential of any of the 
IFV formulations tested. It is also apparent from the studies that the amount of cholesterol also 
influences the encapsulation efficiency of protein.   
Photo-triggered release study showed that rapid and controlled release of protein in a programmed 
fashion was achieved by using Bis-Azo PC sensitized IFV. However, the release of entrapped 
protein is again dependent on the amount of cholesterol and lipid composition. Therefore, IFV 
prepared using DPPC:Chol:Bis-Azo PC (16:2:1) and DPPC:Chol:Bis-Azo PC (16:4:1) could give 
better release as compared to other IFV. But IFV prepared using DPPC:Chol:Bis-Azo PC (16:4:1) 
have less entrapment efficiency than the IFV prepared using DPPC:Chol:Bis-Azo PC (16:2:1). 
These findings also demonstrate that based on the power and intensity of UV lamps, photosensitive 
IFV give different patterns of release of entrapped protein. Indeed, ROHS 36 w professional UV 
curing lamp was superior to the other two UV lamps, cognizant of the expected release pattern and 
thus was used for further investigations. Photo-induced release study also points out that 100 % 
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release is not achievable. Nevertheless, DPPC:Chol:Bis-Azo PC IFV (16:2:1) could give 84 % 
release after 12 min UV irradiation. 
Stability studies showed that inclusion of increasing amounts of cholesterol, decreases the stability 
of IFV and DPPC:Chol:Bis-Azo PC IFV (16:2:1) could be better choice in comparison to other 
IFV formulations. It is also revealed from stability studies that IFV formulations remain stable at 4 
0C for two weeks and no significant leakage is seen.  
Confocal microscopy study evidences that IFV are bigger than SUV and smaller than MLV. 
Moreover, confocal study established that BSA-FITC was successfully incorporated into MLV, 
SUV and IFV formulations.  
Overall, photosensitive IFV prepared using DPPC:Chol:Bis-Azo PC (16:2:1) seems to be the 
optimal formulation for controlled drug release under UV light. This IFV could have practical 
applications in areas, such as photo-stimulated drug delivery. Even though UV light does not 
penetrate deeply into the tissues, these types of photosensitive IFV would be useful in 
photodynamic therapy in accessible areas such as skin, eyes and mucous membrane. They would 
also be beneficial in cosmetic industry, especially in “sun-tanning apparatus” and ocular drug 
delivery.   
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the Controlled Release of 4’-(6-
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4.1. Introduction 
 
Psoralen (Fig 4.1), also known as psoralene, belongs to the family of furocoumarin and is derived 
from the fusion of furan ring with a coumarin that is found naturally in a few plant species such as 
in the seeds of Psoralea corylifolia and fruits of many plants, such as, fig, lemons, celery, parsley 
and limes, or is synthesized in vitro (Charles and Evans, 2002).  
 
 
 
7H-furo [3, 2-g] chromen-7-one 
 
Fig 4.1: Psoralen compound. 
 
Psoralen has shown a broad spectrum of biological activities which include photosensitization, 
cytotoxicity, phytotoxicity, insecticide, antibacterial, antifungal (Bourgaud et al., 2006; Chen et al., 
2012; Gambari et al., 2007; Ishikawa et al., 2009). Moreover, psoralen has been recommended as a 
potential therapy for the treatment of cancers (Francisco et al., 2012; Kawase et al., 2005; Scaffidi 
et al., 2011), autoimmune diseases (Strauss et al., 2000) and skin disorders, such as vitiligo and 
psoriasis (Adişen et al., 2008; Grimes, 1997). 
 
Much research in recent years has focused on use of psoralen in Psoralen Ultra-Violet A (PUVA) 
treatment for psoriasis. Psoriasis is T-cell mediated multifactorial type-1 autoimmune disorder in 
which the human immune system mistakes a normal skin cell for a pathogen, due to genetic and 
environmental factors, and sends out defective signals that cause overproduction of new skin cells 
(Voorhees, 1996). It generally occurs at any point in the lifespan, affecting children, teenagers, 
adults and older people. As per the survey of US National Institute of Health, 2.7 % of the world 
population suffer from psoriasis. A few researchers have proven that psoriasis patient suffers from 
depression, cardiovascular disease and an impaired quality of life (Nijsten and Wakkee, 2009). It 
also shows different symptoms: skin lesions, cracking of skin, inflammation, itching, joints pain 
and scaly dots on the skin. Various therapies, such as topical therapies and phototherapy can be 
applied to treat psoriasis (Griffiths et al., 2000). If psoriasis is not controlled by topical treatments, 
phototherapy or light therapy maybe recommended. Phototherapy involves the irradiation of human 
skin with UV light on a regular basis under medical supervision (Gawkrodger, 1997). There are 
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two types of ultraviolet (UV) light which can be used for the treatment: ultraviolet A (UVA) (315-
380nm) and ultraviolet B (UVB) (280-315nm). They are different parts of normal sunlight. Due to 
the fact that human skin is sensitive to UVB, psoriasis can be readily treated with UVB exposure 
alone. In contrast, UVA directly penetrates the body but requires a sensitizing medication, such as 
psoralen to treat psoriasis. This process is known as PUVA therapy (psoralen combined with 
ultraviolet A treatment), which is currently approved by the US Food and Drug Agency for clinical 
applications (Gelfand, 2007; Stern, 2007). 
 
There are several routes through which psoralen can be administered as part of PUVA therapy 
(Griffiths et al., 2000). Firstly, psoralen in a capsule dosage form can be taken orally two hours 
prior to the treatment with UVA light. Alternatively psoralen can be added to bath water, known as 
bath PUVA or psoralen can be administered as a topical application of psoralen gel or cream to 
small areas of psoriasis about half an hour prior to UVA light treatment.  
 
PUVA therapy is conducted using one of three psoralen derivatives, i.e. 8-methoxypsoralen                
(8-MOP), 5-methoxypsoralen (5-MOP), and 4, 5, 8-trimethylpsoralen (TMP). All these psoralens 
possess planar aromatic structure and UV absorption bands in the range of 200-350 nm. Because of 
planar aromatic structure, psoralens can easily intercalate with DNA bases. Upon irradiation with 
light of proper wavelength, a psoralen molecule absorbs photons in the ground state and shifts an 
electron to the excited mode (Bryantseva et al., 2008). Subsequently, the adducts with thymine and 
cytosine can be produced that would lead to slower cell proliferation (Fig 4.2). This process may 
also increase tyrosinase activity and encourage the synthesis of melanocytes adjacent to the injured 
cells. 
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Fig 4.2: Interstrand crosslinking between psoralen and DNA base pairs. 
 
Cells get damaged when a psoralen is cross-linked into a nucleic acid duplex in sites containing 
two nucleic acid base pairs (either thymines or uracils) on opposing strands sequentially absorbing 
2 UVA photons. Unfortunately, topical delivery of psoralen in psoriatic skin faces a number of 
challenges. Firstly, as pointed out by Morganti and co-workers (Morganti et al., 2001), stratum 
corneum (SC) acts as an “active wall” that opposes the penetration of xenobiotic i.e. a foreign 
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chemical substance, such as psoralen, and it is also apparent that the major route of penetration 
across the SC is intercellular lipids (Hadgraft, 1996). Secondly, during psoriasis, psoriatic skin 
turns rigid due to increment in the level of cholesterol and reduction in the level of ceramides 
(Wertz et al., 1989). Lastly, due to “rigidization”, psoriatic skin becomes deficient in normal 
moisturizing factors (NMFs), such as water. Thus, targeting psoriatic tissue via topical delivery of 
psoralen is very difficult. However, this problem can be solved by the use of liposomes, the lipoidal 
carrier systems. Liposomes unravel the problem of lipid imbalance by providing the linoleic acid 
that does repair the normal skin conditions (Morganti et al., 2001). Moreover, liposomes are non-
irritant and can be easily excreted through the body. Indeed, it has been proven that liposomes are 
effective drug carrier systems across the psoriatic skin (Menter et al., 2009). Therefore, in this 
study, photosensitive LUV was used to entrap a psoralen derivative. In order to increase drug 
entrapment efficiency of photosensitive LUV, LUV-entrapped psoralen were prepared using two 
common techniques: interdigitation fusion method (as described in Chapter 3) and extrusion 
method. 
 
Large unilamellar vesicles by extrusion method (LUVETs) is a technique in which micrometric 
liposomes, such as MLV suspensions, are forced through polycarbonate filters (100 nm of pore 
size) to generate LUV possessing diameters near the pore size of the polycarbonate filters used 
(Hope et al., 1985; Olson et al., 1979). Preceding extrusion through the polycarbonate filters, MLV 
suspensions are generally disrupted either via several freeze-thaw cycles or via prefiltering of the 
MLV suspensions. This process thwarts the lipid membranes from fouling and recovers particle 
size distribution homogeneity of the final suspension. Moreover, the extrusion should be carried 
out at temperatures above the Tc of the phospholipid because below the Tc, the lipid a vesicle has a 
tendency to entwine with rigid membranes that cannot permit via the pores (Mozafari et al., 2008; 
Nayar et al., 1989). Several studies on the size of the extruded liposomes as a function of 
concentration and pressure has established that the size of the liposomes reduces slightly as the 
extrusion pressure is elevated (Kolchens et al., 1993). The advantages of using the LUVETs are 
that this method can be useful for a wide variety of lipid species and mixtures; it works directly 
from MLV formulations, and is very rapid compared to other methods (Hope, 1993; Patty and 
Frisken, 2003). The extrusion method can generate lipid vesicles with precisely controlled sizes, 
though this technique is limited due to the requirement of highly specialized equipment (Pradhan et 
al., 2008). Recently, a few researchers (Morton et al., 2012) have validated that extrusion, through 
constant pressure-controlled extrusion apparatus, does not influence the entrapped drug because 
drug entrapment is accomplished before the extrusion and that liposomes do not lose their 
biophysical stability. In the present study, extrusion through Avanti mini extruder was performed. 
Furthermore, standard polycarbonate nanomembranes with a pore size of 1 µm were employed in 
this method, which allowed a predetermination of desired liposomes. According to Janoff and co-
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workers (Janoff et al., 1991), the polydispersity of liposomes diminished with the increasing 
number of extrusion cycles. Thus, in the present study, liposomes were extruded through the 
polycarbonate membranes for several times in order to minimise the polydispersity of the prepared 
liposomes.  
 
Numerous experiments have demonstrated that psoralen solubility can influence the intercalation 
between the psoralen and DNA duplexes (Hearst et al., 1978). The same research group also 
revealed that the interstrand crosslinking occurs only when psoralen molecules are present in the 
right position and at the right time. The availability of psoralen molecule at the proper place is 
related to the solubility of psoralen in aqueous solution and upon the dissociation constant resulting 
from non-covalent binding of psoralen with DNA. Hence, the higher the solubility, the greater the 
number of psoralen molecules available for intercalation and ultimately psoralen solubility is very 
important for psoriasis treatment. For this reason, psoralen derivative i.e. 4’-(6-Hydroxyhexyloxy) 
methyl-4, 5’, 8-trimethylpsoralen (HMT) was used in this project, as it has high aqueous solubility 
and fast photochemical kinetics compared to other psoralen derivatives (Isaacs et al., 1982). The 
higher solubility of HMT is due to presence of 6-Hydroxyhexyloxy i.e. OH containing side chain.  
Apart from this, HMT is well known for its use in the study of secondary structure of DNA (Piette 
and Hearst, 1983). 
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4.2. Aims and objective 
 
As discussed in the previous section (4.1), it has been proven that psoralen along with 320-400 nm 
UVA light is an effective treatment for a variety of dermatologic disorders such as psoriasis and 
vitiligo. Unfortunately, topical delivery of psoralen in psoriatic skin faces a number of challenges, 
however it has been reported that liposomes are effective drug carrier systems across the psoriatic 
skin (Menter et al., 2009). Furthermore, it has been demonstrated that a higher psoralen dose has a 
greater success rate than a lower dose and needs a lower mean cumulative UV dose to achieve 
success (Mouli et al., 2013). The aim of this study is to look at whether it is possible to achieve a 
higher psoralen dose through a photo-activated burst release of psoralen i.e. to apply psoralen gel 
containing photo-active liposomes to the areas of psoriasis to achieve the release of psoralen and 
treating the affected areas with UV irradiation.   
 
 The objectives of this work were: 
 Incorporation of Bis-Azo PC (Chapter 2) into a mixture of DPPC and cholesterol to a ratio 
of 16:2:1 (DPPC: Chol: Bis-Azo PC), to form IFV and to entrap HMT. 
 Morphological analysis of HMT-entrapped IFV and empty IFV through confocal 
microscopy   
 Use of ROHS 36w professional UV curing lamp for the photo-triggered release. 
 Quantification of the amount of HMT release from IFV using UV spectroscopy. 
 Determination of the liposomal stability in order to detect the leakage of HMT using UV 
spectroscopy. 
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4.3. Materials and Methods  
 
4.3.1. Materials 
 
4.3.1.1. Chemicals 
Chloroform and Methanol were from Fisher Scientific, Loughborough, UK. Triton- X; and 
phosphate buffered saline (PBS) tablets were purchased from Sigma-Aldrich, Poole, and Dorset, 
UK. Distilled water was used throughout. All the chemicals and reagents used were of analytical 
grade.  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT), with chemical structure shown 
in Fig.4.3 was purchased from Berry & Associates, Inc., USA.  
 
 
 
Fig 4.3: Chemical structure of HMT. 
 
4.3.1.2. Lipids 
 
1, 2-Dimyristoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (its chemical structure can 
be shown in section 3.3.1.2.) were purchased from Avanti Polar lipids, Alabama, USA. 
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4.3.2. Methods 
 
4.3.2.1. Synthesis of photosensitive lipid Bis-Azo PC 
The chemical synthesis of photosensitive lipid 1, 2-bis (4-(n-butyl) phenylazo-4’-phenylbutyroyl) 
phosphatidylcholine (Bis-Azo PC) was as per the previously described method by Sandhu and co-
workers (Sandhu et al., 1986) which is described in chapter 2 (Section 2.3.3.4).  
 
4.3.2.2. Preparation of LUV 
 
Photosensitive LUV were prepared using two methods: a) Interdigitation fusion method and b) 
Extrusion method. 
 
4.3.2.2.1. Preparation of photosensitive IFV by interdigitation fusion method 
 
Photosensitive IFV were prepared as described by Ahl and co-workers (1994) (Ahl et al., 1994). In 
brief, MLV were prepared by thin film hydration method using DPPC, cholesterol and Bis-Azo PC 
in ratio of 16:2:1. The lipids were dissolved in a mixture of chloroform and methanol (9:1, v/v) at a 
concentration of 10 mg/mL. The solvent was then evaporated under reduced pressure using rotary 
evaporator (Buchirotavapor-R 3) at 150 rpm for 15 min. Intermittent vortexing at 55 °C resulted in 
deposition of thin dry lipid film on the sides of the flask which was further dried with a stream of 
nitrogen to remove any residual solvent. The lipid film was then hydrated with 2 mL of a 10 μg/mL 
hydration media (PBS) and then mixed, at intermittent vortexing, with 4'-hydroxymethyl-4, 5’-8-
trimethylpsoralen (HMT) which had been prewarmed above the transition temperature [Tm (41 ± 1 
°C)] of the lipids. The mixed suspension was heated at 50 °C for 30 min until a milky coloured 
suspension was obtained. The resulting multilamellar vesicles were sonicated using a bath 
sonicator (Fischer Scientific, UK) for 35 min at 55 °C. Moreover, absolute ethanol was added to 
the SUV suspension while stirring at room temperature until the ethanol concentration in the 
sample was 4 M. The samples were then instantly vortexed. This process quickly altered the 
transparent SUV suspension into an extremely viscous, opaque white suspension of interdigitated 
phospholipid sheets. Following the inclusion of absolute ethanol, the samples were sealed and 
incubated for 15 min at room temperature, then incubated for 15 min at 50 °C (> Tm of the lipid). 
The caps of the sample vials were then loosened to allow ethanol evaporation, and the incubation 
was continued for another 30 min at the same temperature. Following this, the samples were 
bubbled at a temperature of above the Tm with a gentle stream of N2 to remove ethanol. 
Subsequently, these samples were washed three times with a solution containing 50 mM NaCl, 10 
mM Tris-Hcl (pH 7.4) by centrifugations for 30 min at 27,000×g at 4 °C using Beckman coulter 
ultracentrifuge equipped with TLN-100 rotor until no drug could be detected in the supernatant. 
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The resultant pellets were then suspended with PBS and the vesicles stored at 4 °C. Similarly, 
photosensitive IFV (DPPC:Chol:Bis-Azo PC 16:2:1) without HMT were prepared via 
interdigitation fusion method using 2 mL of PBS in the place of  HMT in PBS .  
 
4.3.2.2.2. Preparation of photosensitive IFV by extrusion method 
 
This was carried out by following the procedures below 
1. Photosensitive multilamellar vesicles were prepared by vortexing dry lipid (DPPC:Chol;Bis-
Azo PC16:2:1µmoles) in the presence of a prewarmed solution of 4'-Hydroxymethyl-4, 5’-8-
trimethylpsoralen (2 mL, 10 µg/mL) in PBS. 
2. In order to increase the entrapment efficiency of 4'-Hydroxymethyl-4, 5’-8-trimethylpsoralen, 
photosensitive multilamellar vesicles suspension were subjected to 1 to 3-5 freeze/thaw cycles 
by alternately placing the sample vial in a dry ice bath and warm water bath. 
3. Photosensitive LUV were produced by transferring the resulting photosensitive multilamellar 
vesicle dispersion into a mini extruder (manufactured by Avanti Polar Lipids, INC., Fig 4.4), 
which allowed the extrusion of the multilamellar vesicles through standard 19 mm 
polycarbonate filters with 1.0 μm pore size. 
4. Similarly, photosensitive LUV (DPPC:Chol:Bis-Azo PC 16:2:1) without HMT were prepared 
via extrusion method using 2 mL of PBS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.4: Lipid mini extruder for LUV preparation. 
Hot plate 
Gas tight syringe 2 Gas tight syringe 1 
Extruder outer casing containing 19 mm 
Polycarbonate filters with 1.0 μm pore size 
Retainer nut Heating block 
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4.3.2.3. Liposome characterisation 
 
4.3.2.3.1. Particle size measurement 
 
The average diameter and polydispersity index (P.I.) of the MLV and LUV were determined by 
Dynamic light scattering (DLS) using a Sympatec (Helos, UK) particle sizer. For the measurement 
of size, 100 μL of a liposome formulation was pipetted into a glass quartz cuvette (with a marked 
signal of at least 15 % was being mandatory for an ample reading) containing distilled water and 
stirred at 1200 rpm to reduce inter-particulate aggregation, and thereafter, the laser beam was 
focused using Helos software, and the assay was repeated in triplicate. 
 
For SUV, the average diameter and polydispersity index (PDI) were determined by using a Zeta 
plus (Brookhaven Instruments, UK). Concisely, 100 µL of SUV suspension was diluted to 4.5 mL 
with double-distilled water and the z-average diameter of SUV was recorded at 25 0C. 
Measurements were reported as a mean value of three readings and each reading was an average 
value of measurements recorded for 3 min. The P.I. was used as a measure of the width of the size 
distribution. 
 
4.3.2.3.2. Zeta potential measurement 
 
Zeta potential was measured using the Zetaplus (Brookhaven Instruments, UK) by means of the 
photon correlation spectroscopy, which measures the particle electrophoretic mobility in a 
thermostated cell. For the zeta potential measurement, 100 µL of liposomal dispersions were 
diluted to 4.5 mL with 0.01 M PBS prior to analysis and the final measurements were the mean 
values of ten readings. 
 
4.3.2.4. 4'-Hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT) standard curve 
 
Using a Varian Cary 1 spectrophotometer, the λmax of HMT was determined by measuring its UV 
spectrum and its λmax was found to be at 249 nm. A stock- solution of HMT (1 mg/mL) was 
prepared by dissolving 1 mg of 4'-hydroxymethyl-4, 5’-8- trimethylpsoralen (HMT) in 1 mL of 
phosphate buffer saline solution at pH 6.8. A set of standard solutions of trimethylpsoralen in the 
range of 0.0786 to 20 µg/mL were prepared by dilution of the above stock solution with PBS 
buffer. UV absorbances of all these solutions were measured at 249 nm with 0.01 M PBS (pH 7.4) 
as the reference. A calibration curve was constructed by plotting absorbance versus concentration 
of the above standard solutions (path length was fixed at 1 cm). Results of regression analyses and 
the correlation coefficients (R2) are demonstrated in Appendix-2. 
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4.3.2.5. Determination of HMT entrapment efficiency in IFV 
 
The loading efficiency of 4’-hydroxymethyl-4,5,8-trimethylpsoralen (HMT)-entrapped 
interdigitation fusion vesicles was determined by measuring the supernatant of IFV present in 3.9 
mL wash media (PBS, 0.01M) following separation of IFV by centrifugation in TLN-100 rotor of a 
Beckman coulter ultracentrifuge for 30 min at 27,000 rpm (×g) at 4 °C. This washing stage was 
repeated a second time in order to make sure that free HMT are separated from IFV (Casals et al., 
1996). The amount of HMT in supernatant was analysed using UV spectroscopy (Varian Cary 1 
spectrophotometer) at 249 nm. The entrapment efficiency (EE %) values expressed as entrapment 
percentage for the prepared IFV were then calculated according to the following equation 
(Ghanbarzadeh and Arami, 2013; Hathout et al., 2007): 
Drug content = Initial amount of drug added – drug remaining in supernatant after centrifugation 
EE % = (drug content / total amount of drug added initially) × 100.....................Equation (4.1) 
 
4.3.2.6. Fourier transform infrared spectrum (FTIR) study 
 
Fourier transform infrared spectroscopy analysis was performed on a Nicolet iS5 FT-IR 
spectrometer using a Miracle Micro ATB attachment with diamond crystal (Thermo scientific,UK). 
Subsequent to the formulation steps, photosensitive IFV with or without HMT were centrifuged at 
the speed of 27,000 rpm for 30 min at 4 °C using Beckman coulter ultracentrifuge equipped with 
TLN-100 rotor  and supernatant was removed. The particle sediments were subjected to freeze 
drying overnight. After that, small amount of IFV powder samples were placed on the diamond 
crystal and compressed gently using the pressure clamp. The diamond crystal was cleaned carefully 
with 95 % ethanol prior to each use. Measurement was performed in transmission mode in the 
range of 4000-400 cm-1 region with a resolution of 4 per cm from 64 parallel scans. The obtained 
spectra were documented and evaluated using Omnic software version 4.1b (Thermo scientific) 
software. Similarly, HMT powder samples were analysed and spectra were recorded. 
4.3.2.7. Photo-triggered release of 4’-Hydroxymethyl-4, 5’-8-trimethylpsoralen-entrapped   
interdigitation fusion vesicles 
 
With the desire of 100% HMT release from liposomes, IFV (DPPC:Chol:Bis-Azo PC (16:2:1) 
formulations with and without 4’-Hydroxymethyl-4, 5’-8-trimethylpsoralen that had been stored in 
the dark were taken and irradiated using a ROHS 36 w professional UV curing lamp for different 
time intervals i.e. 0, 1, 3, 6, 9, 12 and 15 min respectively. The samples were then diluted, 
centrifuged and the amount of HMT in the supernatant was determined HMT using UV assay as 
described above in sections 4.3.2.4 and 4.3.2.5.  
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4.3.2.8. Determination of the short-term stability of 4'-Hydroxymethyl-4, 5’-8-
trimethylpsoralen (HMT)-entrapped interdigitation fusion vesicles 
 
In order to evaluate the short term stability of the formulated IFV during storage, liposomes were 
stored at room temperature (∼23 °C) in the dark and evaluated at the following time courses: 3, 6, 
9, 12, 15 min, 24 h, 48 h and 96 h; both physical and chemical stability of liposomal formulations 
were evaluated. Physical stability of IFV was assessed by visual observation for particle size 
determination after specified time intervals (i.e. 3, 6, 9, 12, 15 min, 24 h, 48 h and 96 h ) and 
chemical stability of IFV was determined by calculating the percentage leakage of 4'-
Hydroxymethyl-4, 5’-8-trimethylpsoralen from the IFV after specified time intervals (i.e. 3, 6, 9, 
12, 15 min, 24 h, 48 h and 96 h) through the UV assay as described in sections 4.3.2.4 and 4.3.2.5.  
 
4.3.2.9. Determination of the long-term stability of 4'-Hydroxymethyl-4, 5’-8-
trimethylpsoralen (HMT)-entrapped interdigitation fusion vesicles 
 
In order to estimate long term stability, both physical and chemical stability of IFV, the formulated 
IFV were stored at fridge temperature (∼4 °C) in the dark for one and two weeks. Physical stability 
of IFV was assessed by visual observation for particle size determination after one and two weeks 
of sample storage while chemical stability of IFV was analysed by checking the percentage leakage 
of 4'-Hydroxymethyl-4, 5’-8-trimethylpsoralen from the IFV after one week and two weeks of 
sample storage, using the UV assay method, as described in sections 4.3.2.4 and 4.3.2.5.  
 
4.3.2.10. Confocal microscopy  
 
Leica confocal microscope was used and IFV prepared using interdigitation fusion method and 
extrusion methods were examined under a 60 X oil objective along with Helium and Argon lasers. 
Following the formulation steps, the un-entrapped HMT was removed through centrifugation for 
30 min at 27,000×g at 4 °C using Beckman ultracentrifuge and subsequently, liposomal 
formulation was placed into a microslide and a cover slip was mounted on it to avoid immediate 
drying out of sample. Furthermore, confocal microscopy was used for the HMT analysis. 
 
4.3.2.11. Statistical analysis 
 
Graph pad software was used for statistical analysis using one-way analysis of variance (ANOVA) 
and a multiple comparison post-test Tukey for determining statistical significance (set at P<0.05 or 
P<0.0001) between data sets. 
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4.4. Result and Discussion 
 
Efficiency of drug encapsulation and stable drug retention in liposomes are strongly correlated to 
vesicle bilayer characteristics, such as charge distribution and perviousness and the physico-
chemical properties of the drug, such as molecular weight, surface charge, solubility and partition 
behaviour between the hydrophilic and hydrophobic regions, as well as method of drug loading 
(Morrow et al., 2007). 
 
Numerous methods are available for LUV preparation, such as ether vaporisation methods (Deamer 
and Bangham, 1976; Schieren et al., 1978), detergent removal methods (Milsmann et al., 1978; 
Philippot et al., 1985), reverse phase evaporation method (Szoka and Papahadjopoulos, 1978), 
calcium induced fusion method (Papahadjopoulos et al., 1975), microfluidization method 
(Gregoriadis, 1990), and freeze-thaw method (Pick, 1981). However, only few of these methods are 
efficient for scaling up. 
 
The objective of this study was to incorporate the HMT into the photosensitive LUV and to study 
its release and stability of HMT. In this investigation, a particular lipid composition 
(DPPC:Chol:Bis-Azo PC 16:2:1) was selected to obtain lipid bilayers rigidity necessary to avoid 
drug leakage after encapsulation while conferring photo-release property upon UV irradiation. 
DPPC has phase transition temperature of 41 0C which is unfavourable for liposomal stability; the 
inclusion of 2 μmoles of cholesterol should give the stability and eliminate the phase transition of 
liposomes (New 1990) while the addition of 1 μmoles of Bis-Azo PC should result in 
photosensitive liposomes (Sandhu et al., 1986). 
 
4.4.1. Effect of large unilamellar vesicles preparation method on vesicle size, zeta potential 
and drug entrapment efficiency 
 
In order to evaluate the drug entrapment efficiency, LUV with or without HMT were prepared by 
two methods: interdigitation fusion method (Ahl et al., 1994) and extrusion method (Hope et al., 
1985). In comparison to interdigitation fusion method, extrusion method is a straightforward 
process and forms smaller LUV vesicles within a short period of time. However, it requires 
polycarbonate filters and LUVET apparatus. It has been noted that SUV increase in size, on the 
other hand remain unilamellar following a freeze-thaw cycle (Hope et al., 1986; Mayer et al., 
1985). Therefore, in this investigation prior to extrusion, freeze-thaw procedure was employed in 
order to improve the entrapment efficiency of LUV.  
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4.4.1.1 Effect of large unilamellar vesicles preparation method on vesicle size, zeta potential 
 
Liposome size affects drug encapsulation and thus impacts drug loading capacity of hydrophilic drug substances into the aqueous region (Franzen and 
Ostergaard, 2012) Physical instability, such as aggregation of lipid vesicles is due to change in the size and charge distribution. Therefore, liposome size and 
surface charge are very important factors in drug delivery. The mean diameter, size distribution and zeta potential of LUV formulations prepared through 
interdigitation fusion method are shown in Table 4.1a for an empty IFV and 4.1b for HMT-entrapped IFV. Table 4.2 a empty LUV and b HMT-entrapped 
LUV illustrates the characterisation of LUV prepared by extrusion method.  
Table 4.1a: Effect of empty photosensitive IFV content on vesicle size, zeta potential 
MLV SUV IFV 
No. of set 
Size Polydispersity 
index (PDI) 
ZP Size 
PDI 
ZP Size 
PDI 
ZP 
(μm) (mV) (μm) (mV) (μm) (mV) 
1 8.70± 0.04 2.11±0.04 -10.08 ± 0.41 0.18±4.3 0.257 -10.49 ± 1.59 10.38 ± 0.15 2.29±0.03 -5.53 ± 2.65 
2 8.93±0.09 2.15±0.02 -5.61±1.14 0.10±5.7 0.37 -5.53±1.10 10.26±0.10 2.08±0.01 -8.96±1.87 
3 8.55±0.13 2.12±0.03 -6.37±3.91 0.15±1.7 0.266 -4.66±1.73 11.74±0.17 2.16±0.03 -10.37±0.56 
4 8.77±0.11 2.09±0.04 -3.79±1.00 0.10±9.6 0.35 -4.24±2.25 10.43±0.27 2.10±0.05 -3.05±2.86 
5 8.62±0.22 2.11±0.03 -4.28±2.09 0.13±6.1 0.332 -6.68±2.47 10.24±0.14 2.24±0.03 -7.03±3.24 
6 8.51±0.11 2.14±0.04 -3.60±2.40 0.15±8.5 0.186 -4.30±2.87 10.11±1.56 2.26±0.09 -3.42±2.79 
Empty photosensitive IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. All formulations were prepared by the 
interdigitation fusion method entrapping the PBS. Results denote the mean ± SD from at least 3 independent batches.   
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Table 4.1b: Effect of HMT-entrapped photosensitive IFV content on vesicle size, zeta potential 
MLV SUV IFV 
No. of set 
Size Polydispersity 
index (PDI) 
ZP Size 
PDI 
ZP Size 
PDI 
ZP 
(μm) (mV) (μm) (mV) (μm) (mV) 
1 8.50± 0.11 2.10±0.03 -6.28 ± 3.91 0.15±5.3 0.272 -5.05 ± 2.51 10.87 ± 0.12 2.29±0.03 -5.53 ± 2.65 
2 8.34±0.13 2.14±0.03 -9.20±1.50 0.17±4.5 0.306 -9.11±1.47 10.64±0.09 2.08±0.01 -8.96±1.87 
3 9.35±0.13 2.08±0.02 -10.42±1.32 0.18±4.0 0.267 -10.29±1.01 11.04±0.14 2.16±0.03 -10.37±0.56 
4 8.08±0.20 2.04±0.08 -4.28±0.83 0.15±4.8 0.204 -4.44±3.06 10.89±0.14 2.10±0.05 -3.05±2.86 
5 8.43±0.05 2.0±0.03 -4.74±1.30 0.13±6.1 0.272 -4.22±0.91 10.64±0.08 2.20±0.02 -4.39±1.54 
6 8.85±0.15 1.95±0.04 -6.58±5.10 0.13±2.4 0.094 -6.37±3.61 10.61±0.18 2.18±0.04 -5.92±1.59 
7 8.62±0.09 1.93±0.03 -7.77±5.41 0.15±9.5 0.111 -7.69±4.31 10.89±0.14 2.20±0.03 -7.11±6.96 
8 8.84±0.09 1.97±0.01 -7.95±1.01 0.15±4.6 0.327 -4.47±0.53 10.70±0.49 2.14±0.06 -8.26±5.36 
9 8.77±0.08 1.94±0.03 -4.31±1.27 0.16±7.3 0.376 -7.29±0.95 10.58±0.27 2.10±0.03 -4.54±4.82 
HMT-entrapped photosensitive IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. All formulations were prepared by 
the interdigitation fusion method entrapping the PBS. Results denote the mean ± SD from at least 3 independent experiments. 
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Table 4.2a: Effect of empty LUV (obtained via extrusion method) content on vesicle size, zeta 
potential 
MLV LUV 
No of set 
 size  
(μm)             
Polydispersity 
Index(PDI) 
ZP  
 (mV)                     
Size 
 (μm)             
Polydispersity 
Index(PDI) 
ZP 
  (mV)                     
1 8.38±0.09  2.10±0.06 
-3.71 
±1.99  
1.59±0.26 1.13±0.05 
-3.64 
±3.31  
Empty LUV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo 
PC. LUV were prepared by extrusion method entrapping the HMT. Results denote the mean ± SD from at 
least 3 independent experiments. 
Table 4.2b: Effect of HMT-entrapped LUV (obtained via extrusion method) content on    
                                                  vesicle size, zeta potential 
MLV LUV 
No of 
set 
 size  
(μm)             
Polydispersity 
Index(PDI) 
ZP  
 (mV)                     
size  
(μm)             
Polydispersity 
Index(PDI) 
ZP  
(mV)                     
1 9.66±0.64 3.79±0.22 -6.21± 
1.01 
1.54±0.03 1.75±0.31 -3.44 
±1.99 
HMT-entrapped LUV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles 
of Bis-Azo PC. LUV were prepared by extrusion method entrapping the HMT. Results denote the mean ± SD 
from at least 3 independent experiments. 
In this study, DPPC:Chol:Bis-Azo PC based liposomes generated by interdigitation fusion method 
had diameters of 10.34 nm whereas DPPC:Chol:Bis-Azo PC based liposomes generated by 
extrusion method were 1.5 nm in diameter. The resultant smaller diameter of LUV formed by 
extrusion method is due to the use of polycarbonate filters (1µm). Although these preparation 
methods had major impact on the size of LUV, the differences were not statistically significant (P > 
0.05). 
 
In addition to size evaluation of the liposomes, uniformity and size distribution were also 
determined. Polydispersity index (PDI) was used as a measure of liposome uniformity. As shown 
in Tables 4.1a, b and 4.2a, b, PDI of LUV prepared by extrusion method was lower than that of 
IFV prepared using interdigitation fusion method. This clearly indicates that the LUVs prepared by 
extrusion method were homogenously distributed in terms of particle size (Bally, 1988). 
 
Zeta potential is another parameter that affect thermodynamic stability of liposomes (Attama and 
Muller-Goymann, 2007). From Tables 4.1a, b and 4.2a, b, zeta potential of all vesicle formulations 
was negative. These results are inconsistent with the results obtained by Pincet et al (Pincet et al., 
  
Chapter 4- Development of Photosensitive Liposomes for the Controlled Release of  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT) 
 
169 
 
1999) and Wiedmer et al (Wiedmer et al., 2001) who demonstrated that liposomes made from pure 
zwitterionic phosphatidylcholine (PC) carry a negative charge at neutral pH. Since all liposomes in 
this study were composed of zwitterionic phospholipids (DPPC), photosensitive lipid (Bis-Azo PC) 
and neutrally charged cholesterol at pH 7, the final outcome of net negative charge on the 
liposomal formulations could be due to the conformational effects of lipids in the assembly, that is 
a buffer dependent orientation of the phosphatidylcholine’s dipole head group that creates shielding 
of the positive charge (Jones, 1995; Makino et al., 1991). In theory, this shielding might be 
reinforced via the cholesterol, where more of the negative side of the dipole sticks-out of the 
surface of the vesicle and the positive side pulls more into the inside of the membrane due to 
hydrogen-bonding with the cholesterol–OH group. The phosphatidylcholine’s dipole head 
orientation that is responsible for imparting a net negative charge to IFV can be represented 
schematically (Fig 4.5) as suggested by Jones (Jones, 1995). 
 
 
 
Fig. 4.5: Charge in the orientation of phosphatidylcholine head groups at the surface of IFV. 
[adapted from (Jones, 1995; Makino et al., 1991)] 
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4.4.1.2. Effect of large unilamellar vesicles preparation method on drug entrapment 
 
Liposomal encapsulation has a considerable effect on the pharmacokinetics and tissue distribution 
of the administered drugs (Ranade, 1989; Szoka and Papahadjopoulos, 1978; Yavlovich et al., 
2011). Therefore, drug entrapment within the system is a key consideration for successful in vivo 
application. Drug loading is entirely based on the chemistry of drug molecules and their partition 
coefficient (Chimote and Banerjee, 2010). Consequently, water soluble drugs are readily entrapped 
within the aqueous interior of lipid vesicles. On the other hand, lipid soluble drugs are carried 
within the lipid bilayer of vesicles. In this study, LUV were used to encapsulate HMT. HMT is a 
highly water soluble psoralen and hence can get entrapped in the hydrophilic core of liposomes. 
Following the formulation step, the percent encapsulated HMT in LUV was investigated using UV 
spectrophotometry. This technique has also been used in the past for quantification of hydrophilic 
drugs such as capreomycin sulphate and 5-fluorouracil (Giovagnoli et al., 2003; Glavas-Dodov et 
al., 2003) , respectively.  
 
Assessment of encapsulation through UV analysis 
 
In theory, UV analysis is primarily used to quantify the amount of an analyte usually in an aqueous 
medium. However, in order to perform this, the analyte should absorb in UV/VIS region. 
Subsequently, Beer-Lambert’s Law is used to estimate its concentration (Ingle and Crouch, 1988). 
HMT is sensitive to UV (Oh et al., 1997). Thus, in this investigation, UV spectrophotometry is 
used to analyse the HMT content. Previously, Gursoy and co-workers (Gursoy et al., 2004) 
described UV/visible analysis as a rapid and efficient way of quantifying drug contents. 
 
HMT loading of LUV was determined by measuring the non-entrapped drug presented in the 
supernatant, following the separation of liposomes via centrifugation. Furthermore, the amount of 
drug in the supernatant was measured by UV spectrophotometric analysis. The concentration of 
entrapped drug into liposomes was determined indirectly after centrifugation and separation of the 
supernatant solution from the resultant pellet. The supernatant was evaluated for the free drug and 
the amount of encapsulated HMT into LUV was calculated after deducting the HMT presented in 
the supernatant from the total amount of HMT added initially (this is described in detail in section 
4.3.2.5). 
 
As mentioned earlier (in section 4.2), one of the objective of this study is to investigate the 
encapsulation efficiency of HMT in LUV prepared by two different methods - interdigiation fusion 
  
Chapter 4- Development of Photosensitive Liposomes for the Controlled Release of  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT) 
 
171 
 
method (also referred as Ahl method in this thesis) and extrusion method. The encapsulation 
efficiency was then determined using the UV/visible spectrophotometry (as shown in Fig 4.6). 
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Fig 4.6: Effect of IFV and LUV formulations on drug entrapment. 
IFV formulations were prepared by the interdigitation fusion method entrapping the HMT and LUV 
formulations were prepared by extrusion method entrapping the HMT. All liposomes composed of 16 μmoles 
of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. The entrapment efficiency of HMT was 
determined by using UV spectroscopy. The data are expressed as means ± standard deviation of three 
independent batches. 
It is evident from the Fig 4.6, the entrapment efficiency of IFV prepared by interdigitation fusion 
method (Ahl et al., 1994) is 25.84±2.02 % while the entrapment efficiency of LUV prepared using 
extrusion method is 35.1±0.08 %. This means encapsulation efficiency of DPPC:Chol:Bis-Azo PC 
(16:2:1) liposomes prepared from extrusion method was higher than those obtained by 
interdigitation fusion method. The results obtained from the interdigitation fusion method is close 
to the results obtained by Smith and co-workers (Smith et al., 2007). However, Smith and co-
workers used calcium chloride as standard drug in their study which is more soluble in water than 
the HMT. In regard to extrusion method, the results are similar to the LUV prepared by  Hope and 
co-researchers (Hope et al., 1985). However, the trapping efficiencies of LUV could be 
significantly enhanced by freezing and thawing the multilamellar vesicles prior to extrusion (Mayer 
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et al., 1986). In 1998, Messersmith and co-workers (Messersmith et al., 1998) proved that calcium-
loaded vesicles prepared using the interdigitation fusion approach were more efficient in 
encapsulating calcium than those prepared by the extrusion method. Thus, further studies, 
particularly release and stability studies, were carried out using LUV prepared from interdigitation 
fusion method. 
 
On the basis of statistical analysis using ANOVA, the results of UV measurements were not 
significantly different (P˂0.05), an indication that similar liposomal formulations prepared through 
two methods resulted in slightly different entrapment efficiencies.  
 
4.4.2. Morphological analysis of DPPC:Chol:Bis-Azo PC based liposomes 
 
One of the aspects of this study was to use confocal microscopy for morphological analysis of 
HMT- entrapped LUV. Psoralen is well known as photosensitizer, which makes one’s skin and 
eyes very sensitive to light (Pathak, 1984). There is extensive literature on the determination of 
two-photon excitation of HMT (Denk et al., 1990; Fisher et al., 1997; Oh et al., 1997). Two-photon 
excitation has been principally investigated as a method of selectively irradiating a small amount of 
sample with applications in a three dimensional microscopic imaging and optical information 
storage (Parthenopoulous and Rentzepis, 1989). Indeed, two-photon excitation of psoralens is 
beneficial in pharmaceutical applications in which photochemical reactions between two non-
covalently complexed molecules that might be initiated in tissues or condensed media ultimately 
generating the fluorescence and image of the molecule (Oh et al., 1997). In addition, due to the fact 
that two-photon excitation provides access by visible light to excitation energies corresponding to 
single UV photon excitation, a whole new class of fluorophores, such as psoralen and several 
fluorescent indicators, such as Indo-1 for calcium, SBFI for sodium and Mag-Indo-1 for 
magnesium have become accessible through laser scanning fluorescence microscopy (Haugland, 
1989). Based on these principles i.e. two photon excitation of HMT, multiphoton laser system may 
be used for the determination of HMT-entrapped lipid vesicles. It requires a short duration of 
pulsed laser system to achieve the high proton flux needed. As a result, fluorescence lifetimes can 
also be measured in these systems (Gerritsen et al., 1997; Lakowicz et al., 1992). In summary, apart 
from treating psoriasis, HMT can also be used as fluorescent material in order to visualise the 
psoriatic skin. To date, little attention has been given on psoralens as fluorescent materials. 
Therefore, one of the objectives of this study is to detect HMT entrapped LUV through confocal 
microscopy.  
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With the aim of assessing the morphological feature of HMT- entrapped LUV, microscopic 
analysis was conducted via Leica confocal microscopy in order to scrutinize the membrane 
structures of the LUV formulations prepared using the two methods i.e. IFV and extrusion 
methods. As during liposomal characterization, particle sizing via laser diffraction provides the 
information of liposome size, the application of microscopic imaging analysis can further assure 
the structural integrity of the liposomes produced (Bibi et al., 2011). In this study, vesicles with or 
without entrapped fluorescent HMT were prepared using formulations of DPPC:Chol:Bis-Azo PC 
(16:2:1) and visualized on a Leica multiphoton confocal microscope using an 63 X oil objective as 
described in section 4.3.2.10. Particle size distribution was not determined by confocal microscopy 
owing to the difficulty in obtaining a sufficient number of vesicles. On the other hand, the 
diameters of imaged liposomes may give a sign of vesicle size. Figs 4.7 (a) and (b) illustrate the 
size and morphology of IFV with or without HMT prepared by interdigitation fusion vesicles 
method (Ahl et al, 1994) while Fig 4.8 (a) and (b) represent the size and morphology of LUV with 
or without HMT prepared by extrusion method (Hope et al., 1985). 
 
                              4.7 (a)                                                                      4.7 (b) 
            
 
 
Fig 4.7: Confocal microscopy images of empty IFV (a) and HMT-entrapped IFV (b).  
IFV: DPPC:Chol:Bis-Azo PC ( 16:2:1 μmoles) based IFV with or without HMT taken with a multiphoton 
Confocal Microscope using a 63 X objective. The green fluorescent marker shown (b) is HMT and is present 
inside the liposomes i.e. internal aqueous compartment of liposomes. 
 
HMT-entrapped IFV IFV without HMT 
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4.8 (a)                      4.8(b) 
 
 
 
 
 
 
 
                                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.8: Confocal microscopy images of empty LUV (a) and HMT-entrapped LUV (b). 
DPPC:Chol:Bis-Azo PC ( 16:2:1 μmoles) based LUV with or without HMT taken with a multiphoton 
Confocal Microscope using a 63 X objective. The green fluorescent marker shown is HMT and is present 
inside the liposomes i.e. internal aqueous compartment of liposomes. 
It was evident from Figs 4.7 (a) (b) and 4.8 (a) (b) that the particle size of LUV prepared through 
IFV and extrusion method is  ̴  4.6 and 1.17 microns, respectively. LUV prepared by IFV method 
were substantially larger than LUV prepared by extrusion method. Further, micrographs reveal that 
all LUV are well-formed vesicles with generally a spherical morphology. Furthermore, HMT can 
be seen entrapped within the internal aqueous core of the vesicles. Although spherical structures 
indicative of LUV formation was evident, these vesicles had particle sizes that were greater than a 
micrometer and thus are in good agreement with corresponding analysis determined via DLS.  
 
Overall, confocal microscopy confirmed the defined morphology and the successful encapsulation 
of HMT within the LUV prepared via IFV and extrusion methods. 
 
 
 
LUV without HMT 
HMT-entrapped LUV 
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4.4.3. FTIR analysis 
 
IR spectroscopy was carried out on the obtained products, as this technique can be used to ascertain 
stability of chemicals in liposomes (Okoro et al., 2014) and the possible interaction between the 
drug and liposomes (Bensikaddour et al., 2008). The IR spectroscopy generates sample peak that 
correlate with the frequency of vibration obtained due to the presence of certain function groups 
and the sample structure can be easily ascertained (Stuart, 1997). 
The Infrared absorption spectra of free HMT, empty and HMT-entrapped IFV are presented in Figs 
4.9, 4.10 (A) and (B). The spectral analysis of HMT  (Fig 4.9) showed characteristic aromatic C-H 
stretch at 3068.58 cm -1 , overtone band at 2919.90 cm -1, C=O stretching of vibration of unsaturated 
lactones at 1760.79 cm -1, C-C(=O)-C stretching vibration at 1682.56 cm-1 ,O-C-C band stretching 
vibration at 1178.20 cm -1, symmetric C-O-C band stretching at 1062.22 cm -1 ,and plane C-H 
bending stretching at 758.35 cm -1. The strong band at 3378 cm -1 represented O-H stretching in 
HMT. All these peaks disappeared in the case of HMT- entrapped IFV (Fig 4.10 B), indicating that 
these groups of the HMT are included in the IFV cavity.  
As depicted in Fig 4.10 (A), the spectrum of IFV without HMT showed strong absorbance at 
2916.90 and 2849.26 cm -1 denoted the C-H stretching, analogous to vibrational stretching in the 
CH2 groups of alky chains, with little influence from the stretching vibration in the CH3 group at 
2956.31 cm -1. Even though, the stretching vibration of C-H significantly reduced after HMT 
entrapment into liposomes, suggesting loading of HMT into the IFV (Fig 4.10 B), the lack of any 
shift in each peak position after the addition HMT demonstrated that HMT did not chemically 
change the composition of IFV.  
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Fig 4.9: IR spectrum of HMT.  
Aromatic C-H stretch = 3068.58 cm -1, overtone band = 2919.90 cm -1, C=O stretching of unsaturated 
lactones = 1760.79 cm -1, C-C (=O)-C stretching = 1682.56 cm -1, O-C-C band stretching = 1178.20 cm -1, C-
O-C band stretching = 1062.22 cm -1, C-H bending stretching = 758.35 cm -1, O-H stretching = 3378 cm -1. 
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(A)  
 
(B)  
 
Fig 4.10: Comparison of the FTIR spectrum of A) Empty IFV B) HMT-entrapped IFV. 
IFV were generated via interdigitation fusion method. Results denote the mean ± SD from at least 3 
independent batches. 
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4.4.4. Photo-induced drug release  
 
A fundamental issue in the assessment of liposomal drug delivery systems is the rate at which the 
drug is released from liposomes. Drug delivery from photosensitive liposomes is based on 
disruption of membrane integrity upon exposure to a UV light source (Bisby et al., 2000a). In order 
to accomplish this, photosensitive molecules (molecules that alter their geometry or conformation 
upon exposure to UV or Visible light), such as retinoids (Gursel and Hasirci, 1995), azobenzene-
based moiety (Hamada et al., 2009) or photochromic lipid Bis-Azo PC (Morgan et al., 1987b) are 
integrated into the lipid bilayer. Several reports document the mechanisms involved in 
photoresponsiveness that include photopolymerization of lipid tails (Wang, 2005), azobenzene 
isomerization (Morgan et al., 1985), cleavage of the lipid tail of plasminogen and diplasmalogen 
through photooxidation (Gerasimov et al., 1999) and a photocleavable NOVC-DOPE (Zhang and 
Smith, 1999).  
 
Much research in recent years has focused on employing azobenzene derivatives as the photo-
control switch. In 1999, Hurst and co-workers incorporated single chain of azobenzene derivatives 
into liposome which could release drug multi-pulsatilely (Lei and Hurst, 1999). However, it has 
been documented that single chain amphiphilic azobenzene derivatives encourage the phase 
separation and fusion of liposomes (Shimomura and Kunitake, 1981; Shimomura and Kunitake, 
1987), thus promoting the spontaneous release of liposomes. Earlier Morgan and co-workers 
(Morgan et al., 1987b) accepted that phospholipid molecules containing the isomerisable group can 
reduce perturbation to bilayer membranes of single chain amphiphilic azobenzene derivatives. 
Therefore, they inserted Bis-Azo phosphatidylcholine (Bis-Azo PC) into liposomes as a photo-
trigger (Bisby et al., 1999b; Bisby et al., 2000b; Morgan et al., 1995). It should be noted that this 
photo-triggered system led to a rapid drug release upon UV light irradiation which may not be 
desirable. However, spontaneous drug release can be controlled by the inclusion of cholesterol. 
Cholesterol is an essential component in biomembranes and plays major roles in stabilizing the 
membrane, increasing rigidity of vesicles and reducing the permeability of the biomembranes to 
water soluble molecules (Ohvo-Rekilä et al., 2002).  
 
In this investigation, light-triggered release was achieved by using photosensitizer i.e. Bis-Azo PC 
along with appropriate amounts of cholesterol and DPPC. Psoralen, the drug investigated in this 
study, is very valuable for the treatment of vitiligo and psoriasis (Griffith et al, 2000). It is worth 
studying whether photosensitive liposomes containing Bis-Azo PC is effective for skin drug 
delivery as little attention has been paid onto photo-triggered release of psoralen via photosensitive 
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liposomes. To demonstrate that these liposomes may serve as promising candidate for light-
triggered release of psoralen, optimal liposomal formulation (based on previous protein study in 
chapter 3) i.e. DPPC:Chol:Bis-Azo PC (16:2:1) was investigated for the release of HMT. The 
results presented below describe the effect UV light on the kinetics and extent of HMT release 
from photo-sensitive liposomes. 
 
DPPC (16 μmoles) liposomes containing 1 μmoles of Bis-Azo PC and 2 μmoles of cholesterol 
were treated with a ROHS 36 w professional UV curing lamp with emission centered at 365 nm for 
different time intervals i.e. 0, 1, 3, 6, 9, 12 and 15 min at room temp, and HMT release was 
measured (see section 4.3.2.7) with DPPC:Chol:Bis-Azo PC (16:2:0) liposome as a control. The 
obtained results are represented in Fig 4.12. Initial drug loading of respective liposomes for various 
studies are presented in Fig 4.11. 
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Fig 4.11: Initial HMT loading of liposomes for various studies.  
Red column (IFV set 1): liposomes for photo-induced drug study; blue column (IFV set 2): liposomes for 
short term stability study, and green column (IFV set 3): liposomes for long term stability study. IFV: 
Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. Results 
denote the mean ± SD from at least 3 independent batches. 
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Fig 4.12: Photo-triggered release of psoralen from IFV.  
IFV: lipid vesicles were prepared via interdigitation fusion method. IFV composed of 16 μmoles of DPPC, 2 
μmoles of cholesterol and 1 μmoles of Bis-Azo PC. The 100 % releases of HMT were done by ROHS 36w 
professional UV curing lamp and measured using UV spectroscopy. The data are expressed as means ± 
standard deviation of three independent batches. Significance was measured by one-way ANOVA (**** 
p<0.0001). 
 
The data obtained from this study also shows that no release was observed prior to exposure to UV 
irradiation (not shown in Fig 4.12), however, after UV exposure, release of HMT from the 
liposomes occurred (as shown in Fig 4.12). It should be noted that the presence of photosensitive 
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lipid Bis-Azo PC in the DPPC liposomes promotes a triggered release of the Drugs (Bisby et al., 
1999a). The data presented in Fig 4.12 also show that significant HMT release (up to 70.59 % of 
total entrapped) occurred from DPPC:Chol:Bis-Azo PC (16:2:1) liposome within 3 min of UV 
treatment. UV treatment for longer times resulted in 74.46 % and 78.10 % release of HMT after 6 
min and 9 min respectively. 83.57 % release of HMT was observed from the liposomes with 12 
min UV treatment. However no obvious increase of the drug release occurred after 12 min and 15 
min which is considered as maximum leakage of HMT from liposomes. In contrast, control 
liposomes prepared from 16 μmoles of DPPC along with the 2 μmoles of cholesterol did not 
promote any substantial HMT release under the identical conditions. This formulation is not 
sensitive to the UV light at 365 nm and thus no release of HMT was seen after UV irradiation. 
These results are consistent with results reported by Smith (Smith et al., 2007) who also suggested 
that threshold concentration of photosensitive lipid Bis-Azo PC was required for the photo-induced 
release of solutes in response to UV light. 
 
Statistical analyses (P < 0.05) shows that the % of HMT release from IFV after 1 min, 3 min and 6 
min of UV exposure compared to % of HMT release after 9 min, 12 min and 15 min, as statistically 
significant (P < 0.0001) ( Fig 4.12). However, it was also noted from the Fig 4.12 that the % of 
HMT release from IFV after 12 min UV exposure compared to % release of HMT after 15 min UV 
exposure was not significant. 
 
Overall, this study supports the notion that a wavelength-specific tunable photosensitizer (Bis-Azo 
PC) is important for photo-destabilization of DPPC:Chol:Bis-Azo PC (16:2:1) liposomes in the UV 
wavelength.  
 
4.4.5. Stability assessment 
 
The capability of liposomes to retain their drug load in vitro and in vivo depends on the liposome 
construction which can be affected by fatty acid chain length, saturation state of the phospholipids, 
the existence of cholesterol and temperature (Langner and Kral, 1999). A general sequence of 
various solutes permeability is: water ˃ ˃ small nonelectrolytes ˃ ˃ anions ˃ cations (Szoka and 
Papahadjopoulos, 1980). Permeability behaviour of liposomes is highest at the lipid phase 
transition temperature (Tc), and is generally lower in gel phase compared to fluid phase (Mouritsen 
and Jørgensen, 1998). As outlined in the introduction section (1.9), the lipid phase transition 
temperature is influenced by the alkyl hydrocarbon chain length. Therefore, increment in the alkyl 
hydrocarbon chain  leads to stronger van der Waals interaction between the lipids which ultimately 
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requires higher energy to disrupt the stable lipid bi-layer, and consequently lipid phase transition 
temperature increases. Earlier researchers have indicated that the drug retention for liposomes 
prepared from DPPC lipid (Tc = 41 0C) is higher and more stable than that of liposomes produced 
from egg PC lipids, Tc = 0 0C (Chen et al., 2010; Mohammed et al., 2004a). As a result, these 
stable and strong lipid bi-layers reduce the efflux of drug from lipid vesicles and thus ensuring drug 
is retained during incubation. Interestingly, numerous experiments have established that cholesterol 
may be included in various types of liposomes in order to improve bilayer characteristics of 
liposomes; increasing microviscosity of the bilayers, reducing the permeability of the membrane to 
water soluble molecules, stabilizing the lipid vesicle and increasing the rigidity of membrane 
(Demel et al., 1972; Gregoriadis and Davis, 1979b; Semple et al., 1996). According to 
Papahadjopoulos and co-workers (Papahadjopoulos et al., 1973b), inclusion of cholesterol up to 33 
mol % into the liposomes decreases the permeability by eliminating transition temperature of lipid. 
Another study also reveals that incorporation of cholesterol into liposomes impedes the diffusion of 
water deep into the lipid membranes and thus enhances the liposomal stability by reducing 
hydrolytic degradation of liposomes (Simon and McIntosh, 1986). In order to develop successful 
photosensitive controlled release system, the formulated liposomes must have high retention of the 
loaded drug in a non-photoreactive environment. Hence, in this study, HMT-entrapped 
photosensitive IFV was formulated by using the optimal liposomal formulation i.e. 
DPPC:Chol:Bis-Azo PC (16:2:1) [results obtained from chapter 3]. The stability study of these 
formulated liposomes was carried out for short- term stability at room temperature and for long-
term at 4 °C. 
 
4.4.5.1. Short term stability 
 
In this stability study, IFV formulations prepared as described in section 4.3.2.8, were stored in 
PBS at room temperature for 15 min, 24 h, 48 h and 96 h, respectively. As pointed out by Stark B. 
et al (Stark et al., 2010), physical and chemical instabilities of carrier systems often limit their 
application in drug delivery. Therefore, the stored formulations were assessed at the above time 
courses in terms of their particle size, zeta potential, span and drug retention inside the liposomes. 
The results are presented in Figs 4.13, and 4.14. No sedimentation was found in any formulations 
after fresh preparation. Initial drug loading of prepared IFV was approximately 25.84 % (Fig. 
4.11). 
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Fig 4.13: Stability assessment of IFV formulation stored at room temperature for 15 min, 24 
h, 48 h and 96 h. 
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. 
Stability measurements were taken of (a) Size (µm) and (b) zeta potential (mV) and (c) span measurement 
after 15 min, 24 h and 48 h at room temperature and analysed via UV spectroscopy. Results represent mean ± 
SD of n=3 batches. 
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Fig 4.14: Drug leakage (%) from IFV stored at room temp for 15 min, 24 h and 48 h.  
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. % 
leakages were taken after 15 min, 24h and 48h at room temperature and measured by UV spectrophotometer. 
Results represent mean ± SD of n=3 batches. 
According to the results (Fig 4.13 a, b), the formulations remained relatively stable in PBS with 
regard to size, zeta potential and heterogenicity during the observation period and there was no 
statistical significance across the assessed parameters over a period of 96 h at room temperature, 
suggesting that IFV formulations are stable as the storage conditions assessed were not above the 
phase transition temperature of liposome (Bisby et al., 2000a). 
 
DPPC:Bis-Azo PC IFV containing 2 µmoles of cholesterol stored in the dark at room temperature 
exhibited no release after 15 min but with leakage of 25.83 % , 50.78 %, 82.08 % and 84.40 % (of 
total amount entrapped ) after 24 h, 48 h, 76 h and 96 h, respectively (Fig 4.14). As can be seen in 
the figure the percentage release could be a linear manner up to 76 h and the release increased after 
one day despite the incorporation of cholesterol in the IFV. This is in contrary to the fact that 
liposomes with neutral charge containing phosphotidylcholines (Yadav AV, 2011) were the most 
stable and inclusion of cholesterol into neutral liposomes increases the stability of liposomes 
(Tamba et al., 2004). The inclusion of Bis-Azo PC into the liposome bilayers was shown to 
remarkably reduce stability thereby limiting the controlled release effect required (Smith et al., 
2007). 
  
Chapter 4- Development of Photosensitive Liposomes for the Controlled Release of  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT) 
 
185 
 
 
Statistical analyses (P < 0.05) show that the leakage from the IFV after 24 h is statistically 
significant (P < 0.0001) compared to the protein leakage from the same liposome after 48 h, 76 h 
and 96 h (Fig 4.14). It can thus be said that statistically the DPPC:Chol:Bis-Azo PC based 
liposome is not stable after 24 h. 
 
In general, DPPC:Chol:Bis-Azo PC based liposomes size, zeta potential and heteroginicity does not 
change in PBS stored at 25 0C for a period of 96 h confirming the fact that IFV formulations are 
stable. However, there is notable drug leakage after 24 h due to the presence of Bis-Azo PC.  
 
4.4.5.2. Long term stability 
 
Long term stability is a factor to be taken into consideration when liposomes are to be applied as a 
pharmaceutical dosage form. Even though much research in past years has focused on the stability 
of liposomes, when they were either in solution (Crommelin and van Bommel, 1984; Gregoriadis 
and Davis, 1979a) or freeze-dried (Fransen et al., 1986; Kirby et al., 1980), little attention has been 
paid to the leakage of drug entrapped- photosensitive IFV with composition changes of IFV on 
long term storage. Therefore, in the present study, stabilities of HMT-encapsulated photosensitive 
IFV (DPPC:Chol:Bis-Azo PC 16:2:1) were assessed by storing it at fridge temperature (4 °C) in the 
dark for two weeks. The physical (Particle size, size distribution, zeta potential) and chemical (drug 
retention inside the liposomes) stability of the vesicles are presented in Figs 4.16, 4.17 and 4.18. 
No sedimentation was found in any IFV formulations after fresh preparation. Initial drug loading 
was approximately 25 % (Fig. 4.11). 
 
As can be seen from Fig (4.15 a), there was no significant changes in size after IFV formulations 
was kept at 4 0C for two weeks. Similarly, long term stability study revealed that there was no 
major changes on the heterogenicity of IFV (Fig 4.15c). In terms of Zeta potential measurement 
(Fig 4.15b), there was no significant difference in surface charge of IFV comparing one week and 
two weeks of storage in the dark at 4 0C. These results demonstrate that photosensitive IFV are 
stable at 4 0C for two weeks. It is worth noting that the enhanced physical stability of HMT-
entrapped IFV stored in dark at 4 0C supports the interpretation of the Ghanbarzadeh and Arami 
results (Ghanbarzadeh and Arami, 2013) who demonstrated that good stability in terms of size, 
span and zeta potential could be achieved by storing liposomes in fridge at 4 0C.   
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Fig 4.15: Stability assessment of IFV formulation stored at 4 0C for two weeks.  
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. 
Stability measurements were taken of (a) Size (µm) and (b) zeta potential (mV) and (c) span measurement 
after one week and two weeks at 4 0C and analysed via UV spectroscopy. Results represent mean ± SD of 
n=3 batches. 
 
 
 
 
 
 
  
Chapter 4- Development of Photosensitive Liposomes for the Controlled Release of  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT) 
 
187 
 
 
 
 
%  L e a k a g e  V s  T im e
0 .0 0 .5 1 .0 1 .5 2 .0 2 .5
0
1 0
2 0
3 0
4 0
5 0
T im e  (w e e k s )
%
 
L
e
a
k
a
g
e
****
****
 
Fig 4.16: Leakage of psoralen from IFV formulation stored at 4 0C. 
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. % 
leakages were measured after one week and two week at 4 0C and measured by UV spectrophotometer. 
Results represent mean ± SD of n=3 batches. 
When evaluating the chemical stability of the IFV, it was found out that the percentage of HMT 
was 33.15 % (of total amount entrapped) after one week and of 41.34 % following two weeks of 
storage at   4 0C (Fig 4.16). These results are similar to the long term stability studies obtained with 
BSA-FITC –entrapped IFV (see section 3.4.6.2). These observations are inferred by Freytag 
(Freytag, 1985) who developed LUV and stored vesicles at 4 0C.  
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Statistical analyses (P < 0.05) show that the difference in HMT leakage from IFV DPPC:Bis-Azo 
PC (16:2:1) after one week storage at 4 0C vs protein leakage from IFV DPPC:Bis-Azo PC (16:4:1) 
after two week storage at 4 0C was statistically significant (P < 0.0001). All the HMT release data 
in Fig 4.16 passed the normality test using one-way analysis of variance (ANOVA) and a multiple 
comparison post-test Tukey. 
 
On the whole, the short-term and long-term stability studies of the DPPC: Cholesterol: Bis-Azo PC 
(16:2:1) based IFV showed that higher percentage of HMT retained in formulations stored at 4 0C 
compared to those stored at room temperature (∼25 °C). This data is in consistent with the results 
obtained by Liu and co-workers (Liu et al., 2002). However, they had developed LUV and 
indicated that LUV on storage at 4 0C are more stable when compared to the storage at 25 0C. It 
should be noted that keeping the IFV formulations under refrigerated conditions reduces the 
liposome instability in terms of psoralen leakage from IFV, even though % leakage of HMT from 
IFV could be observed. This may be either due to the fact that the presence of Bis-Azo PC in IFV 
causes higher drug leakage, a phenomenon which was also reported by Smith et al. (Smith et al., 
2007) or that the inclusion of 2 µmoles of cholesterol alter the fluidic nature of the membrane and 
that its behaviour in the bi-layer is dictated by the temperature of the surrounding environment 
(Chen et al., 2010). However, long-term shelf life of HMT-entrapped photosensitive IFV should be 
improved by the use of Freeze-drying (lyophilisation) technique that stabilises the lipid vesicles 
without compromising their physical state or encapsulation capacity (Lasic et al., 1995). 
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4.5. Conclusion 
 
The research undertaken was aimed at formulating HMT-entrapped photosensitive liposomes for 
the triggered release of HMT and further analyse the physicochemical properties and stability 
profiles of all these liposomes in order to determine HMT retention within liposomal bilayer. This 
is, to our knowledge, the first time that it has been demonstrated that photosensitive liposomes can 
be used for the controlled release of HMT, a psoralen derivative that can treat psoriasis condition. 
 
The results from the study of protein-entrapped liposomes (Chapter 3) revealed that IFV prepared 
from DPPC:Chol:Bis-Azo PC (16:2:1) was optimal for the trigger release of the model protein 
(BSA). Therefore, similar liposomal composition was used in this part of the project and thus LUV 
were prepared by two different methods - interdigitation fusion method and extrusion method. Data 
obtained from the characterisation measurements indicated that no notable difference was observed 
in physicochemical characterization of DPP:Chol:Bis-Azo PC (16:2:1) based liposomes, although, 
the size of LUV was slightly reduced in case of extruded vesicles compared to IFV due to use of 
polycarbonate filters (1 µM). Furthermore, detailed examination of DLS demonstrated that PI of all 
LUV did not show a significant increase. Thus all LUV formulations demonstrated minimum 
aggregation. 
 
In terms of incorporation studies, it was shown in Fig 4.7 that HMT can be successfully 
incorporated into LUV (prepared via two methods) containing DPPC:Chol:Bis-Azo PC (16:2:1) 
effectively. This was further confirmed through confocal microscopy. The microscopic images 
revealed that all tested LUV were successfully able to entrap the HMT. It should be noted that 
extruded vesicles encapsulated slightly higher amount of HMT compared to vesicles prepared via 
interdigitation fusion method. A disadvantage with the extrusion method is that it requires 
polycarbonate filters and extruder. Therefore, LUV prepared from interdigitation fusion method 
could be used for further studies. 
 
Photo-triggered release study shows that rapid and controlled release of HMT in a programmed 
fashion can be achieved by using Bis-Azo PC sensitized LUV. However, the release of entrapped 
drug is again dependent on the amount of cholesterol and lipid composition. Photo-induced release 
study also points out that 100 % release is not achievable. Nevertheless, DPPC:Bis-Azo PC IFV 
(16:2:1) could have 84 % release after 12 min of UV irradiation. These results are similar to protein 
results (as described in chapter 3).  
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A number of LUV formulations prepared through IFV method were subjected to  short-term 
stability studies up to 96 h and long-term stability studies over two weeks period. These studies 
demonstrated that no significant change in average vesicle (10.89 μm) formed from 
DPPC:Chol:Bis-azo PC (16:2:1) IFV at 4 0C over two weeks and 25 0C over 96 h despite the slight 
enhanced leakage of HMT in general at 25 0C when compared to 4 0C .These observations are in 
line with those observed in protein study (as discussed in Chapter 3) and all photo-sensitive IFV 
were stable at 4 0C  . 
 
In conclusion, all liposomal formulations tested showed successful release of HMT after UV 
irradiation and were stable. Thus, photosensitive liposomes DPPC:Chol:Bis-Azo PC (16:2:1) could 
potentially be employed as carrier systems for the controlled release of HMT offering a potential 
new strategy for psoriasis and vitiligo treatment. 
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5.1. Introduction 
Over the last decade, dermal and transdermal drug delivery has been an attractive alternative to oral 
therapy, because it avoids hepatic first-pass metabolism, potentially reduces the side effects and 
boosts patient compliance (Barry, 1983). In addition, transdermal delivery systems are inexpensive 
and can give release for extended periods of time (up to one week) (Prausnitz and Langer, 2008). In 
order to treat dermatological diseases, a wide array of vehicles ranging from solids to semisolids 
and liquid preparations are available. Among these, topical delivery of drugs via liposomal 
formulations has become increasingly popular due to bioavailability and improved therapeutic 
effects (Cevc, 1996; Schmid and Korting, 1996). Numerous experiments have demonstrated the 
potential use of lipid vesicles in dermal applications for skin and eyes conditions (Mezei and Singh, 
1983; Schaeffer and Krohn, 1982). Even though the principal function of the skin is to offer a 
protective barrier (Downing et al., 1987; Potts and Guy, 1992), it is nevertheless important to 
determine how particles as large as liposomes can diffuse pass through the layers of skin. The 
permeation of transdermal pharmaceuticals via skin can be measured by in vivo and in vitro 
techniques (Baert et al., 2010). 
In vitro techniques are principally designed to create experimental method that can predict the 
penetration kinetics of drugs into the human body in vivo, and simultaneously measure skin 
permeability and metabolic activity of drugs (OECD, 2004). It is generally accepted that in vitro 
experimentation offers a number of advantages over in vivo studies, including saving time and 
money, generating better results with reduced degree of parameter variations (van Ravenzwaay and 
Leibold, 2004). There is extensive research in the literature on the application of the in vitro 
techniques to important problems in dermatopharmacology (Amann et al., 2015; Hermann et al., 
1988; Lee and Maibach, 2006; Newbold and Stoughton, 1972; Ostrenga et al., 1971; Scheuplein et 
al., 1969). 
 
In general, transdermal absorption measurement can be performed by applying test formulations to 
the surface of a skin sample, which is mounted as a barrier between the donor chamber and the 
receptor chamber of diffusion cell. Diffusion cells are of two types 1) static type (Franz, 1975) and 
2) flow-through type (Bronaugh and Stewart, 1985). Static diffusion cell sample receptor 
compartment and replace with new perfusate at each time interval whereas flow-through cells 
utilize a pump to transfer perfusate through the receptor compartment and collect flux by constantly 
collecting perfusate. Based on the skin membrane orientation, static diffusion cell can be further 
subdivided into vertical or horizontal diffusion cell.  
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Horizontal diffusion cell possess parallel sized receptor and donor chambers situated on either side 
of the absorption barrier under assessment (Langguth et al., 1986). The absorption barrier is sited in 
the vertical order (Fig 5.1). The advantage of this diffusion cell is that air bubbles can be easily 
removed and continuous agitation of the vehicle ensures the homogeneity of formulation 
(Durrheim et al., 1980; Galey et al., 1976). A disadvantage of this system is the requirement for 
large volume of donor solution (Flynn and Smith, 1971). Most of the horizontal diffusion cells also 
require large section skin membrane which is why this type of systems is not useful for human skin 
(Chien and Valia, 1984). With this type of cells, pre-treatment of skin membrane is impossible. 
Therefore these cells are beneficial for assessing the molecule diffusivity via membrane or to study 
the effect of partition coefficient, and pH on diffusion of a molecule (Southwell and Barry, 1981; 
Southwell and Barry, 1984). 
 
 
Fig 5.1: The Horizontal diffusion cell [ taken from (Smith, 1997)]. 
 
The vertical cell assembly, also known as Franz diffusion cell, was initially projected by Coldman 
(Coldman et al., 1969). Since then this diffusion cell has been modified by many scientists 
(Chowhan et al., 1978). Thereafter, Franz was the one who proposed vertical diffusion cell based 
upon a dumbbell-shaped receiver chamber, commonly referred as Franz diffusion cell (FDC) 
(Franz, 1975). Franz diffusion cell is widely used in drug delivery systems such as sonophoresis, 
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iontophoresis or electroporation, and it requires the immersion of both surfaces of skin membrane 
that may damage skin due to hydration (Pendlington, 2008). The Franz diffusion cell assembly (as 
shown in Fig 5.2) is composed of two compartments (with a volume of between 0.5 to10 mL) 
separated by artificial membrane or skin membrane (Brain et al., 1998). Even though animal or 
artificial skin can be used as skin membrane, the preferred option is human skin. Apart from the 
skin, the cell can also be used with artificial membranes mainly because artificial membranes are 
inert and do not show any biological variation. Synthetic membranes, which are commonly used 
for in vitro study, are of two types. The primary one is either silicon–based membranes 
polymethylsiloxane or Carbosil that are lipophilic and can be used as barrier similar to SC whereas 
the second type, such as cellulose esters and polysulphones, can be used to check the release 
performance of formulations. These artificial membranes also contain pores, therefore they are 
termed as porous membranes (Ng et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.2: Franz cell assembly 
In a typical in vitro permeation study, both compartments, i.e. donor and receiver compartments are 
maintained at a constant temperature of 37 0C via a water jacket. A clinically relevant test 
formulation is applied to the excised skin membranes mounted in FDC through donor 
compartment. Ideally, the Skin should not be exposed for more than 24 hours as it deteriorates after 
Donor compartment 
Receiver compartment 
compartment 
Sampling port 
Circulator pipe Heater /Circulator  
          Hot plate 
Skin membrane 
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24 hours. The bottom chamber also known as receiver compartment contains diffusion fluid that is 
continuously stirred, using magnetic stirrer and from which test samples are withdrawn from the 
sampling port at regular intervals for analysis. These fluid samples are then analysed through the 
use of various analytical methods such as LC/MS, HPLC, and UV that can determine the amount of 
active substance which is permeated through the membrane at each time interval. Based on the type 
of vehicles, the kinetics of drug permeability using Franz cell analysis can vary remarkably (10 to 
50 fold). It should be noted that the donor compartment cannot be stirred in this type of diffusion 
cell; hence active substances must diffuse through the absorption surface.  
Both the Franz cell and horizontal diffusion cell possess the advantage that temperature can be 
readily maintained using water jackets. However, sampling often needs someone to withdraw the 
aliquots at various time intervals while with traditional flow-through diffusion cell, receptor fluid 
can be automatically collected and samples can be removed for analysis through scintillation 
counter, though the traditional flow-through diffusion cells can usually suffer from lack of 
convenient temperature control. Moreover in vitro diffusion cell suffers from evaporation of 
diffusion fluid from the sampling port and inadequate stirring of the receiver chambers (Chien and 
Valia, 1984; Gummer et al., 1987). The Keshary-Chien diffusion cell is as an alternative option that 
gives adequate stirring and the use of stoppers onto the sampling port can reduce the evaporation of 
diffusion fluid (Keshary and Chien, 1984). 
In this investigation, DPPC was used due to the complexity of the skins lipids and it is normal to 
conduct fundamental experiment on well characterized phospholipid membrane such as DPPC 
liposomes (El Maghraby et al., 2008). Apart from DPPC lipids, small amount of cholesterol was 
added for stability and Bis-Azo PC was added in order to make it light sensitive. HMT was selected 
as potent drug material because it is highly water soluble and few researchers have addressed the 
evaluation of HMT-entrapped liposomes for topical drug delivery through the use of Franz cell 
techniques (Fang et al., 2008). For permeation study, rat skin was used. As numerous studies have 
demonstrated that skin permeability of drugs across the species occurred in the following 
descending order: rabbit > rat > guinea-pig > mini pig > Rhesus monkey > human (Sato et al., 
1991; Wester, 1987). Overall, rat skin is highly permeable (three to five times more) than human 
skin (Barber et al., 1992). Moreover, Franz cell was also used in order to study the skin permeation 
of HMT. Moreover, physicochemical characteristics of the obtained DPPC:Chol:Bis-Azo PC based 
liposomes, such as size, zeta potential, drug loading and viscosity results were investigated. 
Furthermore, in vitro permeation of HMT-entrapped IFVs was performed using Franz cell. 
Morphological analysis was assessed by using Leica confocal (Confocal laser scanning 
microscopy).   
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5.2. Aim and Objectives 
Recently, several attempts have been made to evaluate psoralen-entrapped liposomes for topical 
drug delivery via using Franz diffusion cell (in vitro techniques) (Kumari and Pathak, 2013). 
However, little attention has been paid to the development of photosensitive liposomes for the 
delivery of psoralen and subsequently on the evaluation of these liposomes by using in vitro 
techniques. Therefore, the aim of this study was to investigate the permeation behaviour of HMT-
entrapped photosensitive IFV through rat skin using Franz diffusion cell. The objectives of this 
study were as follows:  
 
 To prepare IFV formulations with or without HMT and perform the physicochemical 
characterization of these liposomes using different parameters such as size, zeta potential, 
drug loading and viscosity. 
 To assess the permeation behaviour of free HMT and HMT-entrapped photosensitive IFV 
using Franz cell through rat skin and subsequently to calculate skin deposition of free HMT 
and HMT-entrapped IFV.  
 To carry out the morphological analysis of rat skin after Franz cell study via confocal 
microscopy.  
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5.3. Materials and Methods 
 
5.3.1. Materials 
 
5.3.1.1. Chemicals 
 
Chloroform and methanol were purchased from Fisher Scientific, Loughborough, UK. Triton-X; 
and phosphate buffered saline (PBS) tablets were purchased from Sigma-Aldrich, Poole, Dorset, 
UK. Distilled water was used throughout. All the chemicals and reagent used were of analytical 
grade.  
4’-(6-Hydroxyhexyloxy) methyl-4, 5’, 8-trimethylpsoralen (HMT) (its chemical structure can be 
shown in section 4.3.1.) was purchased from Berry & Associates, Inc., USA.  
 
5.3.1.2. Lipids 
 
1, 2-Dimyristoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol (its chemical structure can 
be shown in section 3.3.1.2.) were purchased from Avanti Polar lipids, Alabama, USA. 
 
5.3.2. Methods 
 
5.3.2.1. Ethics statement: Rat skin 
 
Female Wistar rats, weighing 500 g, were used and kept in an agreeable environment with free 
access to rodent diet and water. The rat skin cells were obtained from Female wistar rats killed 
under PPL 30/3183 (Prof. G L Woodhall). The post mortem rat skin study was approved by the 
Bioethics Committee at Aston University.  
 
5.3.2.2. Preparation of rat skin (hairless rat skin) 
 
Female wistar rats weighing around 500 g and 3 months old were sacrificed in Aston animal lab. 
After cervical dislocation, the abdominal and dorsal skin was separated surgically with scissors and 
scalpel (as shown in Fig 5.3). Hair on the dorsal side of the animal was removed with the help of a 
shaver, shaving in the direction from tail to head. Dermis part of the skin was wiped 5 to 6 times 
with a wet cotton swab soaked in ethanol and PBS to remove any underlying fats and muscle 
tissues. Rat epidermis was prepared by the heat separation method just like human epidermis 
method (Kligman and Christophers, 1963).  
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Fig 5.3: Schematic representation of rat skin preparation. 
Step1-2: Healthy wistar rat was anaesthetized by using NO and sacrificed; Step 3-4: cervical dislocation, the 
abdominal and dorsal skin was separated surgically with scissors and scalpel; Step 5-8: rat epidermis was 
prepared by the heat separation method. 
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The full-thickness skin sample was submerged in sterilised water at 60 °C for 3 min. Then the 
epidermis layer was tactfully separated from the dermis layer with a blunt scalpel. The separated 
epidermis layer was laid flat and cut roundly into approximately 2 cm in diameter sections before 
being stored in plastic petri dishes and wrapped in aluminium foils at -22 °C until used. 
 
The thickness of the skin was determined by a micrometre gauge. Aston animal lab uses the same 
gauge to measure the thickness of tumours. 
 
5.3.2.3. Synthesis of photosensitive lipid Bis- Azo PC 
 
The chemical synthesis of photosensitive lipid 1, 2-bis (4-(n-butyl) phenylazo-4’-phenylbutyroyl) 
phosphatidylcholine (Bis-Azo PC) was as per the method of Sandhu and co-workers (Sandhu et al., 
1986), which is described in Section 2.3.3.4. 
 
5.3.2.4. Preparation of photosensitive IFV by interdigitation fusion method 
 
Photosensitive IFV were generated as described by Ahl and associates (Ahl et al., 1994) which is 
briefly outlined in section 4.3.2.2.1. 
 
5.3.2.5. Liposome characterisation 
 
Particle size and zeta potential of 4'-Hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT)-entrapped 
IFV were measured by the same characterization methods as previously used in the HMT study 
(see sections 4.3.2.3.1 and 4.3.2.3.2). 
 
5.3.2.6. Determination of the initial drug loading  
 
The loading efficiency of 4’-Hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT)-entrapped IFV was 
determined by removing the un-entrapped 4'-hydroxymethyl-4, 5’-8-trimethylpsoralen with 
centrifugation at 27,000 rpm until there was no 4'-hydroxymethyl-4, 5’-8-trimethylpsoralen present 
in the supernatant. Subsequently, the resulting pellet was treated with Triton X-100 to release the 
entrapped trimethylpsoralen. Briefly, samples were prepared by addition of 500 μL aliquot of 
liposome suspension to 1 ml solution of phosphate buffer saline followed by addition of 500 μL 
Triton X-100 (0.1 % solution). Triton X-100 solubilized the liposome membranes and induced 
release of entrapped contents. All samples were diluted, centrifuged and the supernatant was 
measured. The drug content of the supernatant was determined by fluorescence spectroscopy 
(Perkin-Elmer Life Sciences) at excitation and emission wavelengths of 360 nm and 438 nm, 
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respectively.  A calibration curve was constructed by plotting fluorescence versus concentration of 
the above standard solutions. Results of regression analyses and the correlation coefficients (R2) are 
demonstrated in Appendix-3. 
 
5.3.2.7. Dynamic viscosity measurement 
 
Dynamic viscosity measurements were performed to compare the viscosity of the photosensitive 
IFV with or without HMT in PBS. Prior to analyses, photosensitive IFV with and without HMT 
dispersions were generated using the IFV method. Subsequently, the viscosity measurement was 
carried on Anton Par AMVn automated micro viscometer at room temperature. Approximately 1 
mL of liposomal suspension was filled into the glass capillary tube and the measurements were 
noted at an angle tilt of 700 and -700. All the viscosity analyses were repeated three times.  
 
5.3.2.8. Skin permeation studies 
 
The Franz diffusion cells (Rasotherm, Germany) were used to measure the percutaneous 
permeation of free HMT and HMT-entrapped IFV. The Franz diffusion cell is made up of donor 
and receptor phases, and the skin is attached between them. Prior to the experiments, the receptor 
and the donor phases were washed with distilled water and acetone. After drying, Franz diffusion 
cells were filled with 45 mL of phosphate buffer saline (PBS) with a pH of 7.4 as the receptor 
medium. With the purpose of providing support to the skin fragments, the top cover of receptor 
phase was covered by silk netting (Silk Fibre, UK) attached to the device with rubber band. Later 
on, the frozen epidermis skin samples (described in section 5.3.1.3.) were removed and allowed to 
thaw at room temperature for about 5 min followed by ethanol treatment in order to prevent skin 
deterioration. Then rounded epithelial skin fragments were gently placed on top of the silk netting 
attached with previously filled receptor phase of Franz cell so that the epidermis was facing the 
donor phase. Each cell had diffusion area of 2.49 cm2 which was measured by Vernier calliper 
(Chemtool, UK). Then the donor phase was positioned on top, with joint packing in between. A 
metallic clamp was used to hamper any intrusion of air in the Franz –type vertical diffusion cell. If 
air bubbles were spotted, the Franz diffusion cell was flicked to manage release of entrapped air 
bubble. The receptor medium was continuously stirred throughout the experiment by a magnetic 
stirrer at mode 3. The Franz diffusion cells were connected to a closed circuit circulating water bath 
(Churchill, England) with a constant temperature of 37 °C to keep the skin surface at 
approximately 33 °C. The epithelial skin fragment was equilibrated for 45 min with the receptor 
cell circulating with water jacket while the donor compartment was dehydrated. 
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With the help of plastic syringe, 2 mL of free HMT (10µg/mL) was introduced into the donor 
phase of each cell. At appropriate time points (30 min, 1 h, 3 h, 6 h, 9 h, 12 h and 24 h) sample 
aliquots of 1,000 µL were withdrawn from the receptor phase with Hamilton syringe and instantly 
added an equal volume of fresh receptor medium to the donor compartment in order to ensure sink 
conditions, and to maintain contact between the skin membrane and the receptor medium. While 
doing this, bubbles generated below the skin were removed. The sampling ports were enclosed with 
parafilm and the donor compartments were padlocked with rubber plug with the aim to prevent any 
cross contamination and vaporization of sample and receptor fluid. Samples taken at various time 
intervals were analysed by using a Perkin Elmer micro-plate reader. 200 µL of the samples were 
placed in well of 96 well plate and fluorescence of all these solutions was measured by 
fluorescence spectroscopy (Perkin Elmer Life Sciences) at excitation and emission wavelengths of 
360 and 438 nm, respectively. The whole experiment was carried out at least in triplicate. 
 
Flux of the drug was calculated by using following formulae- 
 
𝐐 = (𝐂𝐧𝐕 + ∑ 𝐂𝐢 𝐒
𝐧−𝟏
𝐢=𝟏 )/𝐀………………………       (Equation 5.1) 
 
Q = Cumulative amount of 4'-Hydroxymethyl-4, 5’,8-trimethylpsoralen released per surface area of 
skin (µg/cm2) 
Cn = Concentration of 4'-Hydroxymethyl-4, 5’,8-trimethylpsoralen (µg/mL) determined at nth 
sampling interval 
V = Volume of individual Franz diffusion cell 
∑ 𝐂𝐢 
𝐧−𝟏
𝐢=𝟏
= Sum of concentrations of HMT(µg/mL)determined at sampling intervals 1    
                  through n − 1          
S = Volume of sampling aliquot, 1 mL 
A= Surface area of skin. For this work the surface area was 2.49 cm2 
 
The permeation profile of HMT was obtained by plotting the mean cumulative amount of drug 
permeated through skin (µg/cm2) versus time. Similarly, in vitro permeation of 2 mL of HMT-
entrapped IFV (10 µg/mL) was carried out as described above. 
 
5.3.2.9. Determination of skin deposition following permeation studies 
 
Towards the end of 24 hours permeation study, the full skin fragment was taken from the Franz 
diffusion cell and the remaining formulation which remained on the skin surface was swabbed and 
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washed three times with PBS (pH 7.4) and then with ethanol. The same protocol was repeated for 
three times in order to ensure that no traces of free drug were left onto skin surface. With the 
intention of extracting drug present in skin, the permeation area of epithelium skin was cut into 
small pieces using a pair of surgical scissors and the resulting pieces introduced into a vial 
containing 10 mL of PBS. The resulting suspension was then made uniform by stirring overnight 
(24 h) and maintained at 37 °C. Subsequently resulting suspension was centrifuged at 27,000rpm 
for 30 min, and the supernatants were analysed by using a Perkin Elmer micro-plate reader. 200 µL 
of the supernatants were placed in well of 96 well plate and fluorescence of all these solutions was 
measured by fluorescence spectroscopy (Perkin Elmer Life Sciences) at excitation and emission 
wavelengths of 360 and 438 nm, respectively. The whole experiment was carried out at least in 
triplicate. 
 
Similarly, skin deposition of 2 mL of HMT-entrapped IFV (10µg/mL) was also determined.  
 
5.3.2.10. Confocal microscopy  
 
Following the permeation study, both the photosensitive IFV and HMT treated skin was washed 
and cross-sectioned by means of scissors. Subsequently, this cross-section skin was mounted onto a 
microslide. Furthermore, depth permeation of HMT and IFV were examined under Leica confocal 
microscope at 20× at an optical excitation of 488 nm with argon laser beam as the light source and 
fluorescence emission was detected above 770 nm. In theory, skin permeation behaviour was 
examined at multiphoton IR region.  
 
5.3.2.11. Statistical analysis 
 
Graph pad software was used and statistical analysis of the experimental results was performed by 
ANOVA. Differences were considered statistically significant at P<0.05. All the data values are 
represented as mean± standard deviation of the 3 batches. 
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5.4. Results and Discussion 
 
Stability and photo-triggered release data from previous chapter (Chapter 4) showed that HMT-
entrapped IFV are stable and give controlled release of HMT after UV irradiation. This is a novel 
method and can be beneficial in PUVA therapy for psoriasis treatment. However, for successful 
trans-dermal drug delivery, it is also vital to assess the drug deposition and permeation of HMT-
entrapped IFV through skin models. The potential application of liposomes as novel drug carriers 
for the skin was initially demonstrated by Mezei and Gulasekharam (Mezei and Gulasekharam, 
1980) who proved five times greater skin delivery from the liposomes than an ointment containing 
the same drug concentration. In terms of psoriasis, there is extensive literature on the delivery of 
antipsoriatic agents to psoriatic skin by employing liposomes (Li et al., 2010; Nagle et al., 2011). 
As mentioned earlier, little attention has been given on the permeability studies of psoralen-
entrapped photosensitive liposomes. Therefore the aim of this chapter was to investigate whether 
HMT-entrapped photosensitive IFV alter the skin permeability using Franz cell techniques or to 
synergically improve the dermal delivery of loaded HMT. 
With intention to this, photosensitive IFV were generated by using interdigitation fusion technique 
(Ahl et al., 1994), as this is a simple and straightforward method. Moreover, it is easy and cheaper 
than other methods such as extrusion method (Hope et al., 1985), reverse phase evaporation (Szoka 
and Papahadjopoulos, 1978). It has been shown that the skin drug deposition is dependent on lipid 
composition (Couarraze, 1995) which can significantly affect the physicochemical properties and 
drug release profile. Hence, the lipid composition used to prepare photosensitive IFV in this 
investigation is parallel to those used in the previous chapter (Chapter 4) i.e. DPPC: Chol: Bis-Azo 
PC (16:2:1). 
5.4.1. Characterization of liposomes 
DPPC: Chol: Bis-Azo PC (16:2:1) based liposomes with and without HMT were developed using 
interdigitation fusion method and characterized in terms of size distribution, charge and 
incorporation efficiency. Particle sizes, polydispersity index and surface charge of the prepared 
photosensitive IFV with and without HMT are shown in Table 5.1a and Table 5.1b.  
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            Table 5.1 a) Vesicle size, polydispersity index and zeta potential of various liposomes containing HMT 
MLV SUV IFV 
No. of set Size Polydispersity 
index(PDI) 
ZP Size (PDI) ZP Size (PDI) ZP 
(μm) (mV) (μm) (mV) (μm) (mV) 
1 6.06 ± 0.01 1.76 ± 0.01 -7.39 ± 1.06 0.10 ± 2.4 0.123 -8.07 ± 3.66 10.44 ± 0.72 2.43 ± 0.23 -9.83 ± 1.89 
2  6.77±0.28     2.11±0.04 -10.08±0.41  0.18±4.3 0.257 -10.49±1.59   12.78±0.31   1.95±0.09 -10.57±0.05 
3  7.90± 0.54   2.34±0.21  -5.61±1.14  0.10±0.5  0.370 -5.53±1.10 10.12±0.48 2.29±0.03 -5.17± 4.99 
 
Table 5.1 b) Vesicle size, polydispersity index and zeta potential of various liposomes without HMT 
MLV SUV IFV 
No. of set Size Polydispersity 
index(PDI) 
ZP Size (PDI) ZP Size (PDI) ZP 
(μm) (mV) (μm) (mV) (μm) (mV) 
1 
 
8.60± 0.04 2.11±0.04 -10.08±0.41 0.18±4.3 0.257 -10.49±1.59 10.56±0.10 2.18±0.01 -8.96±1.87 
2 
 
8.33±0.05 2.00 ±0.03 -4.74±1.30 0.13±6.1 0.272 -4.22±0.91 10.79±0.14 2.01±0.05 -3.05±2.86 
Photosensitive IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. All formulations were prepared by the Interdigitation 
fusion method entrapping the PBS. Results denote the mean ± SD from at least 3 independent batches.
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It can be seen from Tables 5.1a and b that the vesicle size was found to be around 10 µm. 
Photosensitive IFV were relatively uniform in size because dynamic light scattering measurements 
indicated a narrow peak in the particle size distribution. Liposome size has major impact on the 
transdermal drug delivery, even though no dedicated study was performed until now to shed light 
on this subject. Several researchers have shown better penetration of hydrophilic drugs from 
reverse-phase evaporation liposomes than from MLV consisting of egg lecithin vesicles 
(Gabrijelčič et al., 1994). Apart from this, Esposito and co-workers (Esposito et al., 1998) 
documented that the permeability coefficient of methyl nicotinate is inversely related to size. 
Furthermore, Plessis and co-workers (Plessis et al., 1994) studied the influence of liposome size on 
skin deposition of cyclosporine and they concluded that intermediate sized vesicles rather than 
small vesicles induced better drug penetration. Based on these findings, it is reasonable to predict 
the particle size of developed IFV here has a good potential for drug delivery.  
As depicted in Tables 5.1a and 5.1 b, the zeta potentials of all photosensitive IFV were negative. 
As mentioned previously (section 4.4.1.1.) the negative charge is due to conformational effects of 
lipids in the assembly that is a buffer dependent orientation of the phosphatidylcholine’s dipole 
head group that creates shielding of the positive charges.  
5.4.1.1. Drug entrapment efficiency of HMT-entrapped IFV 
 
The amount of HMT entrapped into the photosensitive IFV was also determined. The percentage of 
entrapment efficiency of all photosensitive IFV was found to be 25 % (Fig 5.4). These results are 
similar to the results obtained in the previous chapter (Chapter 4).  
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Fig 5.4: Drug entrapment efficiency of HMT-entrapped IFV. 
Photosensitive IFV composed of composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of 
Bis-Azo PC. Results denote the mean ± SD from at least 3 independent batches. 
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5.4.2. Viscosity Measurements 
To develop photosensitive controlled release formulations, viscosity is a crucial factor to consider. 
Müller et al documented that the viscous and elastic properties of liposomal dispersions are 
imperative for their application to skin (Müller et al., 2002). 
Therefore, prior to Franz cell study, it is essential to confirm whether there were any difference in 
viscosity for the IFV with and without HMT (Table 5.2). 
Table 5.2: Viscosity of IFV with or without HMT 
Formulation  Lipid Composition  
Angle 
   [0] 
Temp 
  [0C] 
Dynamic 
Viscosity  
(mPa.s) 
Kinetic Viscosity 
(mm2/s) 
IFV without 
HMT 
DPPC:Chol:Bis-Azo PC  
(16 µmoles:2 µmoles:1 
µmoles) 
70.00 25.00 
0.76573 ± 
0.00335 
0.76573 ± 
0.00335 
 
HMT-
entrapped IFV  
DPPC:Chol:Bis-Azo PC  
(16 µmoles:2 µmoles:1 
µmoles) 
70.00 25.00 
0.75407 ± 
0.01895 
0.75407 ± 
0.01895 
IFV: Liposomes composed of 16 μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. All 
formulations were prepared by the interdigitation fusion method. Each value represents the mean ± SD from 
at least 3 independent batches. 
As depicted in Table 5.2, it was verified that there was no statistical difference in viscosity of 
photosensitive IFV formulations with and without HMT. This means that addition of HMT into the 
formulations has minor effect on the viscosity of liposomes. Viscosity may directly impact on the 
diffusion rate of drug at the miniature level and as per the diffusion coefficient equation, viscosity 
is inversely proportional to the diffusion rate of the drug (Dash et al., 2013). Therefore, transdermal 
drug products with moderately high viscosity can exhibit low diffusion rates while compared to 
transdermal products of comparatively lower viscosity. In this study, addition of HMT into the 
formulations has null effect on the viscosity of liposomes. As a result photosensitive IFV 
formulations with or without HMT are ideal for Franz cell work.   
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5.4.3. In vitro skin permeation studies 
 
With the purpose of assessing the influence of photosensitive IFV on the diffusion of HMT through 
skin, in vitro permeation studies was carried with stripped Albino Wistar rat skin and Franz 
diffusion cell device. A previous report indicated that nanostructured lipid carriers (NLC) enhanced 
the permeation and controlled release of psoralen derivatives such as 8-Methoxypsoralen 8-MOP, 5 
Methoxypsoralen (5-MOP) and 4, 5, 8-trimethylpsoalen (TMP) (Fang et al., 2008). The same group 
also reported that TMP has lower permeation rate as compared to 8-MOP and 5-MOP due to the 
low water solubility of TMP instigated the difficulty of TMP diffusion from the lipid core. Based 
on these results, HMT was used in this study because it is highly water soluble due to the presence 
4-hydroxymethyl group in the drug TMP.  
 
In the actual investigation, rat skin was mounted in Franz diffusion cell, and a solution of the test 
formulations such as aqueous solution of HMT (10 µg/mL) and HMT-entrapped IFV (10 µg/mL) 
was applied to the epicutaneous side of rat skin. Two parameters were obtained: 1) Flux (the rate of 
permeation) of test formulation via rat skin into the receptor fluid; 2) Deposition or the 
concentration of formulation in the skin. 
 
5.4.3.1. Determination of flux 
 
The rates of permeation or flux were measured by withdrawing samples from the receptor fluid at 
various time points over the 24 hours. The concentrations of aqueous solution of HMT (10 µg/mL) 
and HMT-entrapped IFV (10 µg/mL) in receptor fluid at different times are shown in Table 5.3. 
 
Table 5.3: In vitro permeation profiles of HMT through rat kin from dilute HMT solution 
and HMT-entrapped IFV 
Time Concentration of HMT in 
receptor cell (µg/ml) 
Concentration of HMT- entrapped 
IFV in receptor cell (µg/ml) 
30 min 0.104 ± 0.013 0.090±0.009 
1 hr 0.182 ± 0.009 0.176±0.012 
3 hr 0.316 ± 0.003 0.307±0.003 
6 hr 0.413 ± 0.021 0.402±0.018 
9 hr 0.558 ± 0.066 0.510±0.050 
12 hr 0.689 ± 0.022 0.642±0.030 
24 hr 1.008 ± 0.099 0.990±0.001 
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Flux of drug was calculated by using following equation (as noted in section 5.3.2.7) 
 
 
𝐐 = (𝐂𝐧𝐕 + ∑ 𝐂𝐢 𝐒
𝐧−𝟏
𝐢=𝟏
) /𝐀 
 
 
The permeation profile of cumulative amount of aqueous solution of HMT (10 µg/ml) and HMT-
entrapped IFV (10 µg/ml) in receptor phase at different times over the 24 hours are shown in Fig 
5.5. 
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Fig 5.5: In vitro cumulative amount – time profiles of HMT through rat skin from dilute 
HMT solution and photosensitive IFV.  
Photosensitive IFV were prepared via interdigitation fusion method. Photosensitive IFV composed of 16 
μmoles of DPPC, 2 μmoles of cholesterol and 1 μmoles of Bis-Azo PC. The data are expressed as means ± 
standard deviation of three independent experiments. Significance was measured by one-way ANOVA (*** 
p<0.001; ** p<0.01; * p<0.05). 
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Table 5.4: Flux analysis 
Formulation 
 
Total flux of drug 
 
Skin deposition of drug 
Aqueous solution of HMT 
 
19.12 ±0.23 (µg/cm2/h) 
 
0.881± 0.086 (µg/cm2/h) 
 
HMT-entrapped  IFV 
 
18.74 ±0.11 (µg/cm2/h) 0.94± 0.01 (µg/cm2/h) 
 
 
It is evident from the Fig 5.5 that the skin permeability of HMT from the photosensitive IFV 
system is nearly the same as that for the aqueous solution of HMT. However, the totals flux of 
HMT from the aqueous solution of HMT after 24 hours is 19.12 ±0.23 (µg/cm2/h) while the total 
flux of HMT from the photosensitive HMT after 24 hours is 18.74 ±0.11 (µg/cm2/h) (Table 5.4). It 
appears that the small variation is due to the rate-determining effect caused by photosensitive IFV. 
Other studies have demonstrated that the release of hydrophilic solutes (glucose) from the 
liposomes is the rate–determining step in the overall skin permeation kinetics of hydrophilic solutes 
(glucose) (Ganesan et al., 1984).  
 
Another research group also validated that hydrophilic materials entrapped principally in aqueous 
spaces of lipid vesicles have considerably inferior permeation rates to their aqueous solution 
counterpart (Ho et al., 1985). Therefore, in this study, the skin uptake rates will largely base upon 
the free HMT concentration that is ruled by the very slow leakage rates from photosensitive IFV. 
The interfacial transfer of the free drug involves epidermis/water partitioning. In general, all the 
results are in line with the observations previously reported by Schaeffer and Krohn (Schaeffer and 
Krohn, 1982) who revealed that the permeation of hydrophilic materials is not enhanced by 
liposomal delivery. 
 
It is also apparent from the Fig 5.5 that the release of HMT from aqueous solution and 
photosensitive IFV showed an initial burst that gradually level headed after 6 hours of 
administration. Surface charge of liposomes also play crucial role in case of permeation. Here, 
HMT-entrapped IFV showed negative charge (Table 5.1a). It has been reported that formulations 
with a negative zeta potential are intensely excluded through the skin and thus would result in 
slower permeation (Fang et al., 2004; Piemi et al., 1999). This could be another reason that the skin 
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permeability of HMT from the photosensitive IFV system is lower than skin permeability of free 
HMT. 
 
Statistical analyses (P < 0.05) shows that the percentage release of HMT from free HMT and 
HMT- entrapped IFV  after 1h permeation vs after 3 h permeation was both statistically significant 
(P<0.05). Moreover, % of free HMT release after 1 h permeation was very significant, (P<0.01) 
and (P<0.001), to % of free HMT after 6 h permeation and 12 h permeation respectively. Whereas, 
% release of HMT from IFV, after 3 h permeation vs after 9 h permeation and after 6 h permeation 
vs after 24 h permeation was very significant (P<0.01). It should be noted that % release of HMT 
from IFV, after 9 h permeation and after 12 h permeation was very significant (P<0.001) to the % 
release of HMT from IFV after 24 h permeation. 
 
5.4.3.2. Determination of HMT deposition in the skin 
 
The skin deposition reported in this project refers to 24 hours time point at the end of the 
experiment and is summarised in Table 5.4. It is conceivable from the results that the HMT 
deposition provided by photosensitive IFV in epidermis was higher than the free HMT solution 
which is why total flux of HMT-entrapped IFV is lower than the flux of free HMT. 
 
 Taken altogether these results show that HMT-entrapped IFV are better carriers for cutaneous 
delivery of HMT and this formulation could be useful for treating skin diseases like psoriasis, 
vitiligo.  However, a more extensive study should be undertaken to elucidate the effect of HMT-
entrapped IFV topical application and their interaction with the skin. Therefore confocal laser 
scanning microscopy (CLSM) observations of cross-sections and surface part of epidermis 
specimens after permeation was carried out by using LEICA confocal. 
 
5.4.4. Confocal microscopy 
 
During the past two decades, Confocal Laser Scanning Microscopy (CLSM) has been widely used 
as a powerful method to visualize fluorescent materials in the skin. In 1996, Kirjavainen and co-
workers documented that the fluorescence from DOPE-(dioleylphosphatidyl ethanolamine) based 
liposomes was proficient to penetrate deeper into the stratum corneum (SC) compared to that from 
liposomes devoid of DOPE (Kirjavainen et al., 1996). Later on, in 1998, Van Kuijk-Meuwissen et 
al proved that the dye applied non-occlusively in stretchy liposomses penetrated deeper into the 
skin in comparison to occlusive application (van Kuijk-Meuwissen et al., 1998). Furthermore, 
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Boderke et al demonstrated in 1997 that CLSM could be a better technique in order to observe the 
amino peptidase activity in the skin and SC showed considerably less amino peptidase activity than 
the epidermis (Boderke et al., 1997). 
 
There is extensive literature on the use of CLSM for the purpose of skin studies and skin diseases 
(Simonetti et al., 1995; Turner and Guy, 1998; Vrhovnik et al., 1998; Zellmer et al., 1998). 
However, it should be noted that all these researchers used fluorescent dye for labelling of psoralen 
in order to visualize the psoralen–skin interaction via CLSM. Very few articles are available on the 
psoralen as fluorescent material. Therefore, in this investigation, psoralen was used as fluorescent 
marker to examine the epidermis specimens after permeation experiment. The advantage of using 
IFV containing psoralen as fluorescent marker is as follows – 
 
 It reduces the photosensitive IFV size (10 µm) (as depicted from table 5.1 a) in comparison 
to the liposome containing fluorescent marker conjugated with the psoralen.  
 
 The use of psoralen as fluorescent label can avoid the problems such as lifetime and 
quantum yield that arises during the selection criteria of fluorescent marker (Sauer et al., 
2011).  
 
Numerous investigations with CLSM on in vivo skin cells also stimulate potential applications of 
two-photon –induced emission and photochemistry in high resolution imaging and labelling of skin 
cells for basic research as well as clinical research (Wilson, 1990; Rajadhyaksha et al., 1995). Oh et 
al (Oh et al., 1997) indicated in 1997 that two-photon excitation relative to one-photon excitation of 
HMT is supposed to boost the depth of penetration and range of cellular targets. Therefore, here 
Leica confocal microscopy was used to observe the cross-sections and surface part of epidermis 
specimens after permeation experiment  
 
Fig 5.6 shows representative CLSM photomicrographs of rat skin treated with: dilute HMT 
solution (a) and HMT- entrapped IFV (b). The images were taken after 24 hours Franz cell 
permeation experiment. For this study, control sample i.e. IFV without HMT (c) was also 
employed. 
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Fig 5.6: The representative CLSM photomicrographs of rat skin treated with various HMT 
formulations.  
a) Dilute HMT solution, b) HMT-entrapped IFV and c) IFV without HMT (control). 
HMT-entrapped IFV Dilute HMT solution 
IFV without HMT 
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As depicted in Fig 5.6, the average particle size of photosensitive IFV with HMT in the skin is 3.20 
µm. Total thickness of epidermis is 7 µm. It can also be seen from the Fig 5.6 that a very high 
fluorescence was observed in the epidermis with the use of HMT-entrapped IFV as compared to 
control photosensitive IFV and free HMT. Moreover, in comparison with the skin treated with 
HMT and empty IFV, cross-sections and surface of the skin treated with HMT-entrapped IFV show 
increment in hydration.   
 
Overall, these results demonstrated that HMT-entrapped IFV seem to be promising for dermal 
delivery as they have shown maximum fluorescence in viable epidermis. To date, nobody has used 
CLSM to visualise photosensitive IFV with HMT. There is extensive research on the use of 
liposomes containing psoralen conjugated fluorophore in order to visualize the skin permeation 
(Kalat et al., 2014; Kumari and Pathak, 2013; Nishigori et al., 1998; Zhang et al., 2014). However, 
few data available on the use of LUV containing psoralen conjugated fluorophore in order to 
visualize the skin permeation. They have used other psoralen derivatives except HMT. Furthermore 
no report has used photosensitive IFV. Here, in this study, it was the first time that photosensitive 
IFV (prepared via interdigitation fusion method) containing HMT was used. 
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5.5. Conclusion 
Skin conditions such as psoriasis and vitiligo often hark back and are rarely cured through topical 
drug treatment alone. Hence physicians might suggest PUVA therapy in which a combination of 
psoralen drugs and long-wavelength UVA light is employed to cure the condition. However, 
topical application of psoralen itself causes skin irritation. Therefore, it is very important to develop 
effectual vehicles for delivering psoralen to treat psoriasis condition, which can avoid or minimise 
the side effects. Photosensitive IFV were developed in this investigation with this aim in mind. 
Based on the results from chapter 4, it was confirmed that HMT-entrapped photosensitive IFV are 
stable and readily give controlled release of HMT with UVA irradiation. Apart from this, it is vital 
to examine the skin permeation of these liposomes. As a result, here, photosensitive IFV were 
formulated and Franz cell was applied to assess the permeation behaviour of the HMT-entrapped 
IFV.   
To investigate transdermal absorption of drug molecules, the most relevant skin membrane is 
human skin. Because the availability of human skin is limited, animal skin is regularly employed. 
That is why in this investigation, rat skin was used and penetration behaviour of photosensitive IFV 
into rat skin was examined. 
From the Franz cell results it could be concluded that inference of photosensitive IFV attributed to 
smaller HMT release from the HMT-entrapped IFV and produced a slight permeation which was 
not significant as evidenced by slightly lower amount of HMT into the receiver chamber (18.74 
±0.11 (µg/cm2/h) after 24 h) (Fig.5.5) and slightly higher skin deposition (0.94± 0.01 (µg/cm2/h) 
in comparison to dilute solution of HMT (Table 5.4). To minimise these difference, one might 
consider to use penetration enhancer in this type of systems. 
CLSM results clearly indicated the penetration behaviour of HMT-entrapped IFV, and 
demonstrated the use of HMT as fluorescent marker for the in vitro skin study. This imaging 
behaviour of psoralen could be beneficial to probe answers to questions such as why skin 
conditions are scaly and non-facile for drug delivery in psoriasis. Hence, psoralen can be used for 
imaging purpose in addition to psoriasis treatment.  
Overall, the work undertaken here has given useful insight into the potential of photosensitive IFV 
as efficient carrier for superior topical delivery of psoralen along with their potential application to 
reduce toxicity associated with photosensitive psoralen. However, extensive research work is 
needed in order to establish in vivo efficacy and long–term safety profile of psoralen-entrapped 
liposomes.  
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6.1. Summary and implications of results 
The aim of this thesis was to develop Bis-Azo PC based photosensitive liposomes that can be used 
for the controlled release of active ingredients through long-wavelength UVA irradiation, 
particularly for therapeutic agents such as psoralen for the treatment of skin disorder such as 
psoriasis, vitiligo and other skin disorders.   
Scientists have already demonstrated that the Bis-Azo PC sensitized liposome system via UV 
irradiation undergoes cis-trans isomerisation (420/360 nm) in a wavelength specific manner 
resulting in programmed release of trapped drugs (Bisby et al., 1999b; Bisby et al., 2000b; Morgan 
et al., 1987b; Sandhu et al., 1986). Moreover, researchers in Aston University have also illustrated 
that Bis-Azo PC based photosensitive liposomes are beneficial for tissue engineering (Smith et al., 
2007). By taking into account the fact that Bis-Azo PC sensitized photosensitive liposomes can be 
potential carriers for the drug delivery, the first part of this research was focused on the synthesis 
and characterisation of photosensitive lipid i.e. Bis-Azo PC by using a lipid chemistry method. This 
synthetic approach was encountered with a few troublesome issues, however, photosensitive lipid 
i.e. Bis-Azo PC was successfully synthesized. Characterisation studies such as NMR, UV, IR and 
mass spectrometry confirmed the correct identity of Bis-Azo PC molecule. 
The second part of this research concentrated on the incorporation of Bis-Azo PC into neutral 
liposomes (DPPC:Chol) and these liposomes was  applied for the controlled release of model 
protein (BSA-FITC). The method for the formulation of Bis-Azo PC sensitized liposome was 
interdigitation fusion method (Ahl et al., 1994). With this method, protein-entrapped IFVs with or 
without Bis-Azo PC were successfully prepared. These IFV were assessed through confocal 
microscopy and characterisation techniques such as particle size analyser, zeta potential. Confocal 
microscopy study revealed that IFV are bigger in size than SUV but are smaller than MLV. The 
stable entrapment of the model protein was feasible as shown through fluorescence spectroscopy. 
Within this study one of the aims was to quantitatively and qualitatively assess the impact of 
cholesterol content on the stability of the prepared IFV to deliver model protein as it is well 
accepted that the presence of cholesterol improves the bilayer stability (Gallova et al., 2004; Li-
Ping Tseng, 2007; Ohvo-Rekilä et al., 2002) . The optimum cholesterol amount in terms of protein 
loading, stability and photo-trigger release of protein was then investigated. These studies showed 
that the content of cholesterol influences the encapsulation efficiency of protein as well as the 
release of entrapped protein, and ROHS 36w professional UV curing lamp was more effective for 
the photo-triggered release of the protein than the other UV lamps (Nichia NSHU590EN UV LED 
lamp and UV curing flood lamp). Photo-induced study also points out that 100 % release is not 
achievable and DPPC:Chol:Bis-Azo PC based IFV could give a maximum of 84 % protein release 
after 12 min of UV irradiation. Results also revealed that the inclusion of increasing amount of 
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cholesterol reduces the stability of photosensitive IFV. Most notably, photosensitive IFV 
formulations stored at 4 0C for two weeks remained stable in comparison to photosensitive IFV 
formulations stored at 25 0C for 96 h. As a consequence from these observations, DPPC:Chol:Bis-
Azo PC (16:2:1) based IFV was chosen as candidate for the controlled release of drugs under UVA 
irradiation.  
Further studies investigated the triggered release of the HMT from DPPC:Chol:Bis-Azo PC 
(16:2:1) based photosensitive liposomes. Psoralene derivative i.e. HMT was selected as a model 
compound. Skin conditions such as psoriasis and vitiligo can be treated through PUVA therapy in 
which combination of psoralen drugs and long-wavelength UVA light is employed to treat these 
diseases. However, topical application psoralen itself causes side effects such as skin irritation. 
Therefore, it is mandatory to develop effectual carrier for delivering psoralen in order to treat 
psoriasis and vitiligo conditions with minima side effects. As a result, HMT-entrapped IFV were 
developed to release HMT via long-wavelength UVA irradiation. Basically, two different methods, 
interdigitation fusion method and extrusion method, were utilized to formulate HMT-entrapped 
liposomes. Results obtained from characterisation studies indicated that no significant difference 
was noted in physicochemical characterization of DPPC:Chol:Bis-Azo PC (16:2:1) based 
liposomes prepared by the two methods. Nevertheless, the size of liposomes prepared by extrusion 
method was slightly smaller than the size of liposomes prepared by interdigitation fusion method. 
Stable entrapment of HMT was achieved with liposomes prepared via these two different methods 
which was verified through confocal microscopy. For entrapment studies, indirect UV based 
method was employed for the quantification of HMT. When compared to interdigitation fusion 
method, the extrusion method requires polycarbonate filters and extruder, which is why liposomes 
prepared with interdigitation fusion method could be used for further investigations. Photo-
triggered release studies were conducted for HMT-entrapped IFV and illustrated that 100 % release 
was not achievable, though DPPC:Chol:Bis-Azo PC (16:2:1) based photosensitive IFV could have 
84 % release after 12 min of UV irradiation. These results are in line with the protein results (as 
described in Chapter 3). Furthermore, stability studies revealed that no notable change in average 
vesicles size (10.89 µm) formed from DPPC:Chol:Bis-Azo PC (16:2:1) based IFV formulations at 
4 0C for two weeks and 25 0C over 96 h despite the slight enhanced leakage of HMT in general at 
25 0C in comparison with 4 0C . These results are also in good agreement with the protein results 
(as described in Chapter 3). 
The final aim of this project was to assess the permeation behaviour of HMT-entrapped 
photosensitive IFV through the skin using Franz diffusion cell. The single most important 
characteristic in the design of transdermal/ topical drug delivery is the rate and extent of drug 
transport across the skin, in essence the flux of drug molecule. Therefore the permeation behaviour 
of the HMT–entrapped IFV was investigated. Franz diffusion cell assembly was utilised to assess 
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the skin permeation of HMT-entrapped IFV. It is generally accepted that the Franz diffusion cell is 
a powerful tool to study the permeation behaviour of drug molecules. The skin selected for this 
study was rat skin as the availability of human skin is limited. The data obtained from Franz cell 
study showed that HMT-entrapped photosensitive IFV attributed to smaller HMT release and 
produced slower skin permeation as compared to the dilute solution of HMT but not at a significant 
level. However, it was also observed that the HMT-entrapped photosensitive IFV contributed to 
higher skin deposition in comparison to the dilute solution of HMT. In order to avoid these 
differences, one can consider to use of chemical penetration enhancer, such as oxazolidionones, 
fatty acids, essential oils, terpenoids into the IFV formulations. Furthermore confocal laser 
scanning microscopy (CLSM) study was conducted to study the permeation behaviour of dilute 
HMT solution, HMT-entrapped IFV and IFV without HMT after 24 hour permeation experiment. 
Results revealed high fluorescence in the epidermis with the use of HMT entrapped-IFV when 
compared with control photosensitive IFV and free HMT. This is due to the fact that HMT- 
entrapped IFV showed slower permeation and higher skin deposition after 24 hour permeation 
experiment. Moreover, in comparison with the skin treated with HMT and empty IFV, cross-
sections and surface of the skin treated with HMT- entrapped IFV showed increment in hydration. 
Results obtained from CLSM also demonstrated that HMT can be used as a fluorescent label for 
the in vitro skin study. This imaging behaviour of psoralen could be beneficial to probe answers to 
questions such as why skin conditions are scaly and non-facile for drug delivery in psoriasis and 
vitiligo. Thus, psoralen can be efficient not only for imaging purpose but also for psoriasis 
treatment.  
In summary, the work undertaken in this thesis has given useful insight into the potentials of Bis-
Azo PC based IFV as a promising “cage” for the controlled release of active ingredients through 
long-wavelength UV irradiation and particularly psoralen derivatives that could possibly offer a 
novel method for the treatment of psoriasis and vitiligo.      
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6.2. Future Direction 
      Further work that can be conducted in continuation of this research may include: 
  Bis-Azo PC based photosensitive IFV might be toxic and/or carcinogenic in humans and 
animals. Therefore, toxicity and biocompatibility studies should be needed in order to set 
the safety profile of these IFV.    
 
 In the immediate future, development of pharmaceutical application of these systems as 
drug delivery systems could be focused on the design of photocleavable lipids that can be 
used in in vivo experiments. In particular, the photocleavable lipids and the products of 
their photodecomposition should be nontoxic. Another direction for the future 
photosensitive liposomes research could be the use of two photon absorption phenomena. 
Near IR light is capable of penetrating the living tissues without significant absorption and 
scattering and, therefore, may represent a promising new way for in vivo photo-induced 
release of therapeutic agents. 
 
 Knowledge of physicochemical interaction between vesicle bilayer and HMT/model 
protein is helpful. This could be investigated using Langmuir trough by recording surface 
pressure isotherm with respect to time. 
 
 During photo-triggered release study, photosensitive liposomes transform from trans to cis 
through UV irradiation (Morgan et al., 1987b). This is why the possible role of phase 
separation in the leakage process needs further evaluation and techniques such as 
calorimetric measurement, NMR data, hyper DSC and freeze-fracture microscopy would 
be beneficial in this study. 
 
 In PUVA therapy for psoriasis or Vitiligo treatment, utilisation of long-wavelength UVA 
light may cause tissue damage (Winterfield et al., 2005; Griffiths et al., 2000). For that 
reason, extensive research work is needed in order to establish in vivo efficiency of HMT-
entrapped IFV. Alternatively, since it is well accepted that tissue damage in PUVA therapy 
can be recovered with the use of Vitamin E (Akyol et al., 2002; Jalel et al., 2009), 
therefore, utilisation of water soluble D-α-tocopheryl polyethylene glycol succinate 
(Vitamin E TPGS) can be beneficial in PUVA therapy. Hence, photosensitive IFV can be 
used as carrier to deliver both HMT and Vit ETPGS for better psoriasis treatment. 
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 Franz cell work described in Chapter 5 demonstrated that HMT-entrapped IFV attributed to 
higher skin deposition and a slightly slower permeation as compared to dilute solution of 
HMT. Therefore, with intention to increase permeation behaviour of these drugs or to 
modify the barrier properties of the skin, further studies needs to be carried out by adding 
penetration enhancers and other excipients into the IFV formulations. 
 
 Photosensitive IFV also can be efficient to deliver Vit D in order to avoid skin cancer. As 
Vit D protect the human skin exposure to sun rays and play a key role in skin cell 
development and repair.            
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Appendix-1 
 
Aim: To establish a calibration curve for quantification of BSA-FITC (protein conjugated with  
          fluorophore )  
 
Method: 
 
A) A standard stock solution was prepared by dissolving 1 mg of BSA-FITC (protein conjugated  
     with fluorophore) in 1 ml of phosphate buffer saline solution at pH 6.8. 
 
B) A set of standard solutions of BSA-FITC in the range of 0.07 to 20 µg/ml were prepared by the   
     proper dilution of the above stock solution with PBS solution. Further, the fluorescent protein     
     content in the supernatant was determined by fluorescence spectroscopy (Perkin-Elmer Life  
     Sciences) at excitation and emission wavelengths of 490 and 515 nm, respectively. 
 
C) A calibration curve was constructed by plotting absorbance versus concentration of the  
     above standard solutions (path length to be fixed at 1 cm).  
 
Results: 
Conc in 
ug/ml   
RFU   RFU   RFU   Mean   SD   
0.07 0.489 0.568 0.693 0.58 0.1 
0.1 1.14 1.16 0.9 1.06 0.14 
0.125 1.34 1.46 1.73 1.51 0.19 
0.15 1.81 1.51 1.96 1.76 0.22 
0.31 11.87 12.15 12.49 12.17 0.31 
0.625 22.31 22.46 25.07 23.27 1.54 
1.25 40.1 42.5 42.1 41.56 1.28 
2.5 74.23 76.15 76.5 75.56 1.95 
5 154.6 156.4 156.1 155.7 0.96 
10 294.5 296.4 296.9 296 1.28 
20 600.5 627.1 625.5 615.7 14.9 
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Absorbance vs Concentration curve 
 
 
 
 
 
 
 
 
Appendix-2 
 
Aim: To establish a calibration curve for quantification of 4'-Hydroxymethyl-4, 5’-8- 
         trimethylpsoralen (HMT). 
 
Method: 
 
A) A standard stock solution was prepared by dissolving 1 mg of 4'-Hydroxymethyl-4, 5’-8- 
    trimethylpsoralen (HMT) in 1 ml of phosphate buffer saline solution at pH 6.8. 
 
B) A set of standard solutions of trimethylpsoralen in the range of 0.0786 to 20 µg/ml were  
     prepared by the proper dilution of the above stock solution with PBS solution. Further,  
     UV absorbance of all these solutions had been measured by Varian Cary 1  
     spectrophotometer at λmax=  249 nm. 
 
C) A calibration curve was constructed by plotting absorbance versus concentration of the  
     above standard solutions (path length to be fixed at 1 cm).  
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Results: 
Conc in 
ug/ml   
 
AU   AU   AU   Mean   SD   
0.0786 0.0275 0.0321 0.0365 0.032 0.004 
0.156 0.0339 0.04193 0.0499 0.041 0.008 
0.31 0.0410 0.05517 0.0706 0.055 0.014 
0.625 0.0501 0.0601 0.0901 0.066 0.020 
1.25 0.0701 0.0800 0.112 0.087 0.021 
2.5 0.1000 0.1012 0.1301 0.110 0.017 
5 0.1706 0.1626 0.2039 0.179 0.021 
10 0.2388 0.3810 0.3129 0.310 0.071 
20 0.4998 0.5989 0.5999 0.566 0.057 
 
Absorbance vs Concentration curve 
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Appendix -3 
Aim: To establish a fluorescent based assay for quantification of 4'-Hydroxymethyl-4, 5’-8-
trimethylpsoralen (HMT) in case of Franz cell study. 
Method: 
I. By using Perkin Elmer Instruments, excitation and emission wavelength of 4’-
hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT) were identified by performing spectral 
scan (between 250-750nm) in a solution identical to phosphate buffer saline (PBS).4’-
hydroxymethyl-4, 5’-8-trimethylpsoralen (HMT) had its excitation λmax at 360 and 
emission λmax at 438. 
II. A standard stock solution was prepared by dissolving 1 mg of 4'-Hydroxymethyl-4, 5’-8-
trimethylpsoralen (HMT) in 1 ml of phosphate buffer saline solution at pH 6.8. 
III. A set of standard solutions of trimethylpsoralen in the range of 0.0786 to 20 µg/ml were 
prepared by the proper dilution of the above stock solution with PBS solution. Further, 
fluorescence of all these solutions was measured by fluorescence spectroscopy (Perkin 
Elmer Life Sciences) at excitation and emission wavelengths of 360 and 438 nm, 
respectively. 
IV. A calibration curve was constructed by plotting fluorescence (FU) versus concentration of 
the above standard solutions. 
 
Results: 
Conc in 
ug/ml   
 
FU   FU   FU   Mean   SD   
0.0708 14.64 14.56 14.49 14.56 0.075 
0.156 22.37 22.68 22.97 22.67 0.30 
0.31 37.71 39.16 42.10 39.65 2.23 
0.625 66.60 67.40 68.80 67.60 1.11 
1.25 130.65 115.11 119.87 121.87 7.96 
2.5 180.43 195.61 188.51 188.18 7.59 
5 264.52 283.38 278.41 275.44 6.77 
10 532.15 510.74 521.42 521.43 9.70 
20 991.64 995.80 998.20 995.21 3.31 
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Fluorescence vs Concentration curve 
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